
Pharmacology & Therapeutics 92 (2001) 179–212

Associate editor: B.L. Roth

# Multiplicity of mechanisms of serotonin receptor signal transduction

John R. Raymond${}^{a,b,*}$, Yurii V. Mukhin${}^{b}$, Andrew Gelasco${}^{a,b}$, Justin Turner${}^{b}$, Georgiann Collinsworth${}^{a,b}$, Thomas W. Gettys${}^{c}$, Jasjit S. Grewal${}^{b}$, Maria N. Garnovskaya${}^{a,b}$

${}^{a}$The Research Service of the Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC 29401, USA  
${}^{b}$Departments of Medicine (Nephrology Division), Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA  
${}^{c}$Departments of Medicine (Gastroenterology Division) and Biochemistry and Molecular Biology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA  

---

## Abstract

The serotonin (5-hydroxytryptamine, 5-HT) receptors have been divided into 7 subfamilies by convention, 6 of which include 13 different genes for G-protein-coupled receptors. Those subfamilies have been characterized by overlapping pharmacological properties, amino acid sequences, gene organization, and second messenger coupling pathways. Post-genomic modifications, such as alternative mRNA splicing or mRNA editing, creates at least 20 more G-protein-coupled 5-HT receptors, such that there are at least 30 distinct 5-HT receptors that signal through G-proteins. This review will focus on what is known about the signaling linkages of the G-protein-linked 5-HT receptors, and will highlight some fascinating new insights into 5-HT receptor signaling. © 2001 Elsevier Science Inc. All rights reserved.

## Keywords: Signal transduction; Adenylyl cyclase; Phospholipase; Kinase; Channel

### Abbreviations:
- AA, arachidonic acid;
- AC, adenylyl cyclase;
- CaM, calmodulin;
- cAMP, cyclic AMP;
- cGMP, cyclic GMP;
- CHO, Chinese hamster ovary;
- cNOS, constitutive nitric oxide synthase;
- iNOS, inducible nitric oxide synthase;
- DAG, diacylglycerol;
- ERK, extracellular signal-regulated kinase;
- GABA, γ-aminobutyric acid;
- GIRK, G-protein-gated inwardly rectifying K⁺;
- GPCR, G-protein-coupled receptor;
- HEK, human embryonic kidney;
- 5-HT, 5-hydroxytryptamine, serotonin;
- IP₃, inositol trisphosphate;
- IRK, inward rectifier K⁺;
- Jak, Janus kinase;
- LSD, lysergic acid diethylamide;
- MAP, mitogen-activated protein;
- MEK, mitogen and extracellular signal-regulated kinase;
- MUPP1, multi-PS-95 discs-large ZO-1 interaction motif-domain protein;
- NMDA, N-methyl-D-aspartic acid;
- NO, nitric oxide;
- NOS, nitric oxide synthase;
- 8-OH-DPAT, (±)-8-hydroxy-2-(di-N-propylamino)tetralin;
- PC-PLC, phosphatidylcholine-specific phospholipase C;
- PDGF, platelet-derived growth factor;
- PDZ, PS-95 discs-large ZO-1, which is a type of protein-protein interaction motif;
- PI, phosphatidylinositol;
- PI-PLC, phosphatidylinositol-specific phospholipase C;
- PKA, protein kinase A;
- PKC, protein kinase C;
- PL, phospholipase;
- RGS, regulators of G-protein signaling;
- SRL, serotonin receptor-like;
- STAT, signal transducers and activators of transcription.

---

## Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
J.R. Raymond et al. / Pharmacology & Therapeutics 92 (2001) 179–212

2.1.7. The 5-hydroxytryptamine${}_{1A}$ receptor causes production of reactive oxygen and nitrogen species. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. The 5-hydroxytryptamine<sub>4</sub> receptor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
be organized so that each major receptor subfamily will be discussed individually.

2. The 5-hydroxytryptamine₁ receptors

There are 5 members of the 5-HT₁ receptor family, termed 5-HT₁A, 5-HT₁B, 5-HT₁D, 5-HT₁E, and 5-HT₁F. A receptor formerly termed the 5-HT₁C receptor is no longer felt to be a member of the 5-HT₁ receptor family, having been reclassified as the 5-HT₂C receptor (Hoyer et al., 1994), based on similarities to other 5-HT₂ receptors in structure and second messenger systems. The 5-HT₁ receptors couple primarily through Gᵢ/o-proteins to the inhibition of adenylyl cyclase (AC) (see Fig. 1) and to a multitude of other signaling pathways and effectors. These will be reviewed in Sections 2.1–2.5.

2.1. The 5-hydroxytryptamine₁A receptor

The 5-HT₁A receptor is the best characterized of the 5-HT₁ receptors (Pedigo et al., 1981; Middlemiss & Fozard, 1983), in large part due to the wide availability

![Diagram](attachment:diagram.png)

Fig. 1. Prototypical signaling enzyme linkages of the G-protein-coupled 5-HT receptors. 5-HT₁ receptors typically inhibit AC through pertussis toxin-sensitive G-proteins of the Gᵢ family, whereas 5-HT₄, 5-HT₆, and 5-HT₇ receptors typically stimulate AC through Gₛ family G-proteins. Activation of AC results in increased production of cAMP, leading to activation of PKA. 5-HT₂ receptors activate PLC-β through Gq/11 family G-proteins, resulting in accumulation of phosphatidylinositol 4,5-bisphosphate (PIP₂) to IP₃ and DAG. Generation of IP₃ results in elevation of intracellular Ca²⁺ levels, whereas DAG activates the Ca²⁺ and phospholipid-dependent protein kinase (PKC). 5-HT₂ receptors also typically activate PLA₂ through G-proteins to increase the accumulation of AA.

of many specific pharmacological tools and because its cDNA and gene were cloned (Kobilka et al., 1987) and identified (Fargin et al., 1988) over a decade ago. Like all 5-HT₁ receptors, the 5-HT₁A receptor is characterized pharmacologically by its high affinity for 5-HT. It has a uniquely high affinity for second generation, arylpiperazine anxiolytic agents, such as buspirone, gepirone, and ipsapirone. The 5-HT₁A receptor also has a high affinity for (±)-8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), which previously was thought to be unique. However, it is now known that the 5-HT₇ receptor shares a relatively high affinity for 8-OH-DPAT with the 5-HT₁A receptor. The 5-HT₁A receptor plays potential roles in neuro-endocrine function and thermoregulation (Goodwin et al., 1985, 1987; Hjorth, 1985; Gilbert et al., 1988a; Gartside et al., 1990; Seletti et al., 1995; Balcells-Olivero et al., 1998), vasoreactive headaches (Leone et al., 1998), sexual behavior (Ahlenius & Larsson, 1989; Schnur et al., 1989; Maswood et al., 1998), food intake (Dourish et al., 1985; Gilbert & Dourish, 1987; Hutson et al., 1988; Gilbert et al., 1988b; Yamada et al., 1998), tooth-germ morphogenesis (Moiseiwitsch et al., 1998), memory (Edagawa et al., 1998), immune function (Iken et al., 1995), aggression (Miczek et al., 1998), depression (Blier et al., 1997; Shiah et al., 1998), and anxiety (Parks et al., 1998; Ramboz et al., 1998), as have been demonstrated in various physiological, clinical, behavioral, and pharmacological studies.

The 5-HT₁A receptor was one of the first GPCRs for which the cDNA and gene were cloned (Kobilka et al., 1987; Fargin et al., 1988; Albert et al., 1990; Fujiwara et al., 1990; Stam et al., 1992; Chanda et al., 1993). The human receptor gene is localized on chromosome 5q11.2-q13 (Kobilka et al., 1987), and encodes a predicted protein with 422 amino acids. The gene is intronless, and its mRNA and protein are expressed mainly in the brain, spleen, neonatal kidney, and gut (Kobilka et al. 1987; Fargin et al. 1988; Kirchgessner et al., 1993; Raymond et al., 1993a) (see Table 1). The coding block of the genes for the rat and human 5-HT₁A receptor are 88% homologous with each other at the nucleic acid level (Kobilka et al., 1987; Fargin et al., 1988; Albert et al., 1990; Fujiwara et al., 1990; Stam et al., 1992). Those sequences share substantially less homology with other G-protein-coupled 5-HT receptors, such as the 5-HT₂A (19%), 5-HT₂C (18%), and 5-HT₁D (43%) receptors (Fujiwara et al., 1990). The primordial significance of the 5-HT₁A receptor is underscored by the molecular cloning of putative homologues in non-mammalian species, such as *Xenopus laevis* (Marracci et al., 1997) and *Fugu rubripes* (Yamaguchi & Brenner, 1997).

The 5-HT₁A receptor arguably couples to the broadest panel of second messengers of any of the 5-HT receptors (see Table 2). The 5-HT₁A receptor has been reported to activate or inhibit various enzymes, channels, and kinases, and to stimulate or inhibit production of diverse soluble second messengers. This receptor has been reported to

Table 1  
Characteristics of human 5-HT receptor genes  

| Human receptor | Archaic names | Number of amino acids | Chromosomal location | Introns | Functional splice variants | mRNA editing variants |
|-----------------|---------------|-----------------------|----------------------|---------|---------------------------|------------------------|
| 5-HT₁A          |               | 422                   | 5q11.2-q13           | 0       | 0                         | 0                      |
| 5-HT₁B          | 5-HT₁Dβ       | 390                   | 6q13                 | 0       | 0                         | 0                      |
| 5-HT₁D          | 5-HT₁Dα       | 377                   | 1p34.3               | 0       | 0                         | 0                      |
| 5-HT₁E          |               | 365                   | 6q14-q15             | 0       | 0                         | 0                      |
| 5-HT₁F          | 5-HT₁Eβ       | 366                   | 3q11                 | 0       | 0                         | 0                      |
| 5-HT₂A          | 5-HT2;        | 471                   | 13q14-q21            | 2       | 0                         | 0                      |
|                 | 5-HTD         |                       |                      |         |                           |                        |
| 5-HT₂B          | SRL;          | 481                   | 2q36.3-q37.1         | 2       | 0                         | 0                      |
|                 | 5-HT₂F        |                       |                      |         |                           |                        |
| 5-HT₂C          | 5-HT₁C        | 460                   | Xq24                 | 3       | ?¹                        | ≥ 14                   |
| 5-HT₄          |               | 388                   | 5q31-q33             | ≥ 5     | ≥ 5                       | 0                      |
| 5-ht₅a          |               | 357                   | 7q36                 | 1       | 0                         | 0                      |
| 5-ht₅B          |               | ?                     | 2q11-q13             | 1       | 0                         | 0                      |
| 5-HT₆          |               | 440                   | 1p35-p36             | 2       | ?¹                        | 0                      |
| 5-HT₇          |               | 445                   | 10q21-q24            | 2       | ≥ 3                       | 0                      |

¹ Nonfunctional variants have been described. See text for primary literature citations.

inhibit and activate AC and phospholipase (PL) C, and to stimulate nitric oxide synthase (NOS) and an NAD(P) H oxidase-like enzyme. It can activate K⁺ channels and high-conductance anion channels, inhibit Ca²⁺ conductances,

and regulate a number of channels and transporters. The 5-HT₁A receptor can activate protein kinase C (PKC), Src kinase, and mitogen-activated protein (MAP) kinases. The 5-HT₁A receptor can inhibit or stimulate Ca²⁺ mobiliza-

Table 2  
Signaling characteristics of human 5-HT receptors  

| Receptor | Common signaling linkages                          | Other signaling linkages                              | G-protein coupling                                      |
|----------|----------------------------------------------------|-------------------------------------------------------|---------------------------------------------------------|
| 5-HT₁A   | Inhibits AC                                       | Activates PLC                                        | Gᵢα3 > Gᵢα2 ≥ Gᵢα1 ≥ Gₒα > Gzα                         |
|          | Activates K⁺ channels                             | Activates NOS                                        |                                                         |
|          | Stimulates ERK                                    | Activates NAD(P) H oxidase                            |                                                         |
|          | Inhibits Ca²⁺ conductances                        | Activates NHE-1                                       |                                                         |
| 5-HT₁B   | Inhibits AC                                       | Activates PLC                                        | Gᵢα3 > Gᵢα1 ≥ Gᵢα2 ≥ Gₒα                               |
|          | Stimulates ERK                                    | Activates NOS                                         |                                                         |
|          |                                                   | Activates AC2                                         |                                                         |
|          |                                                   | Activates K⁺ channels                                 |                                                         |
| 5-HT₁D   | Inhibits AC                                       | Inhibits Ca²⁺ conductances                            | Gᵢα & Gₒα                                              |
|          |                                                   | Activates K⁺ channels                                 |                                                         |
| 5-HT₁E   | Inhibits AC                                       |                                                       | Gᵢα & Gₒα                                              |
| 5-HT₁F   | Inhibits AC                                       | Activates PLC                                         | Gᵢα & Gₒα                                              |
| 5-HT₂A   | Activates PLC                                     | Activates NHE-1                                       | Gqα & G₁₁α ≥ Gᵢα                                      |
|          | Activates PKC                                     | Activates AC                                          |                                                         |
|          | Stimulates ERK                                    | Inhibits AC                                           |                                                         |
|          | Activates PLA₂                                    | Activates Jak2/STAT3                                  |                                                         |
|          |                                                   | Activates Ca²⁺ channels                               |                                                         |
| 5-HT₂B   | Activates PLC                                     | Activates cell cycle                                  | Gqα & G₁₁α                                             |
|          | Activates ERK                                     | Activates iNOS                                        |                                                         |
|          | Activates PLA₂                                    | Activates cNOS                                        |                                                         |
| 5-HT₂C   | Activates PLC                                     | Activates Na⁺/Ca²⁺ exchanger                          | Gqα & G₁₁α                                             |
|          | Activates PKC                                     | PDZ motif signals?                                    |                                                         |
|          | Activates PLA₂                                    |                                                       |                                                         |
| 5-HT₄    | Activates AC                                      | Regulates various channels                            | Gₛα                                                    |
|          | Activates PKA                                     |                                                       |                                                         |
| 5-ht₅a   | Unknown                                           | Unknown                                               | Unidentified                                            |
| 5-ht₅B   | Unknown                                           | Unknown                                               | Unidentified                                            |
| 5-HT₆    | Activates AC                                      | Activates PKA                                         | Gₛα                                                    |
| 5-HT₇    | Activates AC                                      | Activates ERK                                         | Gₛα                                                    |
|          |                                                   | Activates PKA                                         |                                                         |

This table is not all-encompassing. See text for more details and for primary literature citations.

tion, activate or inhibit phosphatidylinositol hydrolysis, and stimulate production of reactive oxygen species (both H₂O₂ and superoxide) and arachidonic acid (AA). In nearly every case, the signals have been shown to be almost completely sensitive to pertussis toxin, implicating Gᵢ/o-proteins in the signals initiated by the 5-HT₁A receptor.

### 2.1.1. The 5-hydroxytryptamine₁A receptor both inhibits and activates adenylyl cyclase

The primary coupling of this receptor (and all 5-HT₁ receptors) is to the inhibition of AC (De Vivo & Maayani, 1986; Weiss et al., 1986). In some systems, this is manifested by an ability to suppress basal cyclic AMP (cAMP) levels, whereas in others, it is primarily manifested by an ability to inhibit forskolin-stimulated AC activity. The number of cell types and lines in which the 5-HT₁A receptor inhibits AC is quite extensive. A partial list includes hippocampal and cortical neurons (De Vivo & Maayani, 1986; Weiss et al., 1986), cultured neuronal cells (the NCB-20, F11, P-11, and HN2 lines) (Hensler et al., 1996; Singh et al., 1996), Chinese hamster ovary (CHO) fibroblasts (Raymond, 1991), HeLa cells (Fargin et al., 1991), human embryonic kidney (HEK) 293 cells (Albert et al., 1999; Kellett et al., 1999), NIH 3T3 fibroblasts (Varrault & Bockaert, 1992; Varrault et al., 1992b), COS-7 cells (Fargin et al., 1989), GH₄C₁ pituitary cells and Ltk⁻ fibroblasts (Liu & Albert, 1991), LLC-PK₁ (Langlois et al., 1996), ventral prostate cells (Carmena et al., 1998), and even insect (army worm) Sf9 cells (Mulheron et al., 1994). The inhibition of AC by the 5-HT₁A receptor is universally pertussis toxin-sensitive, suggesting that this effect requires Gᵢ/o-proteins. Numerous studies in diverse expression systems (*Escherichia coli*, *Spodoptera frugiperda*, and mammalian cells) have shown remarkable consistency in the ability of the 5-HT₁A receptor to bind to G-proteins of this class, with a consensus rank order of Gᵢα₃ > Gᵢα₂ ≥ Gᵢα₁ ≥ Gₒα > Gzα (Bertin et al., 1992; Raymond et al., 1993b; Mulheron et al., 1994; Butkerait et al., 1995; Barr et al., 1997; Clawges et al., 1997; Garnovskaya et al., 1997). We would like to point out that the consensus rank order of G-protein coupling has been determined using only two agonists (5-HT and 8-OH-DPAT). This is potentially important in that we have previously shown using cells transfected with the human 5-HT₁A receptor, that the relative efficacies (compared with 5-HT) of a small panel of compounds to activate G-protein α-subunits is clearly different, depending upon whether Gᵢα₃ or Gᵢα₂ was studied (Gettys et al., 1994). Thus, the coupling of the 5-HT₁A receptor to various G-proteins may be influenced by the agonist to which the receptor is exposed.

Several studies strongly support a role for either Gᵢα₃ or Gᵢα₂ in mediating the inhibition of AC activity by the 5-HT₁A receptor in diverse mammalian cells (Fargin et al., 1991; Raymond et al., 1993b; Liu et al., 1994; Langlois et al., 1996), although Gᵢα₁ or Gₒα may play limited roles in some systems (Raymond et al., 1993b; Mulheron et al., 1994).

Surprisingly, the 5-HT₁A receptor does not universally inhibit AC in all cell types. Despite being expressed in high density in dorsal raphe neurons, 5-HT₁A receptors have not been shown to inhibit AC in the rat dorsal raphe (Clarke et al., 1996). Moreover, there is no evidence for functional coupling to the inhibition of AC in cultured astrocytes, although multiple mRNAs for 5-HT₁ receptors (including the 5-HT₁A receptor) are expressed there (Hirst et al., 1998). In contrast to the findings of Clarke et al. (1996) in rat dorsal raphe, Palego et al. (1999, 2000) have shown that 5-HT₁A receptors in human dorsal raphe can inhibit forskolin-stimulated AC, so the lack of coupling of this receptor in the raphe may be species specific.

The 5-HT₁A receptor has been reported to couple positively to AC in the hippocampus (Markstein et al., 1986; Shenker et al., 1987; Fayolle et al., 1988; Cadogan et al., 1994) and the prostate. Some of these responses are possibly due to confusion with another receptor subtype (Shenker et al., 1987), most likely the 5-HT₇ receptor subtype, which can be stimulated by the 5-HT₁A receptor-selective ligand 8-OH-DPAT. The 5-HT₁A receptor in the ventral prostate has been shown to slightly activate AC under very special conditions (Carmena et al., 1998). 8-OH-DPAT, presumably working through the 5-HT₁A receptor, was shown to augment forskolin-stimulated cAMP accumulation, but only after pretreatment of rats or their excised prostate glands with 8-OH-DPAT. Because the effect was small, and because no agents more specific than 8-OH-DPAT were used, there remains the possibility that this effect was mediated through the 5-HT₇ receptor. However, in another report, the authors used microdialysis to detect increases in cAMP in response to 8-OH-DPAT in rat hippocampus, an effect that they were able to attenuate with a selective 5-HT₁A receptor antagonist (*N*-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide) (Cadogan et al., 1994). Their report provided very tantalizing evidence that the 5-HT₁A receptor can activate AC.

This evidence was perplexing in light of a relatively detailed study that could not detect coupling of the 5-HT₁A receptor to Gₛ or increased AC activity in CHO cells (Raymond et al., 1993b). A recent study confirmed that wild-type 5-HT₁A receptors in HEK 293 cells do not stimulate cAMP accumulation; they further demonstrated that the carboxyl terminal region of the i3 loop of the 5-HT₁A receptor could be mutated to induce only a very weak coupling to Gₛ (Malmberg & Strange, 2000). Therefore, if the 5-HT₁A receptor couples positively to AC, it would seem to require a highly specific cellular milieu, perhaps necessitating the expression of particular subtypes of AC. The family of ACs consists of at least nine distinct members, each possessing a diverse repertoire of regulatory inputs (Mons et al., 1998; Taussig & Zimmermann, 1998; Hurley, 1999). Because the 5-HT₁A receptor can activate a multitude of signaling pathways, it could regulate AC in a number of ways, depending upon both the specific signals generated by receptor occupancy and the
types and amounts of ACs expressed in the cells or tissues of interest.

Three studies have suggested that the presence of AC2 is a key determinant for the positive coupling of the 5-HT<sub>1A</sub> receptor to cAMP accumulation. Uezono et al. (1993) used the Xenopus oocyte system to show that β<sub>2</sub>-adrenergic receptor increases in cAMP were enhanced by activation of co-expressed 5-HT<sub>1A</sub> receptors. The additional activation by the 5-HT<sub>1A</sub> receptor was enhanced by co-expression of AC2, but not AC3 (Uezono et al., 1993). Liu et al. (1999) showed that depletion of G<sub>iα1</sub> from GH4 pituitary cells switched the effect of the 5-HT<sub>1A</sub> receptor on cAMP accumulation from an inhibitory to a stimulatory one. Moreover, the stimulatory effect was sensitive to pertussis toxin, suggesting that either a G<sub>i</sub>- or G<sub>o</sub>-protein subtype specifically mediates the effect. The same group performed more detailed studies in HEK 293 cells, showing a requirement for AC2 and G-protein βγ-subunits for the 5-HT<sub>1A</sub> receptor to increase cAMP in an agonist-dependent fashion. Moreover, they demonstrated that the 5-HT<sub>1A</sub> receptor also contributed to agonist-independent increases in basal cAMP accumulation that also depended upon G<sub>iα2</sub> (Albert et al., 1999). Thus, the 5-HT<sub>1A</sub> receptor can stimulate cAMP accumulation in cells that express AC2 via release of βγ-subunits from pertussis toxin-sensitive G-proteins (probably G<sub>iα2</sub>).

### 2.1.2. The 5-hydroxytryptamine<sub>1A</sub> receptor activates and inhibits phosphatidylinositol-specific phospholipase C

Activation of phosphatidylinositol-specific (PI)-PLC results in the generation of two key second messengers. These are inositol trisphosphate (IP<sub>3</sub>), which regulates intracellular Ca<sup>2+</sup> release (Berridge et al., 1998), and diacylglycerol (DAG), which binds to and activates PKC. PLC can be activated by receptors that couple to both pertussis toxin-sensitive and -sensitive G-proteins. Although 5-HT<sub>1A</sub> receptors can clearly activate PLC, this effect is highly host cell-specific. The ability of the human 5-HT<sub>1A</sub> receptor to activate PI-PLC was first demonstrated in transfection studies in HeLa cells (Fargin et al., 1989). The stimulation was similar in magnitude to that induced by endogenous histamine H<sub>1</sub>-like receptors, but was not as efficient as coupling of the 5-HT<sub>1A</sub> receptor to the inhibition of AC (Raymond et al., 1991). The activation of PLC by the human 5-HT<sub>1A</sub> receptor in HeLa cells was confirmed in several other studies (Middleton et al., 1990; Boddeke et al., 1992; Harrington et al., 1994). Liu and Albert (1991) subsequently demonstrated that activation of PI-PLC by the 5-HT<sub>1A</sub> receptor is cell-specific. They showed that the rat 5-HT<sub>1A</sub> receptor increased PI hydrolysis and released Ca<sup>2+</sup> from intracellular stores in Ltk<sup>−</sup> fibroblasts, but not in BALB/c-3T3 cells (Abdel-Baset et al., 1992) or in GH<sub>4</sub>C<sub>1</sub> pituitary cells (Liu & Albert, 1991). The human 5-HT<sub>1A</sub> receptor can also activate PLC when expressed in Xenopus oocytes (Ni et al., 1997). This coupling may be relevant in that endogenous 5-HT<sub>1A</sub> receptors in a human T-cell-like line (Jurkat) activate PLC (Aune et al., 1993).

In contrast, transfected 5-HT<sub>1A</sub> receptors do not stimulate PLC in CHO cells (Newman-Tancredi et al., 1992; Cowen et al., 1997), COS-7 cells (Fargin et al., 1989), or NIH 3T3 cells (Varrault et al., 1992a). It bears mentioning that the 5-HT<sub>1A</sub> receptor has also been shown to inhibit PLC activation in rat hippocampal preparations (Claustre et al., 1991), although this effect was not sensitive to pertussis toxin.

#### 2.1.3. The 5-hydroxytryptamine<sub>1A</sub> receptor activates other phospholipases

The 5-HT<sub>1A</sub> receptor probably can regulate PLs other than PI-PLC. Cowen et al. (1997) proposed that the 5-HT<sub>1A</sub> receptor activates a phosphatidylcholine-specific (PC)-PLC in CHO cells, and that this activity may be important in the regulation of nuclear factor-κB and extracellular signal-regulated kinase (ERK). Their data showed that 8-OH-DPAT elicited release of <sup>3</sup>H from cells preloaded with [<sup>3</sup>H]choline. This effect was attenuated by a PC-PLC inhibitor (tricyclodecan-9-yl-xanthogenate). The 5-HT<sub>1A</sub> receptor in rat hippocampus has been proposed to stimulate PLA<sub>2</sub> based on inhibitor studies (Claustre et al., 1991). The recombinant 5-HT<sub>1A</sub> receptor has also been shown to activate PLA<sub>2</sub> in HeLa cells (Harrington et al., 1994), and to augment Ca<sup>2+</sup>-induced AA metabolism in CHO cells (Raymond et al., 1992). In contrast, 5-HT<sub>1A</sub> receptor agonists attenuate N-methyl-D-aspartic acid (NMDA) receptor-evoked AA release in adult rat hippocampus, raising the possibility that the 5-HT<sub>1A</sub> receptor might inhibit PLA<sub>2</sub> in some settings (Strosznajder et al., 1996).

#### 2.1.4. The 5-hydroxytryptamine<sub>1A</sub> receptor activates protein kinase C

The 5-HT<sub>1A</sub> receptor activates several different protein kinases. These include serine-threonine, tyrosine, and lipid kinases. Not surprisingly, the 5-HT<sub>1A</sub> receptor can activate PKC in cells in which the receptor has been shown to stimulate PLC (Raymond et al., 1989; Middleton et al., 1990; Liu & Albert, 1991). This is not surprising, in that PKC can be activated by Ca<sup>2+</sup> and DAG (Tanaka & Nishizuka, 1994; Nishizuka, 1995). Activation of PKC by the 5-HT<sub>1A</sub> receptor depends upon PLC activation. As this effect is probably mediated by G-protein βγ-subunits, it will depend upon the expression of βγ-regulated PLC in the target cell or tissue. The coupling of the 5-HT<sub>1A</sub> receptor to PKC is as efficacious as that induced by the endogenous histamine receptor expressed in HeLa cells.

#### 2.1.5. The 5-hydroxytryptamine<sub>1A</sub> receptor activates the extracellular signal-regulated mitogen-activated protein kinase

Several groups have documented that the 5-HT<sub>1A</sub> receptor activates ERK MAP kinases in CHO cells (Cowen, D. S. et al., 1996; Garnovskaya et al., 1996, 1998; Della Rocca et al., 1999; Mendez et al., 1999; Mukhin et al., 2000). Likeother GPCRs, the 5-HT<sub>1A</sub> receptor activates ERK through an intricate signaling pathway that involves assembly of a signaling complex that requires many of the same molecules used by growth factor receptor tyrosine kinases (Marshall, 1995; Luttrell et al., 1997). The activation of ERK by the 5-HT<sub>1A</sub> receptor is initiated by βγ-subunits released from pertussis toxin-sensitive G-proteins. This results in activation of the non-receptor tyrosine kinase Src and tyrosine phosphorylation of the docking platform Shc. Shc phosphorylation results in the recruitment of PI-3′ kinase, Grb2 (an adapter protein), and a Ras activator protein called Sos to the signaling platform. Ras activation leads to sequential activation of Raf, mitogen and extracellular signal-regulated kinase (MEK) and ERK (Cowen, D. S. et al., 1996; Garnovskaya et al., 1996, 1998; Mendez et al., 1999). Cowen, D. S. et al. (1996) hypothesized that PC-PLC augments the activation of Raf that is induced by Ras. Thus, it is possible that the 5-HT<sub>1A</sub> receptor in CHO cells activates ERK through the two converging lipid-signaling pathways. The first involves PI-3′ kinase and intersects the ERK pathway upstream of Ras, whereas the second involves PC-PLC and intersects the ERK pathway upstream of Raf.

Other studies have implicated a Ca<sup>2+</sup>/calmodulin (CaM)-dependent endocytosis step between Ras and Raf (Della Rocca et al., 1999) and reactive oxygen species (H<sub>2</sub>O<sub>2</sub> and superoxide) upstream of Src in 5-HT<sub>1A</sub> receptor-mediated ERK activation in CHO cells (Mukhin et al., 2000). Although the coupling of the 5-HT<sub>1A</sub> receptor to ERK has been relatively well characterized in CHO cells, studies in other cells or tissues are still needed.

### 2.1.6. The 5-hydroxytryptamine<sub>1A</sub> receptor stimulates phosphatidylinositol-3′ kinase

The ability of the 5-HT<sub>1A</sub> receptor expressed in CHO cells to activate ERK (Cowen, D. S. et al., 1996; Garnovskaya et al., 1996, 1998) and Na<sup>+</sup>-proton exchange (Garnovskaya et al., 1998) is sensitive to pharmacological inhibitors and cDNA constructs encoding dominant interfering p85 and p110 subunit of PI-3′ kinase. Moreover, Adayev et al. (1999) showed that the 5-HT<sub>1A</sub> receptor can stimulate PI-3′ kinase-γ in HN2-5 cells.

### 2.1.7. The 5-hydroxytryptamine<sub>1A</sub> receptor causes production of reactive oxygen and nitrogen species

The 5-HT<sub>1A</sub> receptor in CHO cells has been shown by inhibitor, biochemical, and fluorometric methods to stimulate production of at least two reactive oxygen species, H<sub>2</sub>O<sub>2</sub> and superoxide (Mukhin et al., 2000). The production of these reactive oxygen species by the 5-HT<sub>1A</sub> receptor appears to occur at a point upstream of Src, and involves an NAD(P)H oxidase-like enzyme. Activation of this enzyme and the resulting production of reactive oxygen species is a critical step in the stimulation of ERK phosphorylation and kinase activity by the human 5-HT<sub>1A</sub> receptor (Mukhin et al., 2000).

The 5-HT<sub>1A</sub> receptor can also regulate the production of nitric oxide (NO), although there is no consensus on whether the major effect is to stimulate or inhibit its production. There is tantalizing evidence that the 5-HT<sub>1A</sub> receptor can increase NO production in at least three settings. First, 8-OH-DPAT-associated hyperphagia in rats (routinely attributed to the 5-HT<sub>1A</sub> receptor) can be inhibited by NOS inhibitors (Yamada et al., 1996; Sugimoto et al., 1999a, 1999b). Second, putative 5-HT<sub>1A</sub> receptor-induced renal vasodilatory effects have been ascribed to the release of NO from endothelial cells in the renal microcirculation (Verbeuren et al., 1991; Verbeuren, 1993). Third, in a single report, putative endogenous 5-HT<sub>1A</sub> receptors in rat ventral prostate cells were shown to stimulate NOS activity (Carmena et al., 1998). In contrast, there is evidence that the 5-HT<sub>1A</sub> receptor can inhibit NMDA-induced NO production in human neocortical slices (Maura et al., 2000) and in adult rat hippocampus (Strosznajder et al., 1996), and that it can inhibit NMDA/α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate receptor-induced cyclic GMP (cGMP) accumulation (a participant in the NO pathway) in rat cerebellar synaptosomes (Maura & Raiteri, 1996). Clearly, more studies are needed in this area.

#### 2.1.8. The 5-hydroxytryptamine<sub>1A</sub> receptor regulates K<sup>+</sup> channels

The 5-HT<sub>1A</sub> receptor has been shown to regulate the function of several distinct types of channels, including inwardly rectified K<sup>+</sup> channels, high conductance anion channels, cystic fibrosis transmembrane regulator Cl<sup>−</sup> channels, and Ca<sup>2+</sup> channels. It has been known for at least 15 years that the 5-HT<sub>1A</sub> receptor can stimulate the opening of G-protein-gated inwardly rectifying K<sup>+</sup> (GIRK) channels in neurons (Andrade & Nicoll, 1987; Colino & Halliwell, 1987; Zgombick et al., 1989; Penington et al., 1993; Doupnik et al., 1997). Those channels mediate hyperpolarizing postsynaptic potentials in the nervous system and in the heart during activation of G<sub>i/oα</sub>-coupled receptors. The regulation of GIRK channels by receptors relies upon the interaction of G-protein βγ-subunits (Doupnik et al., 1996, 1997). The 5-HT<sub>1A</sub> receptor expressed in primary cultures of rat atrial myocytes with a Vaccinia virus vector stimulates an endogenous atrial inward rectifier K<sup>+</sup> current (Karschin et al., 1991). Co-injection of rat atrial RNA, GIRK1 RNA, or rat brain GIRK3 with 5-HT<sub>1A</sub> receptor RNA into Xenopus oocytes resulted in 5-HT<sub>1A</sub> receptor stimulation of GIRK activity (Dascal et al., 1993; Dissmann et al., 1996; Doupnik et al., 1997). An additional intriguing finding is that various regulators of G-protein signaling (RGS) proteins (RGS1, RGS3, and RGS4, but not RGS2) participated in the functional regulation of 5-HT<sub>1A</sub> receptor-mediated GIRK activation (Doupnik et al., 1997).

The 5-HT<sub>1A</sub> receptor, however, does not universally stimulate inwardly rectified K<sup>+</sup> channels in all cell types. When co-expressed by transfection into COS-7 cells, the5-HT<sub>1A</sub> receptor inhibited the cloned rat, strongly rectifying the inward rectifier K<sup>+</sup> (IRK)-type inwardly rectifying K<sup>+</sup> channel IRK1 (Kir 2.1). The inhibition was mimicked by elevations of internal cAMP concentrations and by microinjection of the catalytic subunits of protein kinase A (PKA), and was not present when mutant IRK1 channels lacking a PKA phosphorylation site were studied (Wischmeyer & Karschin, 1996). These results suggest that the 5-HT<sub>1A</sub> receptor can inhibit IRK channels, and support a possible role for this receptor in stimulating cAMP production in COS-7 cells (see Section 2.1.1).

### 2.1.9. The 5-hydroxytryptamine<sub>1A</sub> receptor inhibits neuronal Ca<sup>2+</sup> conductances

The 5-HT<sub>1A</sub> receptor has been demonstrated to inhibit a Ca<sup>2+</sup> current in neurons (Penington & Kelly, 1990) and neuronal cell lines (Singh et al., 1996). These effects have been attributed to inhibition of both N- and P/Q-type Ca<sup>2+</sup> channels (Penington et al., 1991; Bayliss et al., 1995; Sun & Dale, 1998). For example, the 5-HT<sub>1A</sub> receptor in *X. laevis* spinal neurons causes voltage-independent inhibition of ω-agatoxin-IVA-sensitive (P/Q-type) Ca<sup>2+</sup> channels (Sun & Dale, 1998). Liu et al. (1994) confirmed that the rat 5-HT<sub>1A</sub> receptor inhibited Bay K8644-mediated Ca<sup>2+</sup> influx when transfected in GH<sub>4</sub>C<sub>1</sub> cells, and further demonstrated that this effect required expression of G<sub>oα</sub>. The involvement of G-proteins in the inhibition of Ca<sup>2+</sup> currents was confirmed by studies showing that a peptide inhibitor of G-protein βγ-subunit attenuated 5-HT<sub>1A</sub> receptor-mediated inhibition of Ca<sup>2+</sup> current in dorsal raphe neurons (Chen & Penington, 1997).

### 2.1.10. The 5-hydroxytryptamine<sub>1A</sub> receptor regulates other ion channels

The 5-HT<sub>1A</sub> receptor has been shown to regulate several other channels in transfected cells. Ni et al. (1997) demonstrated that the 5-HT<sub>1A</sub> receptor expressed in *Xenopus* oocytes could stimulate an oscillatory Ca<sup>2+</sup>-activated Cl<sup>−</sup> current, although this effect was much less efficient than that associated with the 5-HT<sub>2C</sub> receptor. Uezono et al. (1993) showed that the 5-HT<sub>1A</sub> receptor expressed in *Xenopus* oocytes could indirectly augment the activation of cystic fibrosis transmembrane regulator Cl<sup>−</sup> channels induced by β<sub>2</sub>-adrenoceptors. This effect likely proceeded via G-protein βγ-subunits, and was enhanced by co-expression of AC2 and G<sub>sα</sub> (Uezono et al., 1993). The 5-HT<sub>1A</sub> receptor expressed by transfection in CHO cells inhibits an endogenous high-conductance anion channel through either G<sub>iα2</sub> or G<sub>iα3</sub>.

### 2.1.11. The 5-hydroxytryptamine<sub>1A</sub> receptor regulates miscellaneous transport processes

The 5-HT<sub>1A</sub> receptor has been shown to regulate several transport processes in transfected cells and native tissues. The 5-HT<sub>1A</sub> receptor stimulates Na<sup>+</sup>/K<sup>+</sup>-ATPase through a Ca<sup>2+</sup>-mediated pathway (Middleton et al., 1990) and Na<sup>+</sup>-dependent phosphate uptake through a PKC-mediated pathway (Raymond et al., 1989, 1991) in HeLa cells. In CHO cells, the 5-HT<sub>1A</sub> receptor stimulates an Na<sup>+</sup>/H<sup>+</sup> exchanger (Garnovskaya et al., 1997, 1998) through a pathway that requires G<sub>iα2</sub> and/or G<sub>iα2</sub>, Src, and PI-3′ kinase (Garnovskaya et al., 1997, 1998). The activation of Na<sup>+</sup>-dependent phosphate uptake suggests a potential role for the 5-HT<sub>1A</sub> receptor in regulating cellular energy fluxes, whereas the coupling to Na<sup>+</sup>/K<sup>+</sup>-ATPase and Na<sup>+</sup>/H<sup>+</sup> exchange suggests potential roles in cell volume regulation. The 5-HT<sub>1A</sub> receptor in CHO cells has also been demonstrated to accelerate mediator-facilitated electron fluxes across the plasma membrane, a process that may be linked to the production of reactive oxygen species (Mukhin et al., 2000).

The 5-HT<sub>1A</sub> receptor can also regulate 5-HT, norepinephrine, and acetylcholine release from neurons. Release of 5-HT involves presynaptic receptors (Verge et al., 1985, 1986; Sharp & Hjorth, 1990), whereas release of norepinephrine (Done & Sharp, 1994; Chen & Reith, 1995) and acetylcholine (Bianchi et al., 1990; Izumi et al., 1994) involves postsynaptic receptors (Hall et al., 1985; Verge et al., 1986).

### 2.1.12. The 5-hydroxytryptamine<sub>1A</sub> receptor regulates proliferation and related pathways

The 5-HT<sub>1A</sub> receptor can stimulate proliferative and mitogenic pathways in various cell systems, consistent with its stimulation of ERK (see Section 2.1.5) and nuclear factor-κB (Cowen et al., 1997). 5-HT<sub>1A</sub> receptors stimulate proliferation of T lymphocytes (Iken et al., 1995), pancreatic carcinoid tumor cells (Ishizuka et al., 1992), and human small cell lung carcinoma cells (Cattaneo et al., 1995). Activation of 5-HT<sub>1A</sub> receptors expressed in NIH 3T3 cells induces focus formation and potentiates the stimulation of DNA synthesis by epidermal growth factor (Varrault et al., 1992a). Rat 5-HT<sub>1A</sub> receptors transfected into BALB/c-3T3 cells enhance thymidine uptake and induce focus formation (Abdel-Baset et al., 1992). All of those studies are consistent with a stimulatory effect of the 5-HT<sub>1A</sub> receptor on proliferation. However, this is not a universal effect in that endogenous 5-HT<sub>1A</sub> receptors in lymphocytes have been implicated in the inhibition of mitogenic responses (Ferriere et al., 1996).

The 5-HT<sub>1A</sub> receptor has also been implicated in morphogenesis and cell survival. Blockade of endogenous 5-HT<sub>1A</sub> receptors reverses serotoninergic stimulation of tooth germ development in mouse mandibular explant cultures (Moi-seiwitsch et al., 1998), suggesting a developmental role for this receptor. Transfected 5-HT<sub>1A</sub> receptors have been shown to inhibit a caspase 3-like enzyme and to attenuate (by ≈60–70%) anoxia-induced apoptosis in the neuronal HN2-5 cells via an ERK-dependent pathway (Adayev et al., 1999), suggesting a potential role for the 5-HT<sub>1A</sub> receptor in neuronal survival.
2.1.13. What is the basis for the multiplicity of 5-hydroxytryptamine${}_{1A}$ receptor signaling?

This question is worth addressing briefly, as it is pertinent to all of the 5-HT receptors from the GPCR family. Many possible explanations for the multiplicity of signaling mechanisms of the 5-HT receptors to diverse signaling pathways could be proposed. These include the ability to activate overlapping pools of G-proteins, activation of distinct signals emanating from G-protein $\alpha$- and $\beta\gamma$-subunits, differing repertoires of G-proteins and signaling enzymes expressed in cells, ratio of G-protein/effectors/receptor, ligand-specific effects, differential rates of desensitization, and cellular compartmentalization, to name just a few. This issue has been reviewed in detail (Raymond, 1995).

In that regard, the 5-HT${}_{1A}$ receptor has been identified in both presynaptic and postsynaptic locations (Miquel et al., 1992; Radja et al., 1992). The signaling properties and pharmacology of the presynaptic and postsynaptic 5-HT${}_{1A}$ receptors vary somewhat (Clarke et al., 1996), leading to speculation that there might be subtypes of 5-HT${}_{1A}$ receptors (Barnes & Sharp, 1999). Langlois et al. (1996) demonstrated that 5-HT${}_{1A}$ receptors transfected into polarized epithelial LLC-PK${}_{1}$ cells were expressed on both basolateral and apical membranes. Receptors on both surfaces were able to inhibit cAMP accumulation, albeit with different efficiencies (Langlois et al., 1996). This study demonstrates that the variables that affect the multiplicity of signaling from single receptor types are not likely to be manifested as “all or none” effects. Thus, the specific coupling of single types of 5-HT receptors to signaling pathways is likely to result from the summation of effects specific to the host cell milieu.

One other theoretical possibility is that some signals emanating from 5-HT${}_{1A}$ (or other 5-HT) receptors may be regulated by effector pathways activated through non-G-protein-activated pathways. This intriguing hypothesis has been reviewed recently by Hall et al. (1999).

2.2. The 5-hydroxytryptamine${}_{1B}$ receptor

The 5-HT${}_{1B}$ receptor initially was identified as a low-affinity ${}^{[3]}$H]spiperone-binding site (Nelson et al., 1981; Pedigo et al., 1981), distinguishing it from the 5-HT${}_{1A}$ receptor. There has been considerable confusion over the identities of the 5-HT${}_{1B}$ and 5-HT${}_{1D}$ receptors. Thus, a brief history of these two closely related receptor subtypes is in order. It originally was thought that the 5-HT${}_{1B}$ receptor was primarily or exclusively expressed in rodent (hamster, mouse, and rat) tissues, whereas the closely related 5-HT${}_{1D}$ receptor was believed to be expressed in other species (humans, cows, dogs, and guinea pigs) (Hoyer & Middlemiss, 1989). The two receptors are pharmacologically similar, although not identical. The major pharmacological distinction is that $\beta$-adrenergic receptor antagonists bind with high affinity to the 5-HT${}_{1B}$ receptor, but not to the 5-HT${}_{1D}$ receptor. Because the distributions of the 5-HT${}_{1D}$

and the rodent 5-HT${}_{1B}$ receptors showed significant overlap, Hoyer and Middlemiss (1989) initially proposed that the two were species homologues.

The subsequent identification of two intronless human receptor genes encoding 5-HT receptors with pharmacological characteristics similar to the 5-HT${}_{1D}$ receptor resulted in their temporary designation as 5-HT${}_{1D}$ receptors (5-HT${}_{1D\alpha}$ and 5-HT${}_{1D\beta}$) (Hamblin & Metcalf, 1991; Hamblin et al., 1992; Hartig et al., 1992; Weinshank et al., 1992). The cloning and identification of the rodent 5-HT${}_{1B}$ receptor cDNA and gene revealed a surprisingly high homology with the human 5-HT${}_{1D\beta}$ receptor (Voigt et al., 1991; Adham et al., 1992; Jin et al., 1992; Maroteaux et al., 1992). Whereas the human 5-HT${}_{1D\alpha}$ and 5-HT${}_{1D\beta}$ receptors share 77% sequence homology in the transmembrane domains, the human 5-HT${}_{1D\beta}$ and rodent 5-HT${}_{1B}$ receptors share 96% homology (Hartig et al., 1992; Jin et al., 1992). The uniquely high affinity of the rodent 5-HT${}_{1B}$ receptors for $\beta$-adrenergic receptor antagonists when compared with the human 5-HT${}_{1D\beta}$ receptors was shown to depend upon a single amino acid residue difference (Metcalf et al., 1992; Oksenberg et al., 1992; Parker et al., 1993). Subsequently, the cloning by Hamblin and colleagues (1992) of a rat gene that encodes a 5-HT receptor with pharmacological characteristics more closely resembling the 5-HT${}_{1D}$ receptor than the 5-HT${}_{1B}$ receptor gave further support to the idea that the 5-HT${}_{1B}$ and 5-HT${}_{1D}$ receptors represent separate gene products that are not exclusively expressed in rodent or non-rodent mammals. The preponderance of evidence resulted in a reassessment of the nomenclature of these receptors in which the human 5-HT${}_{1D\alpha}$ and rodent 5-HT${}_{1D}$ receptors were reclassified as 5-HT${}_{1D}$ receptors, and the human 5-HT${}_{1D\beta}$ and all 5-HT${}_{1B}$ receptors were classified as 5-HT${}_{1B}$ receptors (Hartig et al., 1996).

The 5-HT${}_{1B}$ receptor is widely expressed in brain tissue, probably in both presynaptic and postsynaptic locations (Middlemiss & Hutson, 1990; Buhlen et al., 1996). The 5-HT${}_{1B}$ receptor gene is located on chromosome 6q13 in humans and chromosome 9E in mice (Saudou & Hen, 1994). The human gene encodes a protein with 390 amino acids.

2.2.1. The 5-hydroxytryptamine${}_{1B}$ receptor regulates adenyl cyclase

In general, all of the 5-HT${}_{1}$ receptors can be expected to share many of the signaling linkages of the 5-HT${}_{1A}$ receptor (Hoyer et al., 1994). Thus, the 5-HT${}_{1B}$ receptor would be expected to couple mainly to pertussis toxin-sensitive G-proteins and to inhibit AC. The 5-HT${}_{1B}$ receptor, in fact, has been shown to inhibit AC when natively expressed in tissues such as the substantia nigra (Bouhelal et al., 1988; Schoeffter et al., 1988) and rabbit mesenteric artery (Hinton et al., 1999), in opossum kidney cells (Ciaranello et al., 1990; Zgombick & Branchek, 1998), human umbilical endothelial vein cells (Schoeffter et al., 1995), bovine basilar artery vascular smooth muscle cells (Ebersole et al.,

1993), or CHO-K1 cells (Berg et al., 1994b; Giles et al., 1996), and when heterologously expressed in transfected cells (Ltk-, COS-7, Sf9 cells) (Adham et al., 1992; Levy et al., 1992b; Weinshank et al., 1992; Ng et al., 1993). Like the 5-HT<sub>1A</sub> receptor, the 5-HT<sub>1B</sub> receptor has also been documented to increase cAMP in HEK 293 cells through a conditional process that involves ACII and G<sub>i</sub> proteins (Albert et al., 1999).

The 5-HT<sub>1B</sub> receptor has been shown to couple to mammalian G<sub>i/o</sub>-proteins in Sf9 cells when expressed using a *Baculovirus* vector. Slightly different coupling efficiencies were noted, such that high-affinity agonist binding to the 5-HT<sub>1B</sub> receptor was stimulated with the following rank order: G<sub>iα3</sub> > G<sub>iα1</sub> ≥ G<sub>iα2</sub> ≥ G<sub>oα</sub> (Clawges et al., 1997). The same group noted that the 5-HT<sub>1A</sub> receptor coupled to the G-proteins slightly more efficiently than the 5-HT<sub>1B</sub> receptor. Although the G-protein coupling in Sf9 cells was slightly more efficient for the 5-HT<sub>1A</sub> receptor than for the 5-HT<sub>1B</sub> receptor, another group showed that lower numbers of transfected 5-HT<sub>1B</sub> receptors than 5-HT<sub>1A</sub> receptors were needed for efficient inhibition of AC when transfected into mammalian cells (Mendez et al., 1999).

### 2.2.2. The 5-hydroxytryptamine<sub>1B</sub> receptor activates phospholipases

The 5-HT<sub>1B</sub> receptor can activate PLC in several cell types. This effect is manifested by pertussis toxin-sensitive increases in intracellular Ca<sup>2+</sup> in opossum kidney cells (Zgombick & Branchek, 1998). Although 5-HT<sub>1B</sub> receptors natively expressed in CHO cells were not shown to increase accumulation of inositol phosphates (Dickenson & Hill, 1995), transfected human 5-HT<sub>1B</sub> receptors were shown to mediate pertussis toxin-sensitive increases in both intracellular Ca<sup>2+</sup> and accumulation of inositol phosphates in CHO cells through G-proteins and PLC (Dickenson & Hill, 1998). The 5-HT<sub>1B</sub> receptor in vascular smooth muscle cells derived from bovine basilar artery also increases intracellular Ca<sup>2+</sup> through a pertussis toxin-sensitive mechanism (Ebersole et al., 1993), and this signal may be responsible for 5-HT<sub>1B</sub>-induced blood vessel contractions (Ullmer et al., 1995).

5-HT can also stimulate PLD via endogenous 5-HT<sub>1B</sub> receptors in rabbit mesenteric artery through a signaling pathway that requires extracellular Ca<sup>2+</sup> and the activation of PKC, but is independent of PLC activation (Hinton et al., 1999).

### 2.2.3. The 5-hydroxytryptamine<sub>1B</sub> receptor regulates the extracellular signal-regulated kinase, phosphatidylinositol-3' kinase, p70 S6 kinase, and Akt kinase

Over a decade ago, endogenous 5-HT<sub>1B</sub> receptors in fibroblasts were reported to stimulate DNA synthesis through a pertussis toxin-sensitive pathway that does not involve PLC (Seuwen et al., 1988). Subsequent studies have revealed that the 5-HT<sub>1B</sub> receptor can activate ERK in bovine aortic endothelial cells (McDuffie et al., 2000), BE<sub>2</sub>-C neuroblastoma cells (Lione et al., 2000), and CHO cells (Pullarkat et al., 1998; Mendez et al., 1999). In CHO cells, this occurs through a pathway that involves pertussis toxin-sensitive G-proteins, PI-3' kinase, and MEK (Pullarkat et al., 1998; Mendez et al., 1999). Akt kinase is also activated by 5-HT<sub>1B</sub> receptors acting through pertussis toxin-sensitive G-proteins in BE<sub>2</sub>-C neuroblastoma cells (Lione et al., 2000). In CHO cells, 5-HT<sub>1B</sub> receptors activate p70 S6 kinase through a pathway that involves PI-3' kinase and MEK, and is sensitive to rapamycin and pertussis toxin. Interestingly, coupling to ERK of the 5-HT<sub>1B</sub> receptor in CHO cells was shown to be relatively more efficient than that induced by the 5-HT<sub>1A</sub> receptor (Mendez et al., 1999).

#### 2.2.4. The 5-hydroxytryptamine<sub>1B</sub> receptor stimulates endothelial nitric oxide production

The 5-HT<sub>1B</sub> receptor increases NO in cultured human coronary artery rings (Auch-Schweik et al., 2000) and endothelial cells, probably through increasing levels of intracellular Ca<sup>2+</sup> (Ishida et al., 1998). McDuffie et al. (1999) presented evidence that the 5-HT<sub>1B</sub> receptor stimulates endothelial NOS through pertussis toxin-sensitive G-proteins in cultured bovine aortic endothelial cells. This signaling pathway (and another linked to 5-HT<sub>2B</sub> receptors) probably accounts for most of the 5-HT-induced vasorelaxation in diverse vascular beds (Ullmer et al., 1995).

#### 2.2.5. Other signals of the 5-hydroxytryptamine<sub>1B</sub> receptor

Several groups have demonstrated that presynaptic 5-HT<sub>1B</sub> receptors decrease 5-HT release (Sharp et al., 1989; Hjorth & Tao, 1991; Lawrence & Marsden, 1992; Martin et al., 1992; Davidson & Stamford, 1996). Human 5-HT<sub>1B</sub> receptors stably transfected in C6 glioma cells activate Ca<sup>2+</sup>-dependent K<sup>+</sup> channels (Le Grand et al., 1998).

### 2.3. The 5-hydroxytryptamine<sub>1D</sub> receptor

The 5-HT<sub>1D</sub> receptor was discovered by homology screening using the canine RDC4 gene. That screen revealed two similar genes with pharmacology closely linked to each other, which were originally termed 5-HT<sub>1Dα</sub> and 5-HT<sub>1Dβ</sub>. These were later reclassified respectively as the 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors (see Section 2.2). The gene is intronless, is located on chromosome 1p34.3, and encodes a protein of 377 amino acids. The 5-HT<sub>1D</sub> receptor shares 43% sequence homology with the 5-HT<sub>1A</sub> receptor and 59% with the 5-HT<sub>1B</sub> receptor (77% in the transmembrane regions) (Hamblin & Metcalf, 1991; Hamblin et al., 1992; Hartig et al., 1992).

It has been difficult to establish the precise locations of 5-HT<sub>1D</sub> receptors due to the lack of specific ligands and apparently low levels of mRNA and receptor protein in the brain. Binding sites for the 5-HT<sub>1D</sub> receptor have localized to the substantia nigra, globus pallidus, and caudate, and in lower levels in the cortex and hippocampus putamen.
(Bruinvels et al., 1993), although mRNA for this receptor was not detected in the globus pallidus or substantia nigra (Bruinvels et al., 1994a, 1994b). These results suggest that 5-HT<sub>1D</sub> receptors may be transported along axon terminals after their synthesis.

### 2.3.1. The 5-hydroxytryptamine<sub>1D</sub> receptor inhibits adenylyl cyclase

As has been shown for all other 5-HT<sub>1</sub> receptors, the 5-HT<sub>1D</sub> receptor can inhibit AC through pertussis toxin-sensitive G-proteins in transfected C6 glioma and NIH 3T3 fibroblast cells (Maenhaut et al., 1991; Weinshank et al., 1992; Zgombick et al., 1996; Lesage et al., 1998). However, when expressed at high levels in CHO or Y1 adrenal cells, this receptor can also weakly stimulate cAMP accumulation (Van Sande et al., 1993; Watson et al., 1996; Wurch et al., 1997).

### 2.3.2. The 5-hydroxytryptamine<sub>1D</sub> receptor regulates ion channels

Like other 5-HT<sub>1</sub> receptors, the 5-HT<sub>1D</sub> receptor can regulate K<sup>+</sup> and Ca<sup>2+</sup> channels. In *Xenopus* spinal neurons, the 5-HT<sub>1D</sub> receptor was reported to cause voltage-independent inhibition of ω-conotoxin-GVIA-sensitive (N-type) Ca<sup>2+</sup> channels (Sun & Dale, 1998), although the ligands used were not sufficiently discriminative to rule out the involvement of 5-HT<sub>1B</sub> receptors in mediating this effect. Like 5-HT<sub>1B</sub> receptors, recombinant human 5-HT<sub>1D</sub> receptors stably transfected in C6 glioma cells can stimulate Ca<sup>2+</sup>-dependent K<sup>+</sup> channels, with the resultant outward hyperpolarizing current being dependent upon IP<sub>3</sub> receptor-mediated intracellular Ca<sup>2+</sup> release (Le Grand et al., 1998).

### 2.3.3. The 5-hydroxytryptamine<sub>1D</sub> receptor is mitogenic

5-HT<sub>1D</sub> receptors endogenous to two small cell lung carcinoma cell lines (GLC8 and NCI-N-592) have been reported to stimulate DNA synthesis, although effects of 5-HT<sub>1B</sub> receptors were not ruled out (Cattaneo et al., 1994). However, cloned human 5-HT<sub>1D</sub> receptors transfected into C6 glial cells promote cell growth, so there is little doubt that the 5-HT<sub>1D</sub> receptor (like 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors) can be mitogenic (Pauwels et al., 1996).

### 2.3.4. The 5-hydroxytryptamine<sub>1D</sub> receptor inhibits 5-hydroxytryptamine release

5-HT<sub>1D</sub> receptors can inhibit 5-HT release in several brain regions. 5-HT efflux in the ventral lateral geniculate nucleus of the rat is modulated by presynaptic 5-HT<sub>1D</sub> receptors (Davidson & Stamford, 1996). 5-HT<sub>1D</sub> autoreceptors diminish 5-HT release in guinea-pig mesencephalic raphe, hippocampus, and frontal cortical slices through a pathway involving G-proteins. Interestingly, 5-HT<sub>1B</sub> receptors did not decrease 5-HT release in this preparation (el Mansari & Blier, 1996). In contrast, Trillat et al. (1997) showed that the inhibition of cortical and hippo-

campal 5-HT release was absent in 5-HT<sub>1B</sub> receptor knockout mice. Thus, the respective roles of the 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors in the inhibition of 5-HT release remain unresolved in many brain regions.

Inhibition of glutamate release from rat cerebellar synaptosomes and from human neocortex is attributable to 5-HT<sub>1D</sub> receptors (Raiteri et al., 1986; Maura & Raiteri, 1996; Maura et al., 1998). Moldering et al. (1996) demonstrated that presynaptic 5-HT<sub>1D</sub> receptors can inhibit norepinephrine release from isolated human right atrial appendage sections.

### 2.4. The 5-hydroxytryptamine<sub>1E</sub> receptor

The 5-HT<sub>1E</sub> receptor originally was identified as a component of [³H]5-HT binding to human cortical homogenates that was resistant to a cocktail of antagonists of 5-HT<sub>1A</sub>, 5-HT<sub>1B/D</sub>, and 5-HT<sub>2</sub> receptors (Leonhardt et al., 1989). The intronless 5-HT<sub>1E</sub> receptor gene was subsequently cloned from human and rat (Levy et al., 1992a; McAllister et al., 1992; Zgombick et al., 1992; Lovenberg et al., 1993b). The human gene encodes a protein of 365 amino acids. This protein shares 39% homology with the 5-HT<sub>1A</sub> receptor and 47% identity (64% in the transmembrane regions) with the 5-HT<sub>1B/D</sub> receptors. The 5-HT<sub>1E</sub> receptor gene has been localized to human chromosome 6q14-q15 (Levy et al., 1994).

There are few details about signaling pathways linked to the 5-HT<sub>1E</sub> receptor. Low concentrations of agonist have been shown to inhibit AC in HeLa and BS-C-1 cells transfected with the 5-HT<sub>1E</sub> receptor (Lovenberg et al., 1993b; Adham et al., 1994). The 5-HT<sub>1E</sub> receptor can also stimulate AC, as high concentrations of agonist also promote increases in cAMP in BS-C-1 cells (Adham et al., 1994). The 5-HT<sub>1E</sub> receptor has not yet been demonstrated to stimulate PLC and/or PLA<sub>2</sub>. In BS-C-1 cells, 5-HT had no effect on inositol phosphate release, intracellular Ca<sup>2+</sup> levels, or AA mobilization (Adham et al., 1994).

### 2.5. The 5-hydroxytryptamine<sub>1F</sub> receptor

The 5-HT<sub>1F</sub> receptor originally was cloned from mouse, and was termed 5-HT<sub>1EB</sub>, based on pharmacological similarities with the 5-HT<sub>1E</sub> receptor (Amlaiky et al., 1992). The human gene is intronless like the mouse gene, and it is located on chromosome 3q11 (Saudou & Hen, 1994).

The 5-HT<sub>1F</sub> receptor gene encodes a protein of 366 amino acids, with 70% homology to the 5-HT<sub>1E</sub> receptor, 60% to the 5-HT<sub>1B</sub> receptor (60%), and 63% to the 5-HT<sub>1D</sub> receptor. 5-HT<sub>1F</sub> receptor mRNA was detected in human brain, uterus, and mesentery, but not in kidney, liver, spleen, heart, pancreas, and testes (Adham et al., 1993b). When stably expressed in NIH 3T3 cells, the 5-HT<sub>1F</sub> receptor negatively couples to AC (Amlaiky et al., 1992; Adham et al., 1993b).The 5-HT<sub>1F</sub> receptor has been shown to couple to PI-PLC in a cell-specific manner. When transfected into NIH 3T3 cells, no elevation of inositol phosphates or Ca<sup>2+</sup> was observed, whereas in LM(tk-) cells, the receptor stimulated accumulation of inositol phosphates and induced a rapid increase of Ca<sup>2+</sup>. PLC activation was blocked by pertussis toxin, supporting a role for the G<sub>i/o</sub>-protein (Adham et al., 1993a). The significance of the coupling to PLC is uncertain, as the transfected cells used in this study expressed high levels of receptors (4.4 pmol/mg of protein). The 5-HT<sub>1F</sub> receptor has been demonstrated to decrease capsaicin-induced c-fos expression in the rat trigeminal nucleus caudalis, although the signaling pathway of this effect was not defined (Mitsikostas et al., 1999).

### 3. The 5-hydroxytryptamine<sub>2</sub> receptors

There are three members of the 5-HT<sub>2A</sub> receptor family, termed 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> (Hoyer et al., 1994). The 5-HT<sub>2A</sub> receptor is probably the 5-HT M receptor described by Gaddum and Picarelli (1957). The 5-HT<sub>2B</sub> receptor was formerly referred to as the 5-HT<sub>2F</sub> receptor [or serotonin receptor like (SRL)] (Foguet et al., 1992b), and the 5-HT<sub>2C</sub> receptor was previously referred to as the 5-HT<sub>1C</sub> receptor. The 5-HT<sub>2</sub> receptors couple consistently to the PLC-β second messenger pathway (Peroutka, 1995) in native tissues (Conn & Sanders-Bush, 1984) and heterologous cells (Pritchett et al., 1988). Like the 5-HT<sub>1</sub> receptors, the 5-HT<sub>2</sub> receptors can couple to other second messenger pathways in a cell-specific manner. Unlike the 5-HT<sub>1</sub> receptors, the 5-HT<sub>2</sub> receptor genes have introns. Although the 5-HT<sub>2</sub> receptors are similar in structure, pharmacology, and signaling pathways, there are a few differences in their signaling properties (Berg et al., 1994b, 1996; Grotewiel & Sanders-Bush, 1999). These differences will be discussed in Sections 3.1–3.3.

#### 3.1. The 5-hydroxytryptamine<sub>2A</sub> receptor

The 5-HT<sub>2A</sub> receptor originally was identified as a <sup>[3]</sup>H]spiperone-binding site, with low affinity for 5-HT (Leysen et al., 1978; Peroutka & Snyder, 1979). It was classified as a 5-HT receptor based on pharmacological similarities with other 5-HT receptors. The rat receptor gene was identified in 1988 by Pritchett et al., and the human receptor gene was identified in 1990 by Julius et al. The rat and human genes are 87% homologous. The human 5-HT<sub>2A</sub> receptor gene is located on chromosome 13q14-q21 (Hsieh et al., 1990). The 5-HT<sub>2A</sub> receptor shares 45% homology with the 5-HT<sub>2B</sub> receptor and 49% homology with the 5-HT<sub>2C</sub> receptors (80% in the transmembrane regions). The 5-HT<sub>2A</sub> receptor is widely distributed in the brain (cortex, caudate nucleus, olfactory tubercle, nucleus accumbens, and hippocampus) (Pazos et al., 1985), skeletal (Guillet-Deniau et al., 1997; Hajduch et al., 1999) and smooth muscle (Kuemmerle et al., 1995; Ellwood & Curtis, 1997), kidneys (Garnovskaya et al., 1995), and platelets (Cook et al., 1994).

##### 3.1.1. The 5-hydroxytryptamine<sub>2A</sub> receptor activates phospholipase C

The 5-HT<sub>2A</sub> receptor activates PLC-β in most tissues and cells in which it is expressed, resulting in accumulation of inositol phosphates and elevations of intracellular Ca<sup>2+</sup> (Conn & Sanders-Bush, 1984, 1985; Roth et al., 1984, 1986; Tamir et al., 1992; Berg et al., 1998; Briddon et al., 1998; Grotewiel & Sanders-Bush, 1999). These effects can result in activation of L-type Ca<sup>2+</sup> channels (Watts, 1998) and stimulation of PKC (Takuwa et al., 1989).

##### 3.1.2. The 5-hydroxytryptamine<sub>2A</sub> receptor activates other phospholipases

The 5-HT<sub>2A</sub> receptor activates other PLs, such as PLA<sub>2</sub> and PLD. 5-HT<sub>2A</sub> receptors in CHO cells and 1C11 cells activate PLA<sub>2</sub>-mediated AA release (Berg et al., 1996, 1998; Tournois et al., 1998). In C6 glial cells, the 5-HT<sub>2A</sub> receptor is coupled to the mobilization of polyunsaturated fatty acids and AA (Garcia & Kim, 1997). 5-HT<sub>2A</sub> receptor-induced prostaglandin release is thought to play a major role in the acceleration of gastrointestinal transit (Matsuda et al., 2000). The 5-HT<sub>2A</sub> receptor stimulates amyloid precursor protein ectodomain secretion by a PLA<sub>2</sub>-dependent pathway (Nitsch et al., 1996).

The 5-HT<sub>2A</sub> receptor has been shown to couple to PLD in cultured rat renal mesangial cells (Kurscheid-Reich et al., 1995). This effect is cell-specific, as the receptor does not couple to PLD in guinea pig trachea (Cox et al., 1996).

##### 3.1.3. The 5-hydroxytryptamine<sub>2A</sub> receptor can regulate cyclic AMP accumulation in certain cells

The 5-HT<sub>2A</sub> receptor does not typically regulate cAMP formation in most cells or tissues (Lucaites et al., 1996), but it can both stimulate and diminish cAMP accumulation in specific cell types. Berg et al. (1994a) showed that the 5-HT<sub>2A</sub> receptor can amplify cAMP formation in A1A1 cells by the intermediate actions of PKC-α and/or PKC-δ and Ca<sup>2+</sup>/CaM. In FRTL-5 thyroid cells, the 5-HT<sub>2A</sub> receptor increases cAMP through a pertussis toxin-sensitive mechanism (Tamir et al., 1992).

Garnovskaya et al. (1995) demonstrated that the 5-HT<sub>2A</sub> receptor in rat renal mesangial cells could inhibit forskolin-stimulated cAMP accumulation in intact cells and AC activity in washed membranes. The inhibition of cAMP accumulation did not involve PLC, Ca<sup>2+</sup>, or PKC, but was sensitive to pertussis toxin, suggesting that the 5-HT<sub>2A</sub> receptor in mesangial cells might inhibit cAMP through a membrane-delimited pathway that requires activation of G<sub>i/o</sub>-proteins.
3.1.4. 5-hydroxytryptamine${}_{2A}$ receptor activates the extracellular signal-regulated mitogen-activated protein kinase

Several groups have documented that the 5-HT${}_{2A}$ receptor activates ERK MAP kinases in cells with contractile phenotypes, vascular smooth muscle cells (Florian & Watts, 1998; Watts, 1998) and renal mesangial cells (Grewal et al., 1999; Greene et al., 2000). In vascular smooth muscle cells, the activation of ERK was complex, requiring inputs from PLC, L-type Ca${}^{2+}$ channels, and MEK1 (Florian & Watts, 1998; Watts, 1998). In mesangial cells, the pathway also involves stimulation of PKC, activation of an NAD(P)H oxidase-like enzyme, and production of reactive oxygen species (H${}_{2}$O${}_{2}$ and/or superoxide) (Grewal et al., 1999; Greene et al., 2000). The activation of ERK in vascular smooth muscle cells is involved in contraction, whereas the activation in mesangial cells results in proliferation (Takuwa et al., 1989); induction of early response genes, such as Egr-1 and cyclo-oxygenase-2 (Goppelt-Struebe & Stroebel, 1998); and up-regulation of the matrix-regulatory cytokine, TGF-$\beta$ (Grewal et al., 1999). In contrast, ERK does not appear to be involved in the up-regulation of another of the matrix-regulatory cytokines (connective tissue growth factor) by the 5-HT${}_{2A}$ receptor in mesangial cells. Rather, a small G-protein (Rho) and the actin cytoskeleton appear to mediate the up-regulation (Hahn et al., 2000).

3.1.5. The 5-hydroxytryptamine${}_{2A}$ receptor activates the Janus kinase/signal transducers and activators of transcription pathway

Guillet-Deniau et al. (1997) identified a 5-HT${}_{2A}$ receptor in rat skeletal muscle myoblasts that is coupled to the Janus kinase (Jak)/signal transducers and activators of transcription (STAT) pathway. The receptor was detected on the plasma membrane and in T-tubules in contracting myotubes. It was shown to increase the expression of genes involved in myogenic differentiation, and to trigger a rapid tyrosine phosphorylation of Jak2 and STAT3, resulting in translocation into the nucleus of STAT3. The 5-HT${}_{2A}$ receptor co-precipitated with Jak2 and STAT3, indicating that they are physically associated (Guillet-Deniau et al., 1997).

3.1.6. The 5-hydroxytryptamine${}_{2A}$ receptor regulates apoptosis

Increasing levels of 5-HT in the cerebral cortex coincide with developmental events, such as cell proliferation, survival, and differentiation. Dooley et al. (1997) used a cell-survival assay to show that stimulation of the 5-HT${}_{2A}$ receptor promoted the survival of rat cortical progenitor cells in vitro. They further demonstrated that this effect was specific to the glutamate-containing post-mitotic neuron population, and not to dividing neuroepithelial cells in the developing cortex (Dooley et al., 1997).

3.1.7. The 5-hydroxytryptamine${}_{2A}$ receptor regulates channels

The 5-HT${}_{2A}$ receptor increases intracellular Ca${}^{2+}$ levels by liberating intracellular stores of Ca${}^{2+}$ and/or by activating Ca${}^{2+}$ channels, depending upon the cell of interest. The 5-HT${}_{2A}$ receptor may activate L-type Ca${}^{2+}$ channels in some cell types (Eberle-Wang et al., 1994; Jalonen et al., 1997; Watts, 1998). Although because of significant overlap in the pharmacology of the L-type Ca${}^{2+}$ channels and the 5-HT${}_{2A}$ receptor antagonists (Okoro, 1999), one should proceed with prudence before attributing effects of the 5-HT${}_{2A}$ receptor to L-type Ca${}^{2+}$ channels. The Ca${}^{2+}$ channels coupled to the 5-HT${}_{2A}$ receptor have been characterized as both voltage-dependent and -independent (Nakaki et al., 1985; Eberle-Wang et al., 1994; Hagberg et al., 1998). The increases in Ca${}^{2+}$ levels evoked by the 5-HT${}_{2A}$ receptor have been linked to subsequent opening of Ca${}^{2+}$-activated K${}^{+}$ channels in C6 glial cells (Bartrup & Newberry, 1994) and to an inward current mediated through Ca${}^{2+}$-activated Cl${}^{-}$ channels in Xenopus oocytes (Montiel et al., 1997).

In rat cortical astrocytes, the 5-HT${}_{2A}$ receptor activates both an L-type Ca${}^{2+}$ channel and an apamin-sensitive Ca${}^{2+}$-activated small conductance K${}^{+}$ channel (Jalonen et al., 1997).

3.1.8. The 5-hydroxytryptamine${}_{2A}$ receptor causes production of reactive oxygen and nitrogen species

Preliminary reports suggest that the 5-HT${}_{2A}$ receptor can either stimulate or inhibit NO synthesis in certain tissues and cells. For example, gastrointestinal transit is regulated by 5-HT${}_{2A}$ receptor-induced release of NO (Matsuda et al., 2000). On the other hand, 5-HT${}_{2A}$ receptors also inhibit cytokine-stimulated inducible NOS in C6 glioma cells (Miller & Gonzalez, 1998).

The 5-HT${}_{2A}$ receptor in renal mesangial cells has been shown to induce the production of H${}_{2}$O${}_{2}$ and superoxide through the action of an NAD(P)H oxidase-like enzyme (Grewal et al., 1999). The enzyme resides downstream from PKC, and is an important upstream activator of ERK by the 5-HT${}_{2A}$ receptor in those cells (Greene et al., 2000).

3.1.9. The 5-hydroxytryptamine${}_{2A}$ receptor regulates calmodulin

It is not surprising that CaM should be a target for 5-HT${}_{2}$ receptor signaling, in that CaM is a major signaling target of Ca${}^{2+}$ mobilization in most cells types. There are three lines of indirect evidence that the 5-HT${}_{2A}$ receptor signals through CaM. First, agonist-mediated up-regulation of the 5-HT${}_{2A}$ receptor depends upon CaM and Ca${}^{2+}$/CaM-dependent kinase 2 (Chen et al., 1995). Second, Berg et al. (1994a) showed that the 5-HT${}_{2A}$ receptor increases cAMP formation in A1A1 cells by the intermediate action of CaM. Third, inhibition of CaM-dependent kinase 2 or calcineurin (a CaM-dependent phosphatase) inhibits 5-HT-induced cyclo-oxygenase 2 mRNA expression in renal mesangial cells (Stroebel & Goppelt-Struebe, 1994; Goppelt-Struebe et al., 1999).

J.R. Raymond et al. / Pharmacology & Therapeutics 92 (2001) 179–212

3.1.10. The 5-hydroxytryptamine${}_{2A}$ receptor regulates transport processes

Like the 5-HT${}_{1A}$ receptor (see Section 2.1.11), the 5-HT${}_{2A}$ receptor has been linked to a variety of transport processes. It activates the Type 1 Na${}^{+}$-proton exchanger in renal mesangial cells (Saxena et al., 1993; Garnovskaya et al., 1995). The 5-HT${}_{2A}$ receptor in airway smooth muscle stimulates the Na${}^{+}$/K${}^{+}$-ATPase (Na${}^{+}$ pump) through a pathway that might involve activation of the Na${}^{+}$-proton exchange exchanger (Rhoden et al., 2000). In contrast, 5-HT${}_{2A}$ receptor transfected into NIH 3T3 fibroblasts was unable to stimulate Na${}^{+}$ pump activity; rather, it activated Na${}^{+}$/K${}^{+}$/2Cl${}^{-}$ cotransport (Mayer & Sanders-Bush, 1994).

The 5-HT${}_{2A}$ receptor expressed endogenously in rat renal mesangial cells accelerates mediator-facilitated electron fluxes across the plasma membrane through a process that may be linked to the production of reactive oxygen species (Grewal et al., 1999). The 5-HT${}_{2A}$ receptor enhances release of dopamine and norepinephrine, but not 5-HT, in the frontal cortex of freely moving rats (Gobert & Millan, 1999). Both 5-HT${}_{2A}$ and 5-HT${}_{2C}$ receptors stimulate amyloid precursor protein ectodomain secretion through a pathway that involves PLA${}_{2}$ (Nitsch et al., 1996).

3.1.11. A unique signaling role for internalization of the 5-hydroxytryptamine${}_{2A}$ receptor

The 5-HT${}_{2A}$ receptor is internalized in response to both agonists and antagonists, adding a very interesting twist to its signaling properties (Bhatnagar et al., 2000). This feature of the 5-HT${}_{2A}$ receptor may play important roles in its signaling and in the actions of antipsychotic medications. Bhatnagar et al. (2000) examined the internalization process of this receptor in detail, demonstrating that both agonist- and antagonist-induced internalization of the 5-HT${}_{2A}$ receptor were dynamin-dependent. In contrast, both agonist- and antagonist-induced internalizations of a 5-HT${}_{2A}$ receptor-green fluorescent protein fusion protein were insensitive to three different dominant-negative mutants of arrestin. Activation of the 5-HT${}_{2A}$ receptor by agonists, but not antagonists, induced greater translocation of arrestin-3 than arrestin-2 to the plasma membrane, and resulted in differential sorting of arrestin-2, arrestin-3, and 5-HT${}_{2A}$ receptors into distinct plasma membrane and intracellular compartments. It is likely that these differences in distribution of the various signaling components induced by agonists and antagonists may be important in the “ligand-directed” of second messenger signals by the 5-HT${}_{2A}$ receptor, depending upon which ligand is used to stimulate the receptor.

3.2. The 5-hydroxytryptamine${}_{2B}$ receptor

The 5-HT${}_{2B}$ receptor was first described as the receptor that mediates contraction of the gastric fundus (Vane, 1959). The receptor was cloned from rat and mouse in 1992 (Foguet et al., 1992a, 1992b) and from human in 1994 (Kursar et al., 1994). The receptor was formerly termed either 5-HT${}_{2F}$ (Wainscott et al., 1993) or SRL (Foguet et al., 1992b). The human receptor protein is 481 amino acids in length (Kursar et al., 1994), and it has 2 introns similar to the 5-HT${}_{2A}$ and 5-HT${}_{2C}$ receptors. The human receptor has 45% homology with the 5-HT${}_{2A}$ receptor and 42% homology with the 5-HT${}_{2C}$ receptor (Barnes & Sharp, 1999). The human 5-HT${}_{2B}$ receptor gene is localized to chromosome 2q36.3-2q37.1.

mRNA encoding the 5-HT${}_{2B}$ receptor is expressed with greatest abundance in the human liver and kidney. Lower levels of expression have been detected in the pancreas and spleen (Bonhaus et al., 1995), but the presence of mRNA for the 5-HT${}_{2B}$ receptor in the brain appears to be relatively limited (Loric et al., 1992; Kursar et al., 1994). 5-HT${}_{2B}$ receptor immunoreactivity has been reported in neurons in the cerebellum, dorsal hypothalamus, lateral septum, and medial amygdala (Duxon et al., 1997).

3.2.1. The 5-hydroxytryptamine${}_{2B}$ receptor activates phospholipase C

Like the 5-HT${}_{2A}$ and 5-HT${}_{2C}$ receptors, the 5-HT${}_{2B}$ receptor couples consistently to PLC. The cloned rat and human receptors stimulate inositol phosphate accumulation when expressed heterologously in mammalian cells (Wainscott et al., 1993; Kursar et al., 1994; Schmuck et al., 1994; Kellermann et al., 1998) or endogenously in IC11 cells (Loric et al., 1995). The 5-HT${}_{2B}$ receptor also has been reported to stimulate Ca${}^{2+}$ mobilization in astrocytes derived from rat cerebral cortex, hippocampus, and brain stem (Sandén et al., 2000). The 5-HT${}_{2A}$ and 5-HT${}_{2C}$ receptors can activate other PLs, but there is less evidence that the 5-HT${}_{2B}$ receptor can do so. The 5-HT${}_{2B}$ receptor has been shown in one report to activate PLA${}_{2}$ in IC11 cells (Tournois et al., 1998). However, the 5-HT${}_{2B}$ does not couple to PLD in the rat stomach fundus (Cox et al., 1999).

3.2.2. The 5-hydroxytryptamine${}_{2B}$ receptor can stimulate cyclic AMP accumulation

The 5-HT${}_{2B}$ receptor does not typically regulate cAMP production, but when heterologously expressed in AV12 cells, it induces a modest increase in cAMP levels (Lucaites et al., 1996).

3.2.3. The 5-hydroxytryptamine${}_{2B}$ receptor regulates morphogenesis and mitogenesis

Choi et al. (1997) reported that 5-HT${}_{2B}$ receptors regulate embryonic morphogenesis, probably by preventing the differentiation of cranial neural crest cells and myocardial precursor cells. Their evidence was that 5-HT${}_{2B}$ receptor antagonists had specific effects on embryonic cultures, such that they induced morphological defects in the cephalic region, heart, and neural tube. 5-HT${}_{2B}$ receptor antagonists interfered with cranial neural crest cell migration and induced their apoptosis. In the heart, antagonists caused abnormal sarcomeric organization in the subepicardium and induced the specific absence of the trabecular cell layer in the

ventricular myocardium. The specific signaling pathways involved in the regulation of cellular migration, apoptosis, and morphogenesis remain to be defined, but a study by Nebigil et al. (2000a) suggests that ErbB-2 might be involved.

Nebigil et al. (2000a) generated 5-HT₂B receptor knockout mice, which resulted in embryonic and neonatal death caused by specific heart defects. The knockout embryos lacked trabeculae in the heart, leading to midgestation lethality. Surviving newborn mice displayed a severe ventricular hypoplasia associated with impaired proliferative capacity of myocytes. In surviving adult knockout mice, there were severe cardiac histopathological changes, including myocyte disarray and ventricular dilation. They also found that there was a specific reduction in the expression levels of the receptor tyrosine kinase ErbB-2. Their data suggest that the 5-HT₂B receptor probably requires ErbB-2 in the signaling pathway for cardiac differentiation (Nebigil et al., 2000a).

### 3.2.4. The 5-hydroxytryptamine₂B receptor activates the extracellular signal-regulated kinase and cell cycle components

Launay et al. (1996) showed that 5-HT₂B receptors stably expressed in mouse fibroblast LMTK- cells rapidly activate the proto-oncogene Ras and ERK1/ERK2 MAP kinases. This pathway also involves Gαq and Gβγ. This pathway also stimulated 5-HT-dependent proliferation of the transfected cells. The 5-HT₂B receptor expressed in LMTK- cells can induce foci formation, and when injected into nude mice, the foci cause tumors (Launay et al., 1996). This effect is mediated through the Ras-ERK pathway.

Nebigil et al. (2000b) presented evidence that the 5-HT₂B receptor can stimulate cell cycle progression through an ERK-dependent pathway. The pathway also leads to hyperphosphorylation of Rb through up-regulation and activation of both cyclin D1/cdk4 and cyclin E/cdk2 kinases. The pathway leading to up-regulation and activation of ERK and cyclin D1, but not cyclin E, requires the intermediate activation of the platelet-derived growth factor (PDGF) receptor kinase signaling pathways. Moreover, activation of the PDGF receptor, activation of ERK, up-regulation and activation of both cyclin D1 and cyclin E, and cellular proliferation all depend upon the non-receptor tyrosine kinase Src (Nebigil et al., 2000b). Thus, the 5-HT₂B receptor stimulates cellular proliferation through two parallel pathways. These are as follows: (1) 5-HT₂B receptor → Gq → Src → PDGF receptor tyrosine kinase → ERK → cyclin D1/cdk4 → Rb hyperphosphorylation → proliferation and (2) 5-HT₂B receptor → Gq → Src → ? → cyclin E/cdk2 → Rb hyperphosphorylation → proliferation.

### 3.2.5. The 5-hydroxytryptamine₂B receptor causes production of reactive nitrogen species

The 5-HT₂B receptor increases production of NO in human coronary artery endothelial cells (Ishida et al., 1998) and in porcine cerebral artery, where this results in vasorelaxation (Florian & Watts, 1998). In contrast, a role for NO in 5-HT₂B receptor-mediated contraction of the stomach fundus has been challenged (Cox & Cohen, 1995). Manivet et al. (2000) published an elegant study in which they documented that 5-HT₂B receptors expressed endogenously in IC11 cells and *Mastomys natalensis* carcinoid cells or expressed heterologously in LMTK⁻ fibroblasts stimulate intracellular cGMP production through dual activation of constitutive NOS (cNOS) and inducible NOS (iNOS). This coupling relied on the Group I PDZ motif in the carboxyl terminal tail of the 5-HT₂B receptor, a conclusion based on competition with a carboxyl terminal fragment of the receptor and upon studies in which a mutant receptor lacking the PDZ interaction motif could not couple to cNOS or iNOS (Manivet et al., 2000). Neutralizing antibodies raised against Gα₁₃ blocked activation of iNOS, but not cNOS, activity. Thus, the 5-HT₂B receptor can activate NO production through two overlapping pathways: (1) 5-HT₂B receptor → PDZ interaction motif + Gα₁₃ → iNOS → NO/cGMP and 5-HT₂B receptor → PDZ interaction motif → cNOS → NO/cGMP (Manivet et al., 2000). Thus, the ability of the 5-HT₂B receptor to increase NO levels depends upon interactions with two isoforms of NOS.

### 3.2.6. The 5-hydroxytryptamine₂B receptor regulates channels

The 5-HT₂B receptor induces release of Ca²⁺ from ryanodine-sensitive intracellular stores in human pulmonary artery endothelial cells through a pathway that involves activation of ryanodine receptors, but is independent of accumulation of inositol phosphates (Ullmer et al., 1996). In contrast, in *Xenopus* oocytes, the 5-HT₂B receptor activates Ca²⁺ oscillations through a pathway that involves IP₃-dependent release of internal Ca²⁺ stores, as well as Ca²⁺ influx. The increased Ca²⁺ leads to activation of a Ca²⁺-dependent Cl⁻ channel (Foguet et al., 1992a; Parekh et al., 1993).

### 3.2.7. The 5-hydroxytryptamine₂B receptor regulates transport processes

Leung et al. (1999) used the short-circuit current technique to demonstrate that the 5-HT₂B receptor can stimulate bicarbonate secretion through a process that is dependent upon prostaglandin synthesis in cultured rat epididymal epithelium. The 5-HT₂B receptor may be able to regulate other transport processes, in that it has been reported to stimulate phosphorylation of the 5-HT transporter SERT and of the Na⁺/K⁺-ATPase (Launay et al., 1998).

### 3.3. The 5-hydroxytryptamine₂C receptor

The 5-HT₂C receptor (originally called the 5-HT₁C receptor) was identified as a high-affinity [³H]5-HT-binding site in the choroid plexus (Pazos et al., 1985). The cloning of mouse (Lubbert et al., 1987; Yu et al., 1991), rat (Julius et al., 1988), and human (Saltzman et al., 1991) 5-HT₂C receptors led to the

recognition that the 5-HT₂C receptor is much more closely related to the 5-HT₂ receptor family than to the 5-HT₁ receptor family. The receptor gene is located on chromosome Xq24, and contains three introns (Yu et al., 1991; Stam et al., 1994; Xie et al., 1996). A nonfunctional truncated splice variant of the 5-HT₂C receptor has been reported (Canton et al., 1996; Xie et al., 1996). To date, no other splice variants of the 5-HT₂C receptor have been identified. However, the 5-HT₂C receptor exhibits a very unique mechanism of generating multiple functional receptor variants through a process called mRNA editing (Burns et al., 1997). This unique feature will be discussed in Section 3.3.8.

The 5-HT₂C receptor is expressed nearly exclusively in the brain. High levels of 5-HT₂C receptor expression have been detected by ligand autoradiography, immunocytochemistry, and in situ hybridization in the choroid plexus, the cortex, the nucleus accumbens, the amygdala, the hippocampus caudate nucleus, and the substantia nigra (Pazos et al., 1985; Mengod et al., 1990; Palacios et al., 1990; Abramowski et al., 1995).

### 3.3.1. The 5-hydroxytryptamine₂C receptor activates phospholipase C

The 5-HT₂C receptor has long been recognized as being capable of activating PLC in the choroid plexus (Sanders-Bush et al., 1988) and other brain regions (Wolf & Schutz, 1997). A major signal transduction cascade linked to the 5-HT₂C receptor in transfected cells is also stimulation of PLC-mediated inositol phosphate accumulation (Julius et al., 1988; Berg et al., 1994b, 1998; Briddon et al., 1998; Grotewiel & Sanders-Bush, 1999), although it can activate PLA₂-mediated AA release as well (Berg et al., 1996, 1998). The activation of PLC probably is mediated through Gq/11α-proteins, although Chen et al. (1994) presented evidence that the 5-HT₂C receptor could couple to Goα and Giα1 in Xenopus oocytes. Chang et al. (2000) used an elegant method of delivering membrane-permeable blocking peptides to document that 5-HT₂C receptors expressed in the choroid plexus activate PLC through Gqα-proteins and not through βγ-subunits. In their study, peptide mimics of Gqα and the Gqα interaction domain of PLCβ1 prevented 5-HT₂C receptor-mediated accumulation of inositol phosphates, whereas peptides derived from βγ-binding sites of PLCβ2 and a phosducin-like protein C-terminus did not. The latter two peptides were quite effective in blocking the Gβγ-mediated activation of ERK by the α₂A-adrenergic receptor. Tohda et al. (1995) also suggested that botulin toxin-sensitive, low-molecular weight G-proteins are important in the inositol phosphate accumulation induced by the 5-HT₂C receptor in COS-7 cells.

Like the 5-HT₂A and 5-HT₂B receptors, the 5-HT₂C receptor can also activate PLA₂, but the story for the 5-HT₂C receptor has an intriguing twist. Berg and colleagues (1998) compared the ability of a panel of agonists to activate both PLA₂ and PLC in cells expressing transfected 5-HT₂A and 5-HT₂C receptors. They showed that for the 5-HT₂C

receptor, some agonists preferentially activated PLA₂ or PLC, when relative efficacies were referenced to 5-HT. This is probably the best evidence for “agonist-directed trafficking of receptor stimulus,” meaning that a single receptor subtype can couple with different efficacies to several signaling pathways, depending upon the nature of the agonist to which the receptor is exposed. In contrast, the results for the 5-HT₂A receptor showed that all agonists demonstrated greater relative efficacies for PLA₂ than for PLC.

#### 3.3.2. The 5-hydroxytryptamine₂C receptor can modulate cyclic AMP accumulation

When expressed at physiological levels, the 5-HT₂C receptor has not been reported to modulate cAMP levels in cells or tissues. When expressed at high density (12 pmol/mg membrane protein) in stably transformed AV12 cells, however, the 5-HT₂C receptor has been shown to inhibit forskolin-stimulated cAMP production, with an IC₅₀ of ≈ 50 nM. This effect was sensitive to pertussis toxin, suggesting the involvement of Gi/o-proteins. In contrast, the 5-HT₂A and 5-HT₂B receptors expressed at similar levels did not decrease AC activity in those cells. Pretreatment of the cells expressing high levels of 5-HT₂C receptor with pertussis toxin also unmasked a small stimulatory effect of the 5-HT₂C receptor on cAMP accumulation. When expressed at low density, the 5-HT₂C receptor could potentiate forskolin-stimulated cAMP production by ~2-fold (Lucaites et al., 1996).

#### 3.3.3. The 5-hydroxytryptamine₂C receptor regulates channels

The 5-HT₂C receptor can regulate K⁺ and Cl⁻ channels. The cloned 5-HT₂C receptor has been shown to close K⁺ channels in the choroid plexus (Hung et al., 1993) and when expressed in cell lines (Kelly et al., 1991; Panicker et al., 1991). DiMagno et al. (1996) showed that the 5-HT₂C receptor, when co-expressed in Xenopus oocytes with rat brain mRNA, could inhibit an inwardly rectified, Ba²⁺-sensitive K⁺ conductance through a PKC-dependent pathway. When co-expressed in Xenopus oocytes, the 5-HT₂C receptor also suppresses the activity of the Shaker-related K⁺ gene Kv1.3, which encodes the type n K⁺ channel. This effect on Kv1.3 currents proceeds via activation of a pertussis toxin-sensitive G-protein and a subsequent rise in intracellular Ca²⁺, but not via PKC, Ca²⁺/CaM or phosphatases (Aiyar et al., 1993). Timpe and Fantl (1994) used a similar system to show that the 5-HT₂C receptor suppressed the activity of the voltage-activated K⁺ channel Kv1.5 through a PLC-dependent pathway.

The 5-HT₂C receptor has also been shown to stimulate an apical Cl⁻ conductance in mouse choroid plexus (Hung et al., 1993). 5-HT₂C receptors have been shown to inhibit γ-aminobutyric acid (GABA)-A receptor channels by a Ca²⁺-dependent, phosphorylation-independent mechanism in Xenopus oocytes (Huidobro-Toro et al., 1996). 5-HT₂C receptors expressed in Xenopus oocytes can stimulate Ca²⁺

release from IP₃-sensitive intracellular stores, which results in the opening of Ca²⁺-gated Cl⁻ channels (Walter et al., 1991; DiMagno et al., 1996). This effect occurs through endogenous G-proteins in Xenopus oocytes. The same Cl⁻ current could also be stimulated by co-expression of four isoforms of mammalian G-protein α-subunits (Gₒα, Gₒβ, Gqα, G₁₁α), along with the 5-HT₂C receptor. The effect was mediated by a PLC-β endogenous to the Xenopus oocytes. The same assay failed to detect any modulation of cAMP or of three G-proteins (Gtα, Golfβ, Gsα, G₁₁α) by the 5-HT₂C receptor (Quick et al., 1994). The physiological significance of these effects is not known.

### 3.3.4. The 5-hydroxytryptamine₂C receptors regulate mitogenesis

The recombinant 5-HT₂C receptor, when expressed in NIH 3T3 cells, results in the generation of transformed foci. Moreover, the injection of cells derived from transformed foci into nude mice has been shown to result in the generation of tumors (Julius et al., 1989). However, when expressed in CCL36 fibroblasts, the 5-HT₂C receptor mediates only a very weak transforming activity (Kahan et al., 1992).

### 3.3.5. The 5-hydroxytryptamine₂C receptor can regulate nitric oxide levels

The 5-HT₂C receptor has been shown to both inhibit and stimulate production of NO. It inhibits NMDA-induced cGMP production and increases NO in rat cerebellum (Marcoli et al., 1997) and in human neocortical slices (Maura et al., 2000). In contrast, the 5-HT₂C receptor can stimulate cGMP and NO production in the choroid plexus through a pathway that requires Ca²⁺, PLA₂, and lipoygenase activity (Kaufman et al., 1995).

### 3.3.6. The 5-hydroxytryptamine₂C receptor regulates transport processes

The 5-HT₂C receptor has been shown to modulate a number of distinct transport processes. Recombinant 5-HT₂C receptors expressed in 3T3 cells can activate processing of amyloid precursor proteins. This process involves both PKC and PLA₂ (Nitsch et al., 1996).

The 5-HT₂C receptor activates an electrogenic Na⁺/Ca²⁺ exchanger in histaminergic neurons in the rat hypothalamic tuberomammillary nucleus. This results in a doubling of the firing rates of the neurons and depolarization (Eriksson et al., 2001). The 5-HT₂C receptor might also stimulate prolactin (Cowen, P. J. et al., 1996), corticosterone, and ACTH secretion (Fuller, 1996), and inhibit the neuronal release of norepinephrine and dopamine, but not 5-HT (Millan et al., 1998).

### 3.3.7. Possible signaling through PS-95 discs-large ZO-1 interaction motifs by the 5-hydroxytryptamine₂C receptor

The 5-HT₂C receptor has been shown in a yeast two-hybrid screen to interact with a novel multivalent PDZ protein called MUPP1. The C-terminus of the 5-HT₂C receptor selectively interacts with the tenth PDZ domain of MUPP1. Both proteins were shown to interact by confocal microscopy and by co-immunoprecipitation studies in COS-7 cells. Thus, Becamel et al. (2001) proposed that MUPP1 might function as a multivalent scaffold protein, which selectively assembles and targets 5-HT₂C receptor-signaling complexes. The interaction between MUPP1 and the 5-HT₂C receptor is functionally significant in two regards. First, the interaction leads to a conformational change in MUPP1 (Becamel et al., 2001). Second, deletion of the 5-HT₂C receptor PDZ recognition motif prevents phosphorylation of the receptor and delays resensitization of receptor responses (Backstrom et al., 2000). These findings open up an exciting new area of GPCR signaling that may function independently from, or in concert with, G-protein-dependent pathways.

### 3.3.8. Multiple novel functional 5-hydroxytryptamine₂C receptors are created by mRNA editing

The 5-HT₂C receptor exhibits a very unique mechanism of generating multiple functional receptor variants through a process called mRNA editing (Burns et al., 1997). Niswender et al. (1998) examined the possibility that the 5-HT₂A and 5-HT₂B receptors might also undergo RNA editing in the i2 loop using a polymerase chain reaction strategy, but were unable to show any evidence that this process occurs for those receptors. They also noted that five genomically encoded adenosines within the putative i2 loop of the 5-HT₂C receptor were converted to guanosines at the RNA level. These sites are referred to as sites A–E. The editing of the mRNA probably occurs by de-amidation of the adenosines to inosines, which are read at the RNA level as guanosines. In the human 5-HT₂C receptor, various combinations of A → G conversions result in at least 21 discrete mRNA species encoding 14 different editing variants of the 5-HT₂C receptor. The genomic (unedited) receptor expresses amino acids INI (in the sequence IRNPI in i2), whereas conversion of all three amino acids results in VNV, VSV, VGV, or VDV (Niswender et al., 1998; Backstrom et al., 1999; Fitzgerald et al., 1999). These are referred to as 5-HT₂C-INI, 5-HT₂C-VNV, 5-HT₂C-VSV, 5-HT₂C-VGV, and 5-HT₂C-VDV receptors. Other human receptor variants are 5-HT₂C-VNI, 5-HT₂C-VSI, 5-HT₂C-ISI, 5-HT₂C-INV, 5-HT₂C-ISV, 5-HT₂C-IGI, 5-HT₂C-VGI, 5-HT₂C-IDI, and 5-HT₂C-IDV receptors. The situation in rats is not identical, in that only 4 A → G conversion sites (termed sites A–D) have been identified, resulting in 11 discrete mRNAs and 7 different receptor protein isoforms (Fitzgerald et al., 1999; Niswender et al., 1999).

The functional significance of the various edited isoforms of the 5-HT₂C receptor is underscored by their differential abundances of expression in total brain and hypothalamic mRNA populations (Fitzgerald et al., 1999). Moreover, the variant edited receptors exhibit differential abilities to bind various ligands, to mobilize intracellular

Ca²⁺, and to stimulate accumulation of inositol phosphates (Niswender et al., 1998; Backstrom et al., 1999; Fitzgerald et al., 1999).

# 4. The 5-hydroxytryptamine₄ receptor

Three types of 5-HT receptors couple primarily to the activation of AC: the Gₛ-coupled 5-HT₄, 5-HT₆, and 5-HT₇ receptors (Hamblin et al., 1998). Unlike the 5-HT₆ and 5-HT₇ receptors, the 5-HT₄ receptor was well-characterized pharmacologically and functionally (Dumuis et al., 1988; Bockaert et al., 1990) prior to its cloning. The major functional effects of the 5-HT₄ receptors are prokinetic actions in the gut and positive inotropy, chronotropy, and lusitropy in atria, but not ventricles (Kaumann, 1991).

The human 5-HT₄ gene is thought to be highly complex, with multiple introns (Bockaert et al., 1998b). It maps to chromosome 5q31-q33 (Claeyesen et al., 1997). In 1995, Gerald et al. reported the isolation of two rat brain 5-HT₄ receptors. These were originally termed 5-HT₄ₛ and 5-HT₄ₗ to indicate that they are short (387 amino acids) and long versions (406 amino acids) of the 5-HT₄ receptor (Gerald et al., 1995). Similar murine cDNA homologues of these receptors were subsequently reported (Claeyesen et al., 1996), and these were proposed to be renamed 5-HT₄ₐ and 5-HT₄ᵦ receptors, to be more in keeping with the recommendations of the Nomenclature Committee of the International Union of Pharmacology (Hoyer et al., 1994). Two later reports suggested that the correct length of the longer isoform (5-HT₄ᵦ receptor) is actually 388 amino acids (Van den Wyngaert et al., 1997; Bockaert et al., 1998b). The putative protein products share sequence identity from amino acids 1–358, and diverge in amino acid sequence after L³⁵⁸. Subsequently, four other splice variants of this receptor have been shown to differ only in the length of their intracellular carboxyl terminal tails. The human 5-HT₄ₑ and 5-HT₄ᵈ receptors are 380 and 360 amino acids in length, respectively (Blondel et al., 1998; Claeyesen et al., 1998). The human 5-HT₄ₑ receptor is 378 amino acids in length (Claeyesen et al., 1999). The corresponding rodent 5-HT₄ₑ receptor is 371 amino acids in length. The 5-HT₄ᶠ receptor has been identified in the mouse and is 363 amino acids in length; a human 5-HT₄ᶠ receptor has not been identified yet (Claeyesen et al., 1999).

There may be subtle differences in the distribution of 5-HT₄ₐ and 5-HT₄ᵦ receptor splice variants (Shen et al., 1993; Blondel et al., 1997), although this has not been a universal finding (Claeyesen et al., 1996; Vilaro et al., 1996). 5-HT₄ₐ, 5-HT₄ᵦ, and 5-HT₄ₑ receptors are expressed in the brain, the atrium, and the gut, whereas the 5-HT₄ᵈ receptor has only been detected in the gut (Blondel et al., 1998). The human 5-HT₄ᵈ receptor is localized in the atrium and the brain, but not in the gut (Mialet et al., 2000), whereas mouse and rat 5-HT₄ᵈ receptors and mouse 5-HT₄ₑ and 5-HT₄ᶠ receptors are brain-specific (Claeyesen et al., 1999).

## 4.1. The 5-hydroxytryptamine₄ receptor activates adenylyl cyclase

The 5-HT₄ receptors prototypically stimulate AC when expressed endogenously in tissues (Dumuis et al., 1988; Bockaert et al., 1990; Ford et al., 1992; Albuquerque et al., 1998; Bach et al., 2001) or heterologously in cells (Gerald et al., 1995; Blondel et al., 1998; Bockaert et al., 1998b; Claeyesen et al., 1998; Mialet et al., 2000). When transiently expressed in COS-7 cells, four splice variants of the 5-HT₄ receptor displayed similar abilities to stimulate AC activity in the presence of 5-HT (Blondel et al., 1998).

## 4.2. The 5-hydroxytryptamine₄ receptor activates protein kinase A

As would be expected for receptors whose primary effect is to increase cAMP levels, most of the effects of the 5-HT₄ receptors are due to activation of PKA. These include positive inotropic, chronotropic, and lusitropic effects in the atria (Kaumann, 1991); inhibition of a K⁺ current in colliculi neurons (Fagni et al., 1992); facilitation of striatal dopamine release (Steward et al., 1996); relaxation of the circular smooth muscle of the human colon (McLean & Coupar, 1996); and regulation of the Ca²⁺-activated K⁺ current in adult hippocampal neurons (Torres et al., 1995).

## 4.3. The 5-hydroxytryptamine₄ receptor regulates channels

5-HT₄ receptors can regulate a variety of channels. For example, activation of L-type Ca²⁺ channels (Kaumann, 1991; Oudadid et al., 1992) is probably responsible for the prokinetic actions of the 5-HT₄ receptors in the gut and positive inotropy in the heart by activating cardiac L-type Ca²⁺ channels. In human atrial myocytes, activation of L-type Ca²⁺ channels by the 5-HT₄ receptor occurs via an elevation of intracellular cAMP levels and stimulation of PKA (Oudadid et al., 1992). The 5-HT₄ receptor increases the Iₕ pacemaker current in atrial myocytes (Pino et al., 1998) and stimulates a Cl⁻ current in human jejunal mucosa and rat distal colon (Budhoo et al., 1996a, 1996b). The 5-HT₄ receptor stimulates a tetrodotoxin-insensitive Na⁺ current in Type II dorsal root ganglion cells through a diffusible second messenger pathway that does not appear to involve cAMP (Fagni et al., 1992). Thus, this receptor may modulate channel function through pathways other than the cAMP/PKA pathway.

The 5-HT₄ receptor does not universally stimulate channels, in that it inhibits a Ca²⁺-activated K⁺ current responsible for the slow afterhyperpolarization in adult hippocampal neurons (Andrade & Chaput, 1991). This effect is mediated by increased cAMP and activation of PKA (Torres et al., 1995). Ansanay et al. (1995) showed that the 5-HT₄ receptor induces long-lasting inhibition of

a K⁺ current in murine colliculi neurons through a PKA and phosphatase-regulated pathway. 5-HT₄ receptors also inhibit (long-lasting) a delayed rectifier voltage-dependent K⁺ current similar to KV3.2 (Bockaert et al., 1998a). The 5-HT₄ receptor in mouse colliculi neurons inhibits a voltage-activated K⁺ current through cAMP and PKA (Fagni et al., 1992).

### 4.4. The 5-hydroxytryptamine₄ receptor regulates transport

5-HT stimulates aldosterone secretion in humans through 5-HT₄ receptors positively coupled to AC (Lefebvre et al., 1997, 2000). 5-HT₄ receptors also facilitate rat striatal dopamine release in vitro and in vivo (Steward et al., 1996), release of acetylcholine from rat frontal cortex (Consolo et al., 1994), and release of 5-HT from rat hippocampus (Ge & Barnes, 1996).

### 4.5. Functional differences among the 5-hydroxytryptamine₄ receptor splice variants

Although four splice variants of the 5-HT₄ receptor, when transiently expressed in COS-7 cells, were reported to display similar abilities to stimulate AC activity in the presence of 5-HT (Blondel et al., 1998), some interesting differences in the behavior of the splice variants have been observed (Claeysen et al., 1999). The 5-HT₄ₑ and 5-HT₄ᵣ receptors induce significantly more agonist-independent increases in AC activity than do longer isoforms of the 5-HT₄ receptor splice variants. The authors presented data in support of a model in which a serine-threonine rich portion of the carboxyl terminus of the receptor that is shared by all of the splice variants (residues 346–359) holds the receptor in an inactive conformation. Longer splice variants, such as 5-HT₄ₐ and 5-HT₄₆ receptors, augment the inhibitory function of residues 346–359, whereas shorter splice variants, such as the 5-HT₄ₑ and 5-HT₄ᵣ receptors, do not, resulting in increased basal cAMP levels (Claeysen et al., 1999). An alternative interpretation of their data is that the carboxyl terminus may be involved in rapid or constitutive desensitization. Thus, removal of the carboxyterminus could increase basal activity by reducing constitutive desensitization. Evidence for this mechanism has been presented recently for the B₂ bradykinin receptor (Leeb-Lundberg et al., 2001). This fascinating story is likely to become more interesting, as the 5-HT₄₆ receptor splice variants differ in their expression of distinct PDZ interaction motifs (Hamblin et al., 1998; Claeysen et al., 1999), which may alter their signaling properties.

### 5. The 5-hydroxytryptamine₅ receptors

Currently, little is known about 5-ht₅ receptors. As functional 5-ht₅ receptors have not been identified in vivo yet, the lower case designation is used. Cloning experiments have revealed two subtypes of the 5-ht₅ receptor, termed 5-ht₅ₐ and 5-ht₅₆. Both 5-ht₅ₐ and 5-ht₅₆ receptors have been cloned from rat and mouse, but only the 5-ht₅ₐ receptor has been cloned from human (Plassat et al., 1992; Erlander et al., 1993; Matthes et al., 1993; Wisden et al., 1993; Rees et al., 1994). The human 5-ht₅ₐ receptor gene encodes a protein of 357 amino acid residues, has a single intron, and is located on chromosome 7q36 (Rees et al., 1994). The human 5-ht₅₆ receptor cDNA and its gene have not been cloned yet, but the gene is localized to chromosome 2q11-13 (Matthes et al., 1993). The rodent 5-ht₅₆ receptor genes contain a single intron in the middle of the putative i3 loops, and they encode proteins of 370 or 371 amino acids.

The 5-ht₅ receptors have high affinity for lysergic acid diethylamide (LSD) and 5-carboxamidotryptamine. Both receptors are expressed in multiple brain regions, but not in peripheral tissues (Plassat et al., 1992; Rees et al., 1994). Waeber and Moskowitz (1995) were able to identify putative 5-ht₅ₐ receptors by comparative autoradiography with [³H]5-carboxamidotryptamine and [¹²⁵I]LSD in wild-type and 5-ht₅ₐ receptor knockout mice. Studies with [³H]5-carboxamidotryptamine (in the presence of 8-OH-DPAT, GR127935, and spiperone) revealed no binding in knockout mice, but intermediate levels of binding in wild-type mice in the olfactory bulb and neocortex. This binding probably represents the 5-ht₅ₐ receptor. They also observed high densities of [¹²⁵I]LSD binding (in the presence of clozapine and spiperone) in the medial habenula of wild-type and knockout mice. However, 5-carboxamidotryptamine competed for [¹²⁵I]LSD binding with an affinity of 2 nM in the olfactory bulb and neocortex of wild-type mice and of 30 nM in the habenula of knockout mice, suggesting that binding in the habenula might be accounted for by 5-ht₅₆ receptors (Waeber et al., 1998). Those results were somewhat similar to those obtained using an in situ hybridization assay, in which the 5-ht₅ₐ receptor mRNA was located predominantly in the cerebral cortex, the hippocampus, the habenula, the olfactory bulb, and the granular layer of the cerebellum of the mouse (Plassat et al., 1992). Reverse transcription-polymerase chain reaction of the human 5-ht₅ₐ receptor showed expression of mRNA in many brain areas, but none in peripheral tissues (Rees et al., 1994).

#### 5.1. Functional coupling of the 5-hydroxytryptamine₅ receptors to signaling pathways

As of yet, the 5-ht₅ receptors have not been convincingly linked to specific physiological effects or signal transduction cascades in mammalian cells. For example, when expressed in COS-7 cells and NIH 3T3 cells, 5-ht₅ receptors were unable to modulate AC activity (Plassat et al., 1992). Two studies have suggested that 5-ht₅ₐ receptors might be capable of inhibiting forskolin-stimulated cAMP accumulation. Carson et al. (1996) presented evidence that the 5-ht₅ₐ receptor heterologously expressed in C6 glioma cells could inhibit cAMP accumulation. Similarly, when the 5-ht₅ₐ receptor was
expressed at very high levels in HEK 293 cells, it was shown to inhibit cAMP accumulation (Francken et al., 1998). Putative 5-ht$_{5a}$/5-ht$_{5b}$ receptor binding to $[^{125}\mathrm{I}]$LSD in the brain (Waeber et al., 1998) and transfected cells (Plassat et al., 1992) is GTP-sensitive, suggesting that these receptors do couple to G-proteins. However, the specific G-proteins to which these receptors couple, their downstream signals, and physiological effects remain elusive.

### 6. The 5-hydroxytryptamine$_{6}$ receptor

Two groups cloned the rat 5-HT$_{6}$ receptor cDNA in 1993, although there was disagreement over the sequence of this receptor (Monsma et al., 1993; Ruat et al., 1993a). This was subsequently resolved as a sequencing error after the cloning of the human 5-HT$_{6}$ receptor in 1996 (Kohen et al., 1996). The human 5-HT$_{6}$ receptor is a 440 amino acid protein. The gene contains two introns that correspond to regions of the putative i3 and e3 loops (Monsma et al., 1993; Ruat et al., 1993a). The gene for the receptor maps to the human chromosome region 1p35-p36 (Kohen et al., 1996). The 5-HT$_{6}$ receptor stimulates AC and has high affinity for typical and atypical antipsychotics, including clozapine. The receptor is expressed in several brain regions, most prominently in the caudate nucleus, the olfactory tubercle, the striatum, the hippocampus, and the nucleus accumbens (Gerard et al., 1996, 1997; Grimaldi et al., 1998; Sleight et al., 1998). Low levels of 5-HT$_{6}$ receptor mRNA are also expressed in the adrenal gland and the stomach (Monsma et al., 1993; Ruat et al., 1993a).

Surprisingly, 5-HT$_{6}$ receptors appear to regulate cholinergic (rather than dopaminergic) neurotransmission in the brain, implicating it as a target for the treatment of learning and memory disorders (Bourson et al., 1998; Branchek & Blackburn, 2000).

#### 6.1. The 5-hydroxytryptamine$_{6}$ receptor activates adenylyl cyclase

Transfection studies have shown that the 5-HT$_{6}$ receptor activates AC (Ruat et al., 1993a; Kohen et al., 1996; Baker et al., 1998; Grimaldi et al., 1998). 5-HT$_{6}$-like receptors have been shown to stimulate AC in striatal neurons in culture (Sebben et al., 1994) and in pig caudate membranes (Schoeffter & Waeber, 1994). When transfected into HEK 293 cells, the 5-HT$_{6}$ receptor stimulates AC5, a G$_{s}$-sensitive AC, but not AC1 or AC8, which are CaM-stimulated ACs. In contrast, 5-HT$_{7}$ receptors expressed in the same cells could also activate AC1 and AC8 (Baker et al., 1998).

#### 6.2. The 5-hydroxytryptamine$_{6}$ receptor splice variants

Because of the presence of introns in the putative i3 and e3 loops of the 5-HT$_{6}$ receptor, alternative splice variants of

this receptor could exist. Thus far, only two truncation mutants have been identified. The first is expressed in brain, but is probably not functional as it deletes the entire seventh transmembrane region of the receptor (Monsma et al., 1993). Another truncation mutant of the human 5-HT$_{6}$ receptor in which the protein is prematurely terminated in the third transmembrane region has been shown to encode a nonfunctional protein (Olsen et al., 1999).

### 7. The 5-hydroxytryptamine$_{7}$ receptor

The 5-HT$_{7}$ receptor is the third 5-HT receptor subtype shown to couple to G$_{s}$ (Bard et al., 1993; Lovenberg et al., 1993a; Plassat et al., 1993; Ruat et al., 1993b; Shen et al., 1993). It is highly expressed in the CNS, especially in the hippocampus, the hypothalamus, and the neocortex. It has been speculated to participate in the control of circadian rhythm because it is expressed in the suprachiasmatic nucleus (Lovenberg et al., 1993a; Stowe & Barnes, 1998). The 5-HT$_{7}$ receptor is also expressed in glial cells (Hirst et al., 1997; Shimizu et al., 1996), the spleen (Shen et al., 1993), vascular smooth muscle (Becker et al., 1992; Bard et al., 1993; Ullmer et al., 1995; Schoeffter et al., 1996), and the intestine (Bard et al., 1993). It has a high affinity for atypical antipsychotic agents, and it may mediate some of their effects (Shen et al., 1993). It is also expressed in the periphery, where it mediates relaxation of smooth muscle in various organs (Eglen et al., 1997).

5-HT$_{7}$ receptors have been isolated from a number of mammalian species (Bard et al., 1993; Lovenberg et al., 1993a; Meyerhof et al., 1993; Plassat et al., 1993; Ruat et al., 1993b; Shen et al., 1993; Tsou et al., 1994) and also from *X. laevis* (Nelson et al., 1995). These receptors appear to be homologues to the fruit fly 5-HT$_{\mathrm{drol}}$ receptor (Witz et al., 1990). The human 5-HT$_{7}$ receptor initially was reported to be a protein of 445 amino acids, with 57% homology with the *Drosophila melanogaster* 5-HT$_{\mathrm{drol}}$ receptor in the transmembrane regions, but only 39–53% homology with cloned human 5-HT$_{1}$, 5-HT$_{2}$, 5-HT$_{5}$, and 5-HT$_{6}$ receptors. Surprisingly, there is only 39% homology with the 5-HT$_{6}$ receptor within the transmembrane regions (Bard et al., 1993). The human 5-HT$_{7}$ receptor gene is located on chromosome 10 (10q21-q24) (Gelernter et al., 1995), and contains two introns (Ruat et al., 1993b; Erdmann et al., 1996; Heidmann et al., 1997).

#### 7.1. The 5-hydroxytryptamine$_{7}$ receptor splice variants

The presence of introns in the 5-HT$_{7}$ receptor gene is significant in that a number of functional splice variants of this receptor have been identified. No splice variants have been reported for the first intron, which is in the putative i2 loop of the receptor. The second intron corresponds to the carboxyl terminus of the 5-HT$_{7}$ receptor, from which at least
four functional splice variants have been documented. The first clue that functional splice variants existed came from the observation that the sequence identified by Lovenberg and colleagues was truncated by 13 amino acids, compared with other cloned sequences, and that the truncation occurred at the second intron (Bard et al., 1993; Lovenberg et al., 1993a; Shen et al., 1993). Subsequently, four splice variants, termed 5-HT<sub>7a</sub>, 5-HT<sub>7b</sub>, 5-HT<sub>7c</sub>, and 5-HT<sub>7d</sub>, were identified by several groups (Heidmann et al., 1997, 1998; Jasper et al., 1997; Stam et al., 1997). The 5-HT<sub>7a</sub>, 5-HT<sub>7b</sub>, and 5-HT<sub>7c</sub> receptor isoforms have been shown to be expressed in rats, whereas the 5-HT<sub>7a</sub>, 5-HT<sub>7b</sub>, and 5-HT<sub>7d</sub> receptor isoforms have been shown to be expressed in humans (Heidmann et al., 1998). The three human splice variants encode proteins of 448 (5-HT<sub>7a</sub>), 435 (5-HT<sub>7b</sub>), and 479 (5-HT<sub>7d</sub>) amino acids.

The functional consequences of the individual splice variants are not clear, although all of them seem to be able to stimulate AC (Jasper et al., 1997; Stam et al., 1997; Heidmann et al., 1998). However, because the different variants may have differing numbers of phosphorylation sites, their regulation by kinases may be different. An additional difference in the splice variants is the presence or absence of PDZ motifs in the distal carboxyl terminus. The 5-HT<sub>7a</sub> and 5-HT<sub>7d</sub> receptors do not have a PDZ motif, whereas the 5-HT<sub>7b</sub> and 5-HT<sub>7c</sub> receptors have group II and group I PDZ motifs, respectively (Hamblin et al., 1998).

### 7.2. The 5-hydroxytryptamine<sub>7</sub> receptor activates adenylyl cyclase

Transfection studies have shown that the 5-HT<sub>7</sub> receptor stimulates AC in mammalian (Bard et al., 1993; Lovenberg et al., 1993a; Plassat et al., 1993; Ruat et al., 1993b; Shen et al., 1993; Tsou et al., 1994; Heidmann et al., 1997, 1998; Stam et al., 1997) and insect Sf9 cells (Hirst et al., 1997). Presumably, most of the effects of the 5-HT<sub>7</sub> receptor are mediated through coupling to G<sub>s</sub>. In that regard, the i3 loop of the 5-HT<sub>7</sub> receptor has been shown to be critical in coupling to G-proteins (Obosi et al., 1997). The 5-HT<sub>7a</sub> receptor stimulates several forms of AC, including G<sub>s</sub>-sensitive AC5 and AC1 and AC8 (Baker et al., 1998). The ability of the 5-HT<sub>7a</sub> receptor to activate those latter two isoforms of AC raises the issue of whether this receptor can also couple to G-proteins other than G<sub>s</sub>. Baker et al. (1998) partially investigated the question by demonstrating that activation of the receptor resulted in increases in intracellular Ca<sup>2+</sup>, which is consistent with the known Ca<sup>2+</sup>/CaM sensitivity of AC1 and AC8 (Mons et al., 1998; Taussig & Zimmermann, 1998; Hurley, 1999). However, this effect was independent of PKC, phosphoinositide turnover, and G<sub>i</sub>-proteins (Baker et al., 1998). These results are very intriguing in light of studies showing that 5-HT can activate Ca<sup>2+</sup>-stimulated AC in the rat cerebral cortex and hippocampus (Mork & Geisler, 1990).

### 7.3. The 5-hydroxytryptamine<sub>7</sub> receptor activates the extracellular signal-regulated kinase

Errico et al. (2001) recently reported that 5-HT<sub>7</sub> receptors endogenously expressed by cultured rat hippocampal neurons stimulate the MAP kinase ERKs ERK1 and ERK2. Details of the signaling pathway used by the receptor to activate ERK remain to be elucidated, but the stimulation of ERK was not sensitive to pertussis toxin and, therefore, is unlikely to involve G<sub>i/o</sub>-proteins (Errico et al., 2001).

### 7.4. The 5-hydroxytryptamine<sub>7</sub> receptor stimulates vasorelaxation

The 5-HT<sub>7</sub> receptor stimulates vasorelaxation (Ullmer et al., 1995; Terron, 1996; Villalon et al., 1997). The signaling pathway involved in vasorelaxation by the 5-HT<sub>7</sub> receptor is not known, but it has been hypothesized to involve release of NO (Morecroft & MacLean, 1998) or cAMP-induced inhibition of myosin light chain kinase in vascular smooth muscle cells (Ullmer et al., 1995).

### 7.5. The 5-hydroxytryptamine<sub>7</sub> receptor modulates slow afterhyperpolarization

The 5-HT<sub>7</sub> receptor has been implicated in the inhibition of Ca<sup>2+</sup>-spike-induced slow afterhyperpolarization amplitude in CA3 hippocampal neurons, although the signaling pathway used to modulate this conductance is not known (Bacon & Beck, 2000). In contrast, Chapin and Andrade (2000, 2001a, 2001b) have shown that the 5-HT<sub>7</sub> receptor can actually stimulate afterdepolarization. They performed detailed studies of the regulation of afterhyperpolarization by the 5-HT<sub>7</sub> receptor in neurons from the anterodorsal nucleus of the thalamus (Chapin & Andrade, 2001a), and showed that the signal was mediated by cAMP and by the hyperpolarization-activated nonselective cation current (Chapin & Andrade, 2001b). Furthermore, the afterdepolarization was independent of PKA (Chapin & Andrade, 2001b) or alterations in cellular Ca<sup>2+</sup> levels (Chapin & Andrade, 2000), suggesting that novel signal transduction pathways may mediate this effect.

### 8. Conclusion

The rich diversity of coupling of the 5-HT receptors to distinct (and sometimes opposing) signaling pathways is becoming more broadly appreciated as a mechanism of ‘fine-tuning’ receptor response to the requirements of the specific cells and tissues in which they are expressed. The diversity of signaling is mediated by a large number of 5-HT receptors (14 genomically encoded) and their variants (over 20 splice variants or variants resulting from mRNA editing), and also by cell-specific and ligand-specific variables.

diversity of signaling is so staggering that one naturally might ask: “What is the purpose of this immense diversity of signaling mechanisms coupled to 5-HT receptors?” Unfortunately, there currently are no clear-cut answers to this fundamental question. One of us reviewed this topic several years ago, and many of the points that were raised in that review remain pertinent today (Raymond, 1995). We will speculate somewhat on this issue in the next two paragraphs.

The diversity in 5-HT receptor signals may provide different cells with the capacity to determine the specific effectors that are modulated by 5-HT receptors, based on the intrinsic or variable needs of the cells or the organs in which they reside. Thus, different cell types could respond differently to the same stimulus, based on their anatomical location, physiological state, and functions. These differential responses in distinct cell types need not be haphazard; they would most likely be coordinated into some type of “response network.” For example, glial cells and neurons could intrinsically coordinate their responsiveness to 5-HT (or other 5-HT receptor ligands), based on their complements of 5-HT receptors, G-proteins, and effectors. This makes sense, as these cell types should be intrinsically able to function in a coordinated manner. Their coordinated responses should also be plastic, in that they can be shaped by physiological alterations, such as hypoxia or hormonal influences.

Both the coordination and plasticity of cellular responses to 5-HT receptors could be influenced by variables such as (1) the types and numbers of receptors present in each cell type; (2) the subcellular localizations of the receptors and their targets into macrodomains or organelles; (3) physical or functional compartmentalization of the signaling components into microdomains; (4) differential and/or overlapping sensitivities to various ligands; (5) differential rates of receptor synthesis, internalization, degradation, and desensitization; (6) differential signaling from different ligands acting through single receptor subtypes due to “agonist-directed trafficking;” (7) the presence or absence of receptor reserve; (8) different levels of spontaneous (non-agonist-mediated) receptor activity; (9) co-stimulation with other receptor types; (10) non-G-protein-mediated signals; and (11) the presence or absence of regulatory factors. These same differences could also be applied to individual G-proteins and effectors. Moreover, all of those variables need to be recognized as dynamic. Thus, cells can modify their capacity for signaling from 5-HT receptors to effectors in order to produce distinct (or even opposing) responses. Thus, the specific response of a cell to 5-HT will be determined as the sum of many variables. That is why signal transduction studies performed in transfected cells ultimately must be validated contextually in cells, organs, or animals in which the 5-HT receptors are endogenously expressed.

This review has highlighted some fascinating new insights into 5-HT receptor signaling that have resulted from multiple lines of investigation over the last decade.

Substantial recent progress has been made in defining the potential diversity of signaling from 5-HT receptors. The discovery process has been accelerated by the cloning of cDNA and genes for 5-HT receptors, by transfection studies, by the development of new ligands, by the creation of transgenic and receptor knockout animals, and by the generation of receptor-specific tools, such as antibodies and selective mRNA probes. Despite the accelerating pace of exciting discoveries in this field, one is struck by a sense that the most exciting new discoveries are yet to come.

## Acknowledgements

The authors were supported by grants from the Department of Veterans Affairs (Merit Awards to M.N.G. and J.R.R. and a REAP Award to Y.V.M., A.G., J.R.R., G.C., and M.N.G.), the National Institutes of Health (DK52448 and DK54720 to J.R.R., DK053981 to T.W.G., and DK02694 to Y.V.M.), and a laboratory endowment jointly supported by the M.U.S.C. Division of Nephrology and Dialysis Clinics, Incorporated (J.R.R.). A.G. and M.N.G. were Associate Investigators of the Department of Veterans Affairs during the composition of this manuscript.

## References

Abdel-Baset, H., Bozovic, V., Szyf, M., & Albert, P. R. (1992). Conditional transformation mediated via a pertussis toxin-sensitive receptor signaling pathway. *Mol Endocrinol* 6, 730–740.

Abramowski, D., Rigo, M., Duc, D., Hoyer, D., & Staufenbiel, M. (1995). Localization of the 5-hydroxytryptamine<sub>2C</sub> receptor protein in human and rat brain using specific antisera. *Neuropharmacology* 34, 1635–1645.

Adayev, T., El-Sherif, Y., Barua, M., Penington, N. J., & Banerjee, P. (1999). Agonist stimulation of the serotonin<sub>1A</sub> receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells. *J Neurochem* 72, 1489–1496.

Adham, N., Romanenko, P., Hartig, P., Weinshank, R. L., & Branchek, T. (1992). The rat 5-hydroxytryptamine<sub>1B</sub> receptor is the species homologue of the human 5-hydroxytryptamine<sub>1D</sub> beta receptor. *Mol Pharmacol* 41, 1–7.

Adham, N., Borden, L. A., Schechter, L. E., Gustafson, E. L., Cochran, T. L., Vaysse, P. J., Weinshank, R. L., & Branchek, T. A. (1993a). Cell-specific coupling of the cloned human 5-HT<sub>1F</sub> receptor to multiple signal transduction pathways. *Naunyn Schmiedebergs Arch Pharmacol* 348, 566–575.

Adham, N., Kao, H. T., Schechter, L. E., Bard, J., Olsen, M., Urquhart, D., Durkin, M., Hartig, P. R., Weinshank, R. L., & Branchek, T. A. (1993b). Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. *Proc Natl Acad Sci USA* 90, 408–412.

Adham, N., Vaysse, P. J., Weinshank, R. L., & Branchek, T. A. (1994). The cloned human 5-HT<sub>1E</sub> receptor couples to inhibition and activation of adenyllyl cyclase via two distinct pathways in transfected BS-C-1 cells. *Neuropharmacology* 33, 403–410.

Ahlenius, S., & Larsson, K. (1989). Antagonism by pindolol, but not betaxolol, of 8-OH-DPAT-induced facilitation of male rat sexual behavior. *J Neural Transm* 77, 163–170.

Aiyar, J., Grissmer, S., & Chandy, K. G. (1993). Full-length and truncated Kv1.3 K⁺ channels are modulated by 5-HT₁c receptor activation and independently by PKC. *Am J Physiol* 265, C1571–C1578.

Albert, P. R., Zhou, Q. Y., Van Tol, H. H., Bunzow, J. R., & Civelli, O. (1990). Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine₁A receptor gene. *J Biol Chem* 265, 5825–5832.

Albert, P. R., Sajedi, N., Lemonde, S., & Ghahremani, M. H. (1999). Constitutive G₁₂-dependent activation of adenylyl cyclase type II by the 5-HT₁A receptor. Inhibition by anxiolytic partial agonists. *J Biol Chem* 274, 35469–35474.

Albuquerque, F. C., Smith, E. H., & Kellum, J. M. (1998). 5-HT induces cAMP production in crypt colonocytes at a 5-HT₄ receptor. *J Surg Res* 77, 137–140.

Amlaiky, N., Ramboz, S., Boschert, U., Plassat, J. L., & Hen, R. (1992). Isolation of a mouse “5HT1E-like” serotonin receptor expressed predominantly in hippocampus. *J Biol Chem* 267, 19761–19764.

Andrade, R., & Chaput, Y. (1991). 5-Hydroxytryptamine4-like receptors mediate the slow excitatory response to serotonin in the rat hippocampus. *J Pharmacol Exp Ther* 257, 930–937.

Andrade, R., & Nicoll, R. A. (1987). Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. *J Physiol* 394, 99–124.

Ansanay, H., Dumuis, A., Sebben, M., Bockaert, J., & Fagni, L. (1995). cAMP-dependent, long-lasting inhibition of a K⁺ current in mammalian neurons. *Proc Natl Acad Sci USA* 92, 6635–6639.

Auch-Schwenk, W., Paetsch, I., Krackhardt, F., Grafe, M., Hetzer, R., & Fleck, E. (2000). Modulation of contractions to ergonovine and methylergonovine by nitric oxide and thromboxane A₂ in the human coronary artery. *J Cardiovasc Pharmacol* 36, 631–639.

Aune, T. M., McGrath, K. M., Sarr, T., Bombara, M. P., & Kelley, K. A. (1993). Expression of 5HT₁a receptors on activated human T cells. Regulation of cyclic AMP levels and T cell proliferation by 5-hydroxytryptamine. *J Immunol* 151, 1175–1183.

Bach, T., Syversveen, T., Kvingedal, A. M., Krobot, K. A., Brattelid, T., Kaumann, A. J., & Levy, F. O. (2001). 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. *Naunyn Schmiedebergs Arch Pharmacol* 363, 146–160.

Backstrom, J. R., Chang, M. S., Chu, H., Niswender, C. M., & Sanders-Bush, E. (1999). Agonist-directed signaling of serotonin 5-HT₂C receptors: differences between serotonin and lysergic acid diethylamide (LSD). *Neuropsychopharmacology* 21, 77S–81S.

Backstrom, J. R., Price, R. D., Reasoner, D. T., & Sanders-Bush, E. (2000). Deletion of the serotonin 5-HT₂C receptor PDZ recognition motif prevents receptor phosphorylation and delays resensitization of receptor responses. *J Biol Chem* 275, 23620–23626.

Bacon, W. L., & Beck, S. G. (2000). 5-Hydroxytryptamine₇ receptor activation decreases slow afterhyperpolarization amplitude in CA3 hippocampal pyramidal cells. *J Pharmacol Exp Ther* 294, 672–679.

Baker, L. P., Nielsen, M. D., Impey, S., Metcalf, M. A., Poser, S. W., Chan, G., Obrietan, K., Hamblin, M. W., & Storm, D. R. (1998). Stimulation of type 1 and type 8 Ca²⁺/calmodulin-sensitive adenylyl cyclases by the Gₛ-coupled 5-hydroxytryptamine subtype 5-HT₇A receptor. *J Biol Chem* 273, 17469–17476.

Balcells-Olivero, M., Cousins, M. S., & Seiden, L. S. (1998). Holtzman and Harlan Sprague-Dawley rats: differences in DRL 72-sec performance and 8-hydroxy-di-propylamino tetralin-induced hypothermia. *J Pharmacol Exp Ther* 286, 742–752.

Bard, J. A., Zgombick, J., Adham, N., Vaysse, P., Branchek, T. A., & Weinshank, R. L. (1993). Cloning of a novel human serotonin receptor (5-HT₇) positively linked to adenylate cyclase. *J Biol Chem* 268, 23422–23426.

Barnes, N. M., & Sharp, T. (1999). A review of central 5-HT receptors and their function. *Neuropharmacology* 38, 1083–1152.

Barr, A. J., Brass, L. F., & Manning, D. R. (1997). Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells.


A direct evaluation of selectivity in receptor-G protein coupling. *J Biol Chem* 272, 2223–2229.

Bartrup, J. T., & Newberry, N. R. (1994). 5-HT₂A receptor-mediated outward current in C6 glioma cells is mimicked by intracellular IP₃ release. *Neuroreport* 5, 1245–1248.

Bayliss, D. A., Umemiya, M., & Berger, A. J. (1995). Inhibition of N- and P-type calcium currents and the after-hyperpolarization in rat motor neurones by serotonin. *J Physiol* 485, 635–647.

Becamel, C., Figge, A., Poliak, S., Dumuis, A., Peles, E., Bockaert, J., Lubbert, H., & Ullmer, C. (2001). Interaction of serotonin 5-HT₂C receptors with PDZ10 of the multi PDZ protein MUPP1. *J Biol Chem* 275, 12974–12982.

Becker, B. N., Gettys, T. W., Middleton, J. P., Olsen, C. L., Albers, F. J., Lee, S. L., Fanburg, B. L., & Raymond, J. R. (1992). 8-Hydroxy-2-(di-n-propylamino)tetralin-responsive 5-hydroxytryptamine₄-like receptor expressed in bovine pulmonary artery smooth muscle cells. *Mol Pharmacol* 42, 817–825.

Berg, K. A., Clarke, W. P., Chen, Y., Ebersole, B. J., McKay, R. D., & Maayani, S. (1994a). 5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms. *Mol Pharmacol* 45, 826–836.

Berg, K. A., Clarke, W. P., Sailstad, C., Saltzman, A., & Maayani, S. (1994b). Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. *Mol Pharmacol* 46, 477–484.

Berg, K. A., Maayani, S., & Clarke, W. P. (1996). 5-Hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. *Mol Pharmacol* 50, 1017–1023.

Berg, K. A., Maayani, S., Goldfarb, J., & Clarke, W. P. (1998). Pleiotropic behavior of 5-HT₂A and 5-HT₂C receptor agonists. *Ann N Y Acad Sci* 861, 104–110.

Berridge, M. J., Bootman, M. D., & Lipp, P. (1998). Calcium — a life and death signal. *Nature* 395, 645–648.

Bertin, B., Freissmuth, M., Breyer, R. M., Schutz, W., Strosberg, A. D., & Marullo, S. (1992). Functional expression of the human serotonin 5-HT₁A receptor in Escherichia coli. Ligand binding properties and interaction with recombinant G protein alpha-subunits. *J Biol Chem* 267, 8200–8206.

Bhatnagar, A., Willins, D. L., Gray, J. A., Woods, J., Benovic, J. L., & Roth, B. L. (2000). The dynamin-dependent, arrestin-independent internalization of 5-HT2A serotonin receptors reveals differential sorting of arrestins and 5-HT₂A receptors during endocytosis. *J Biol Chem* 276, 8269–8277.

Bianchi, C., Siniscalchi, A., & Beani, L. (1990). 5-HT₁A agonists increase and 5-HT₃ agonists decrease acetylcholine efflux from the cerebral cortex of freely-moving guinea-pigs. *Br J Pharmacol* 101, 448–452.

Blier, P., Bergeron, R., & de Montigny, C. (1997). Selective activation of postsynaptic 5-HT₁A receptors induces rapid antidepressant response. *Neuropsychopharmacology* 16, 333–338.

Blondel, O., Vandecasteele, G., Gastineau, M., Leclerc, S., Dahmoune, Y., Langlois, M., & Fischmeister, R. (1997). Molecular and functional characterization of a 5-HT₄ receptor cloned from human atrium. *FEBS Lett* 412, 465–474.

Blondel, O., Gastineau, M., Dahmoune, Y., Langlois, M., & Fischmeister, R. (1998). Cloning, expression, and pharmacology of four human 5-hydroxytryptamine₄ receptor isoforms produced by alternative splicing in the carboxyl terminus. *J Neurochem* 70, 2252–2261.

Bockaert, J., Sebben, M., & Dumuis, A. (1990). Pharmacological characterization of 5-hydroxytryptamine₄ (5-HT₄) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. *Mol Pharmacol* 37, 408–411.

Bockaert, J., Ansanay, H., Letty, S., Marchetti-Gauthier, E., Roman, F., Rondouin, G., Fagni, L., Soumireu-Mourat, B., & Dumuis, A. (1998a). 5-HT4 receptors: long-term blockade of K⁺ channels and effects on olfactory memory. *C R Acad Sci III* 321, 217–221.

Bockaert, J., Claeyesen, S., Sebben, M., & Dumuis, A. (1998b). 5-HT₄

receptors: gene, transduction and effects on olfactory memory. *Ann N Y Acad Sci* 861, 1–15.

Boddeke, H. W., Fargin, A., Raymond, J. R., Schoeffter, P., & Hoyer, D. (1992). Agonist/antagonist interactions with cloned human 5-HT<sub>1A</sub> receptors: variations in intrinsic activity studied in transfected HeLa cells. *Naunyn Schmiedebergs Arch Pharmacol* 345, 257–263.

Boess, F. G., & Martin, I. L. (1994). Molecular biology of 5-HT receptors. *Neuropharmacology* 33, 275–317.

Bonhaus, D. W., Bach, C., DeSouza, A., Salazar, F. H., Matsuoka, B. D., Zuppan, P., Chan, H. W., & Eglen, R. M. (1995). The pharmacology and distribution of human 5-hydroxytryptamine<sub>2B</sub> (5-HT<sub>2B</sub>) receptor gene products: comparison with 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *Br J Pharmacol* 115, 622–628.

Bouhelal, R., Smounya, L., & Bockaert, J. (1988). 5-HT<sub>1B</sub> receptors are negatively coupled with adenylate cyclase in rat substantia nigra. *Eur J Pharmacol* 151, 189–196.

Bourson, A., Boess, F. G., Bos, M., & Sleight, A. J. (1998). Involvement of 5-HT<sub>6</sub> receptors in nigro-striatal function in rodents. *Br J Pharmacol* 125, 1562–1566.

Branchek, T. A., & Blackburn, T. P. (2000). 5-ht<sub>6</sub> receptors as emerging targets for drug discovery. *Annu Rev Pharmacol Toxicol* 40, 319–334.

Briddon, S. J., Leslie, R. A., & Elliott, J. M. (1998). Comparative desensitization of the human 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors expressed in the human neuroblastoma cell line SH-SY5Y. *Br J Pharmacol* 125, 727–734.

Bruinvels, A. T., Palacios, J. M., & Hoyer, D. (1993). Autoradiographic characterisation and localisation of 5-HT<sub>1D</sub> compared to 5-HT<sub>1B</sub> binding sites in rat brain. *Naunyn Schmiedebergs Arch Pharmacol* 347, 569–582.

Bruinvels, A. T., Landwehrmeyer, B., Gustafson, E. L., Durkin, M. M., Mengod, G., Branchek, T. A., Hoyer, D., & Palacios, J. M. (1994a). Localization of 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub> alpha, 5-HT<sub>1E</sub> and 5-HT<sub>1F</sub> receptor messenger RNA in rodent and primate brain. *Neuropharmacology* 33, 367–386.

Bruinvels, A. T., Landwehrmeyer, B., Probst, A., Palacios, J. M., & Hoyer, D. (1994b). A comparative autoradiographic study of 5-HT<sub>1D</sub> binding sites in human and guinea-pig brain using different radioligands. *Brain Res Mol Brain Res* 21, 19–29.

Budhoo, M. R., Harris, R. P., & Kellum, J. M. (1996a). 5-Hydroxytryptamine-induced Cl- transport is mediated by 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptors in the rat distal colon. *Eur J Pharmacol* 298, 137–144.

Budhoo, M. R., Harris, R. P., & Kellum, J. M. (1996b). The role of the 5-HT<sub>4</sub> receptor in Cl- secretion in human jejunal mucosa. *Eur J Pharmacol* 314, 109–114.

Buhlen, M., Fink, K., Boing, C., & Gothert, M. (1996). Evidence for presynaptic location of inhibitory 5-HT<sub>1D</sub> beta-like autoreceptors in the guinea-pig brain cortex. *Naunyn Schmiedebergs Arch Pharmacol* 353, 281–289.

Burns, C. M., Chu, H., Rueter, S. M., Hutchinson, L. K., Canton, H., Sanders-Bush, E., & Emeson, R. B. (1997). Regulation of serotonin-2C receptor G-protein coupling by RNA editing. *Nature* 387, 303–308.

Butkerait, P., Zheng, Y., Hallak, H., Graham, T. E., Miller, H. A., Burris, K. D., Molinoff, P. B., & Manning, D. R. (1995). Expression of the human 5-hydroxytryptamine<sub>1A</sub> receptor in Sf9 cells. Reconstitution of a coupled phenotype by co-expression of mammalian G protein subunits. *J Biol Chem* 270, 18691–18699.

Cadogan, A. K., Kendall, D. A., & Marsden, C. A. (1994). Serotonin 5-HT<sub>1A</sub> receptor activation increases cyclic AMP formation in the rat hippocampus in vivo. *J Neurochem* 62, 1816–1821.

Canton, H., Emeson, R. B., Barker, E. L., Backstrom, J. R., Lu, J. T., Chang, M. S., & Sanders-Bush, E. (1996). Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine<sub>2C</sub> receptor produced by alternative splicing. *Mol Pharmacol* 50, 799–807.

Carmena, M. J., Camacho, A., Solano, R. M., Montalvo, L., Garcia-Lopez, E., Arias, A., & Prieto, J. C. (1998). 5-Hydroxytryptamine<sub>1A</sub> receptor-mediated effects on adenylate cyclase and nitric oxide synthase activities in rat ventral prostate. *Cell Signal* 10, 583–587.

Carson, M. J., Thomas, E. A., Danielson, P. E., & Sutcliffe, J. G. (1996). The serotonin 5-HT<sub>5A</sub> receptor is expressed predominantly by astro-

cytes in which it inhibits cAMP accumulation: a mechanism for neural suppression of reactive astrocytes. *Glia* 17, 317–326.

Cattaneo, M. G., Palazzi, E., Bondiolotti, G., & Vicentini, L. M. (1994). 5-HT<sub>1D</sub> receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma. *Eur J Pharmacol* 268, 425–430.

Cattaneo, M. G., Fesce, R., & Vicentini, L. M. (1995). Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HT<sub>1A</sub> and 5-HT<sub>1D</sub> receptors. *Eur J Pharmacol* 291, 209–211.

Chanda, P. K., Minchin, M. C., Davis, A. R., Greenberg, L., Reilly, Y., McGregor, W. H., Bhat, R., Lubeck, M. D., Mizutani, S., & Hung, P. P. (1993). Identification of residues important for ligand binding to the human 5-hydroxytryptamine<sub>1A</sub> serotonin receptor. *Mol Pharmacol* 43, 516–520.

Chang, M., Zhang, L., Tam, J. P., & Sanders-Bush, E. (2000). Dissecting G protein-coupled receptor signaling pathways with membrane-permeable blocking peptides. Endogenous 5-HT<sub>2C</sub> receptors in choroid plexus epithelial cells. *J Biol Chem* 275, 7021–7029.

Chapin, E. M., & Andrade, R. (2000). Calcium-independent afterdepolarization regulated by serotonin in anterior thalamus. *J Neurophysiol* 83, 3173–3176.

Chapin, E. M., & Andrade, R. (2001a). A 5-HT<sub>7</sub> receptor-mediated depolarization in the anterodorsal thalamus. I. Pharmacological characterization. *J Pharmacol Exp Ther* 297, 395–402.

Chapin, E. M., & Andrade, R. (2001b). A 5-HT<sub>7</sub> receptor-mediated depolarization in the anterodorsal thalamus. II. Involvement of the hyperpolarization-activated current I(h). *J Pharmacol Exp Ther* 297, 403–409.

Chen, H., Li, H., & Chuang, D. M. (1995). Role of second messengers in agonist up-regulation of 5-HT<sub>2A</sub> receptor binding sites in cerebellar granule neurons: involvement of calcium influx and a calmodulin-dependent pathway. *J Pharmacol Exp Ther* 275, 674–680.

Chen, N. H., & Reith, M. E. (1995). Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin. *J Neurochem* 64, 1585–1597.

Chen, Y., & Penington, N. J. (1997). QEHA27, a peptide that binds to G-protein beta gamma-subunits, reduces the inhibitory effect of 5-HT on the Ca<sup>2+</sup> current of rat dorsal raphe neurons. *Neurosci Lett* 224, 87–90.

Chen, Y., Baez, M., & Yu, L. (1994). Functional coupling of the 5-HT<sub>2C</sub> serotonin receptor to G proteins in Xenopus oocytes. *Neurosci Lett* 179, 100–102.

Choi, D. S., Ward, S. J., Messaddeq, N., Launay, J. M., & Maroteaux, L. (1997). 5-HT<sub>2B</sub> receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. *Development* 124, 1745–1755.

Ciaranello, R. D., Tan, G. L., & Dean, R. (1990). G-protein-linked serotonin receptors in mouse kidney exhibit identical properties to 5-HT<sub>1B</sub> receptors in brain. *J Pharmacol Exp Ther* 252, 1347–1354.

Claeysen, S., Sebben, M., Journot, L., Bockaert, J., & Dumuis, A. (1996). Cloning, expression and pharmacology of the mouse 5-HT<sub>4L</sub> receptor. *FEBS Lett* 398, 19–25.

Claeysen, S., Faye, P., Sebben, M., Lemaire, S., Bockaert, J., Dumuis, A., & Taviaux, S. (1997). Assignment of 5-hydroxytryptamine receptor (HTR4) to human chromosome 5 bands q31->q33 by in situ hybridization. *Cytogenet Cell Genet* 78, 133–134.

Claeysen, S., Faye, P., Sebben, M., Taviaux, S., Bockaert, J., & Dumuis, A. (1998). 5-HT<sub>4</sub> receptors: cloning and expression of new splice variants. *Ann N Y Acad Sci* 861, 49–56.

Claeysen, S., Sebben, M., Becamel, C., Bockaert, J., & Dumuis, A. (1999). Novel brain-specific 5-HT<sub>4</sub> receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. *Mol Pharmacol* 55, 910–920.

Clarke, W. P., Yocca, F. D., & Maayani, S. (1996). Lack of 5-hydroxytryptamine<sub>1A</sub>-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. *J Pharmacol Exp Ther* 277, 1259–1266.

Claustre, Y., Benavides, J., & Scatton, B. (1991). Potential mechanisms involved in the negative coupling between serotonin 5-HT<sub>1A</sub> receptors

and carbachol-stimulated phosphoinositide turnover in the rat hippocampus. *J Neurochem* 56, 1276–1285.

Clawges, H. M., Depree, K. M., Parker, E. M., & Graber, S. G. (1997). Human 5-HT₁ receptor subtypes exhibit distinct G protein coupling behaviors in membranes from Sf9 cells. *Biochemistry* 36, 12930–12938.

Colino, A., & Halliwell, J. V. (1987). Differential modulation of three separate K-conductances in hippocampal CA1 neurons by serotonin. *Nature* 328, 73–77.

Conn, P. J., & Sanders-Bush, E. (1984). Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. *Neuropharmacology* 23, 993–996.

Conn, P. J., & Sanders-Bush, E. (1985). Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions. *J Pharmacol Exp Ther* 234, 195–203.

Consolo, S., Arnaboldi, S., Giorgi, S., Russi, G., & Ladinsky, H. (1994). 5-HT₄ receptor stimulation facilitates acetylcholine release in rat frontal cortex. *Neuroreport* 5, 1230–1232.

Cook, E. H., Fletcher, K. E., Wainwright, M., Marks, N., Yan, S. Y., & Leventhal, B. L. (1994). Primary structure of the human platelet serotonin 5-HT₂A receptor: identify with frontal cortex serotonin 5-HT₂A receptor. *J Neurochem* 63, 465–469.

Cowen, D. S., Sowers, R. S., & Manning, D. R. (1996). Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine₁A receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis. *J Biol Chem* 271, 22297–22300.

Cowen, D. S., Molinoff, P. B., & Manning, D. R. (1997). 5-Hydroxytryptamine₁A receptor-mediated increases in receptor expression and activation of nuclear factor-kappaB in transfected Chinese hamster ovary cells. *Mol Pharmacol* 52, 221–226.

Cowen, P. J., Clifford, E. M., Walsh, A. E., Williams, C., & Fairburn, C. G. (1996). Moderate dieting causes 5-HT2C receptor supersensitivity. *Psychol Med* 26, 1155–1159.

Cox, D. A., & Cohen, M. L. (1995). Is nitric oxide involved in 5-HT₂B receptor-mediated contraction in the rat stomach fundus? *Life Sci* 56, L333–L338.

Cox, D. A., Watts, S. W., & Cohen, M. L. (1996). Neomycin selectively inhibits 5-hydroxytryptamine-induced contraction in the guinea pig trachea. *J Pharmacol Exp Ther* 277, 954–959.

Cox, D. A., Blase, D. K., & Cohen, M. L. (1999). Bradykinin and phorbol ester but not 5-HT₂B receptor activation stimulate phospholipase D activity in the rat stomach fundus. *Prog Neuropsychopharmacol Biol Psychiatry* 23, 697–704.

Dascal, N., Lim, N. F., Schreibmayer, W., Wang, W., Davidson, N., & Lester, H. A. (1993). Expression of an atrial G-protein-activated potassium channel in Xenopus oocytes. *Proc Natl Acad Sci USA* 90, 6596–6600.

Davidson, C., & Stamford, J. A. (1996). Serotonin efflux in the rat ventral lateral geniculate nucleus assessed by fast cyclic voltammetry is modulated by 5-HT₁B and 5-HT₁D autoreceptors. *Neuropharmacology* 35, 1627–1634.

De Vivo, M., & Maayani, S. (1986). Characterization of the 5-hydroxytryptamine₁a receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. *J Pharmacol Exp Ther* 238, 248–253.

Della Rocca, G. J., Mukhin, Y. V., Garnovskaya, M. N., Daaka, Y., Clark, G. J., Luttrell, L. M., Lefkowitz, R. J., & Raymond, J. R. (1999). Serotonin 5-HT₁A receptor-mediated Erk activation requires calcium/calmodulin-dependent receptor endocytosis. *J Biol Chem* 274, 4749–4753.

Dickenson, J. M., & Hill, S. J. (1995). Coupling of an endogenous 5-HT₁B-like receptor to increases in intracellular calcium through a pertussis toxin-sensitive mechanism in CHO-K1 cells. *Br J Pharmacol* 116, 2889–2896.

Dickenson, J. M., & Hill, S. J. (1998). Human 5-HT₁B receptor stimulated inositol phospholipid hydrolysis in CHO cells: synergy with Gq-coupled receptors. *Eur J Pharmacol* 348, 279–285.

DiMagno, L., Dascal, N., Davidson, N., Lester, H. A., & Schreibmayer, W. (1996). Serotonin and protein kinase C modulation of a rat brain inward rectifying K⁺ channel expressed in xenopus oocytes. *Pflugers Arch* 431, 335–340.

Dissmann, E., Wischmeyer, E., Spauschus, A., Pfeil, D. V., Karschin, C., & Karschin, A. (1996). Functional expression and cellular mRNA localization of a G protein-activated K⁺ inward rectifier isolated from rat brain. *Biochem Biophys Res Commun* 223, 474–479.

Done, C. J., & Sharp, T. (1994). Biochemical evidence for the regulation of central noradrenergic activity by 5-HT₁A and 5-HT₂ receptors: microdialysis studies in the awake and anaesthetized rat. *Neuropharmacology* 33, 411–421.

Dooley, A. E., Pappas, I. S., & Parnavelas, J. G. (1997). Serotonin promotes the survival of cortical glutamatergic neurons in vitro. *Exp Neurol* 148, 205–214.

Doupnik, C. A., Dessauer, C. W., Slepak, V. Z., Gilman, A. G., Davidson, N., & Lester, H. A. (1996). Time resolved kinetics of direct G beta 1 gamma 2 interactions with the carboxyl terminus of Kir3.4 inward rectifier K⁺ channel subunits. *Neuropharmacology* 35, 923–931.

Doupnik, C. A., Davidson, N., Lester, H. A., & Kofuji, P. (1997). RGS proteins reconstitute the rapid gating kinetics of Gβγ-activated inwardly rectifying K⁺ channels. *Proc Natl Acad Sci USA* 94, 10461–10466.

Dourish, C. T., Hutson, P. H., & Curzon, G. (1985). Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). *Brain Res Bull* 15, 377–384.

Dumuis, A., Bouhelal, R., Sebben, M., Cory, R., & Bockaert, J. (1988). A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. *Mol Pharmacol* 34, 880–887.

Duxon, M. S., Flanigan, T. P., Reavley, A. C., Baxter, G. S., Blackburn, T. P., & Fone, K. C. (1997). Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. *Neuroscience* 76, 323–329.

Eberle-Wang, K., Braun, B. T., & Simansky, K. J. (1994). Serotonin contracts the isolated rat pylorus via a 5-HT₂-like receptor. *Am J Physiol* 266, R284–R291.

Ebersole, B. J., Diglio, C. A., Kaufman, D. W., & Berg, K. A. (1993). 5-Hydroxytryptamine₁-like receptors linked to increases in intracellular calcium concentration and inhibition of cyclic AMP accumulation in cultured vascular smooth muscle cells derived from bovine basilar artery. *J Pharmacol Exp Ther* 266, 692–699.

Edagawa, Y., Saito, H., & Abe, K. (1998). 5-HT₁A receptor-mediated inhibition of long-term potentiation in rat visual cortex. *Eur J Pharmacol* 349, 221–224.

Eglen, R. M., Alvarez, R., Carter, D., Leung, E., Jakeman, L., To, Z., & Tsou, A. P. (1997). Cloned and native guinea pig 5-ht7 receptors. Characterization using an integrated approach. *Ann N Y Acad Sci* 812, 216–217.

Ellwood, A. J., & Curtis, M. J. (1997). Involvement of 5-HT₁B/₁D and 5-HT₂A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries. *Br J Pharmacol* 122, 875–884.

el Mansari, M., & Blier, P. (1996). Functional characterization of 5-HT₁D autoreceptors on the modulation of 5-HT release in guinea-pig mesencephalic raphe, hippocampus and frontal cortex. *Br J Pharmacol* 118, 681–689.

Erdmann, J., Nothen, M. M., Shimron-Abarbanell, D., Rietschel, M., Albus, M., Borrmann, M., Maier, W., Franzek, E., Korner, J., Weigelt, B., Fimmers, R., & Propping, P. (1996). The human serotonin 7 (5-HT₇) receptor gene: genomic organization and systematic mutation screening in schizophrenia and bipolar affective disorder. *Mol Psychiatry* 1, 392–397.

Eriksson, K. S., Stevens, D. R., & Haas, H. L. (2001). Serotonin excites tuberomammillary neurons by activation of Na⁺/Ca²⁺-exchange. *Neuropharmacology* 40, 345–351.

Erlander, M. G., Lovenberg, T. W., Baron, B. M., de Lecea, L., Danielson, P. E., Racke, M., Slone, A. L., Siegel, B. W., Foye, P. E., Cannon, K., Burns, J. E., & Sutcliffe, J. G. (1993). Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. *Proc Natl Acad Sci USA* 90, 3452–3456.

Errico, M., Crozier, R. A., Plummer, M. R., & Cowen, D. S. (2001). 5-HT₇ receptors activate the mitogen activated protein kinase extracellular

signal related kinase in cultured rat hippocampal neurons. *Neuroscience* 102, 361–367.

Fagni, L., Dumuis, A., Sebben, M., & Bockaert, J. (1992). The 5-HT<sub>4</sub> receptor subtype inhibits K<sup>+</sup> current in colliculi neurones via activation of a cyclic AMP-dependent protein kinase. *Br J Pharmacol* 105, 973–979.

Fargin, A., Raymond, J. R., Lohse, M. J., Kobilka, B. K., Caron, M. G., & Lefkowitz, R. J. (1988). The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT<sub>1A</sub> receptor. *Nature* 335, 358–360.

Fargin, A., Raymond, J. R., Regan, J. W., Cotecchia, S., Lefkowitz, R. J., & Caron, M. G. (1989). Effector coupling mechanisms of the cloned 5-HT<sub>1A</sub> receptor. *J Biol Chem* 264, 14848–14852.

Fargin, A., Yamamoto, K., Cotecchia, S., Goldsmith, P. K., Spiegel, A. M., Lapetina, E. G., Caron, M. G., & Lefkowitz, R. J. (1991). Dual coupling of the cloned 5-HT<sub>1A</sub> receptor to both adenylyl cyclase and phospholipase C is mediated via the same G<sub>i</sub> protein. *Cell Signal* 3, 547–557.

Fayolle, C., Fillion, M. P., Barone, P., Oudar, P., Rousselle, J. C., & Fillion, G. (1988). 5-Hydroxytryptamine stimulates two distinct adenylate cyclase activities in rat brain: high-affinity activation is related to a 5-HT<sub>1</sub> subtype different from 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, and 5-HT<sub>1C</sub>. *Fundam Clin Pharmacol* 2, 195–214.

Ferriere, F., Khan, N. A., Troutaud, D., & Deschaux, P. (1996). Serotonin modulation of lymphocyte proliferation via 5-HT<sub>1A</sub> receptors in rainbow trout (*Oncorhynchus mykiss*). *Dev Comp Immunol* 20, 273–283.

Fitzgerald, L. W., Iyer, G., Conklin, D. S., Krause, C. M., Marshall, A., Patterson, J. P., Tran, D. P., Jonak, G. J., & Hartig, P. R. (1999). Messenger RNA editing of the human serotonin 5-HT<sub>2C</sub> receptor. *Neuropsychopharmacology* 21, 82S–90S.

Florian, J. A., & Watts, S. W. (1998). Integration of mitogen-activated protein kinase activation in vascular 5-hydroxytryptamine<sub>2A</sub> receptor signal transduction. *J Pharmacol Exp Ther* 284, 346–355.

Foguet, M., Hoyer, D., Pardo, L. A., Parekh, A., Kluxen, F. W., Kalkman, H. O., Stuhmer, W., & Lubbert, H. (1992a). Cloning and functional characterization of the rat stomach fundus serotonin receptor. *EMBO J* 11, 3481–3487.

Foguet, M., Nguyen, H., Le, H., & Lubbert, H. (1992b). Structure of the mouse 5-HT<sub>1C</sub>, 5-HT<sub>2</sub> and stomach fundus serotonin receptor genes. *Neuroreport* 3, 345–348.

Ford, A. P., Baxter, G. S., Eglen, R. M., & Clarke, D. E. (1992). 5-Hydroxytryptamine stimulates cyclic AMP formation in the tunica muscularis mucosae of the rat oesophagus via 5-HT<sub>4</sub> receptors. *Eur J Pharmacol* 211, 117–120.

Francken, B. J. B., Jurzak, M., Luyten, W. M. H., & Leysen, J. E. (1998). h5-HT<sub>5A</sub> receptor in stably transfected HEK293 cells couples to G-proteins and receptor activation inhibits adenylate cyclase. Serotonin Club. In P. R. Saxena, R. A. Green, & M. D. Ferrari (Eds.), *4<sup>th</sup> IUPHAR Satellite Meeting on Serotonin*, Rotterdam, Netherlands, July 23-25 (p. 188). Rotterdam: Erasmus University Press.

Fujiwara, Y., Nelson, D. L., Kashihara, K., Varga, E., Roeske, W. R., & Yamamura, H. I. (1990). The cloning and sequence analysis of the rat serotonin-1A receptor gene. *Life Sci* 47, L127–L132.

Fuller, R. W. (1996). Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. *Behav Brain Res* 73, 215–219.

Gaddum, J. H., & Picarelli, Z. P. (1957). Two kinds of tryptamine receptor. *Br J Pharmacol* 12, 323–328.

Garcia, M. C., & Kim, H. Y. (1997). Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT<sub>2A</sub> receptor in rat C6 glioma cells. *Brain Res* 768, 43–48.

Garovskaya, M. N., Nebigil, C. G., Arthur, J. M., Spurney, R. F., & Raymond, J. R. (1995). 5-Hydroxytryptamine<sub>2A</sub> receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation. *Mol Pharmacol* 48, 230–237.

Garovskaya, M. N., van Biesen, T., Hawe, B., Casanas Ramos, S., Lefkowitz, R. J., & Raymond, J. R. (1996). Ras-dependent activation of fibroblast mitogen-activated protein kinase by 5-HT<sub>1A</sub> receptor via a G protein βγ-subunit-initiated pathway. *Biochemistry* 35, 13716–13722.

Garovskaya, M. N., Gettys, T. W., van Biesen, T., Prpic, V., Chuprun, J. K., & Raymond, J. R. (1997). 5-HT<sub>1A</sub> receptor activates Na<sup>+</sup>/H<sup>+</sup> exchange in CHO-K1 cells through G<sub>iα2</sub> and G<sub>iα3</sub>. *J Biol Chem* 272, 7770–7776.

Garovskaya, M. N., Mukhin, Y., & Raymond, J. R. (1998). Rapid activation of sodium-proton exchange and extracellular signal-regulated protein kinase in fibroblasts by G protein-coupled 5-HT<sub>1A</sub> receptor involves distinct signalling cascades. *Biochem J* 330, 489–495.

Gartside, S. E., Cowen, P. J., & Hjorth, S. (1990). Effects of MDL 73005EF on central pre- and postsynaptic 5-HT1A receptor function in the rat in vivo. *Eur J Pharmacol* 191, 391–400.

Ge, J., & Barnes, N. M. (1996). 5-HT<sub>4</sub> receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. *Br J Pharmacol* 117, 1475–1480.

Gelernter, J., Rao, P. A., Pauls, D. L., Hamblin, M. W., Sibley, D. R., & Kidd, K. K. (1995). Assignment of the 5HT<sub>7</sub> receptor gene (HTR7) to chromosome 10q and exclusion of genetic linkage with Tourette syndrome. *Genomics* 26, 207–209.

Gerald, C., Adham, N., Kao, H. T., Olsen, M. A., Laz, T. M., Schechter, L. E., Bard, J. A., Vaysse, P. J., Hartig, P. R., & Branchek, T. A. (1995). The 5-HT<sub>4</sub> receptor: molecular cloning and pharmacological characterization of two splice variants. *EMBO J* 14, 2806–2815.

Gerard, C., el Mestikawy, S., Lebrand, C., Adrien, J., Ruat, M., Traiffort, E., Hamon, M., & Martres, M. P. (1996). Quantitative RT-PCR distribution of serotonin 5-HT<sub>6</sub> receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. *Synapse* 23, 164–173.

Gerard, C., Martres, M. P., Lefevre, K., Miquel, M. C., Verge, D., Lanfumey, L., Doucet, E., Hamon, M., & el Mestikawy, S. (1997). Immunolocalization of serotonin 5-HT<sub>6</sub> receptor-like material in the rat central nervous system. *Brain Res* 746, 207–219.

Gershon, M. D. (1999). Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. *Aliment Pharmacol Ther* 13 (suppl. 2), 15–30.

Gettys, T. W., Fields, T. A., & Raymond, J. R. (1994). Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor. *Biochemistry* 33, 4283–4290.

Gilbert, F., & Dourish, C. T. (1987). Effects of the novel anxiolytics gepirone, buspirone and ipsapirone on free feeding and on feeding induced by 8-OH-DPAT. *Psychopharmacology* 93, 349–352.

Gilbert, F., Brazell, C., Tricklebank, M. D., & Stahl, S. M. (1988a). Activation of the 5-HT<sub>1A</sub> receptor subtype increases rat plasma ACTH concentration. *Eur J Pharmacol* 147, 431–439.

Gilbert, F., Dourish, C. T., Brazell, C., McClue, S., & Stahl, S. M. (1988b). Relationship of increased food intake and plasma ACTH levels to 5-HT<sub>1A</sub> receptor activation in rats. *Psychoneuroendocrinology* 13, 471–478.

Giles, H., Lansdell, S. J., Bolof, M. L., Wilson, H. L., & Martin, G. R. (1996). Characterization of a 5-HT<sub>1B</sub> receptor on CHO cells: functional responses in the absence of radioligand binding. *Br J Pharmacol* 117, 1119–1126.

Gobert, A., & Millan, M. J. (1999). Serotonin (5-HT)<sub>2A</sub> receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. *Neuropharmacology* 38, 315–317.

Goodwin, G. M., De Souza, R. J., & Green, A. R. (1985). The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. *Neuropharmacology* 24, 1187–1194.

Goodwin, G. M., De Souza, R. J., Green, A. R., & Heal, D. J. (1987). The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). *Psychopharmacology* 91, 506–511.

Goppelt-Struebe, M., & Stroebel, M. (1998). Signaling pathways mediating induction of the early response genes prostaglandin G/H synthase-2 and egr-1 by serotonin via 5-HT<sub>2A</sub> receptors. *J Cell Physiol* 175, 341–347.

Goppelt-Struebe, M., Hahn, A., Stroebel, M., & Reiser, C. O. (1999). Independent regulation of cyclo-oxygenase 2 expression by p42/44

mitogen-activated protein kinases and Ca²⁺/calmodulin-dependent kinase. *Biochem J* 339, 329–334.

Greene, E. L., Houghton, O., Collinsworth, G., Garnovskaya, M. N., Nagai, T., Sajjad, T., Bheemanathini, V., Grewal, J. S., Paul, R. V., & Raymond, J. R. (2000). 5-HT₂A receptors stimulate mitogen-activated protein kinase via H₂O₂ generation in rat renal mesangial cells. *Am J Physiol Renal Physiol* 278, F650–F658.

Grewal, J. S., Mukhin, Y. V., Garnovskaya, M. N., Raymond, J. R., & Greene, E. L. (1999). Serotonin 5-HT₂A receptor induces TGF-β1 expression in mesangial cells via ERK: proliferative and fibrotic signals. *Am J Physiol* 276, F922–F930.

Grimaldi, B., Bonnin, A., Fillion, M. P., Ruat, M., Traiffort, E., & Fillion, G. (1998). Characterization of 5-ht₆ receptor and expression of 5-ht₆ mRNA in the rat brain during ontogenetic development. *Naunyn Schmiedebergs Arch Pharmacol* 357, 393–400.

Grotewiel, M. S., & Sanders-Bush, E. (1999). Differences in agonist-independent activity of 5-HT₂A and 5-HT₂C receptors revealed by heterologous expression. *Naunyn Schmiedebergs Arch Pharmacol* 359, 21–27.

Guillet-Deniau, I., Burnol, A. F., & Girard, J. (1997). Identification and localization of a skeletal muscle serotonin 5-HT₂A receptor coupled to the Jak/STAT pathway. *J Biol Chem* 272, 14825–14829.

Hagberg, G. B., Blomstrand, F., Nilsson, M., Tamir, H., & Hansson, E. (1998). Stimulation of 5-HT₂A receptors on astrocytes in primary culture opens voltage-independent Ca²⁺ channels. *Neurochem Int* 32, 153–162.

Hahn, A., Heusinger-Ribeiro, J., Lanz, T., Zenkel, S., & Goppelt-Struebe, M. (2000). Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton. *J Biol Chem* 275, 37429–37435.

Hajduch, E., Dombrowski, L., Darakhshan, F., Rencurel, F., Marette, A., & Hundal, H. S. (1999). Biochemical localization of the 5-HT₂A (serotonin) receptor in rat skeletal muscle. *Biochem Biophys Res Commun* 257, 369–372.

Hall, M. D., el Mestikawy, S., Emerit, M. B., Pichat, L., Hamon, M., & Gozlan, H. (1985). [³H]8-hydroxy-2-(di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. *J Neurochem* 44, 1685–1696.

Hall, R. A., Premont, R. T., & Lefkowitz, R. J. (1999). Heptahelical receptor signaling: beyond the G protein paradigm. *J Cell Biol* 145, 927–932.

Hamblin, M. W., & Metcalf, M. A. (1991). Primary structure and functional characterization of a human 5-HT₁D-type serotonin receptor. *Mol Pharmacol* 40, 143–148.

Hamblin, M. W., Metcalf, M. A., McGuffin, R. W., & Karpells, S. (1992). Molecular cloning and functional characterization of a human 5-HT₁B serotonin receptor: a homologue of the rat 5-HT₁B receptor with 5-HT₁D-like pharmacological specificity. *Biochem Biophys Res Commun* 184, 752–759.

Hamblin, M. W., Guthrie, C. R., Kohen, R., & Heidmann, D. E. (1998). Gₛ protein-coupled serotonin receptors: receptor isoforms and functional differences. *Ann N Y Acad Sci* 861, 31–37.

Harrington, M. A., Shaw, K., Zhong, P., & Ciaranello, R. D. (1994). Agonist-induced desensitization and loss of high-affinity binding sites of stably expressed human 5-HT₁A receptors. *J Pharmacol Exp Ther* 268, 1098–1106.

Hartig, P. R., Branchek, T. A., & Weinshank, R. L. (1992). A subfamily of 5-HT₁D receptor genes. *Trends Pharmacol Sci* 13, 152–159.

Hartig, P. R., Hoyer, D., Humphrey, P. P., & Martin, G. R. (1996). Alignment of receptor nomenclature with the human genome: classification of 5-HT₁B and 5-HT₁D receptor subtypes. *Trends Pharmacol Sci* 17, 103–105.

Heidmann, D. E., Metcalf, M. A., Kohen, R., & Hamblin, M. W. (1997). Four 5-hydroxytryptamine₇ (5-HT₇) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization. *J Neurochem* 68, 1372–1381.

Heidmann, D. E., Szot, P., Kohen, R., & Hamblin, M. W. (1998). Function and distribution of three rat 5-hydroxytryptamine₇ (5-HT₇) receptor isoforms produced by alternative splicing. *Neuropharmacology* 37, 1621–1632.

Hensler, J. G., Cervera, L. S., Miller, H. A., & Corbitt, J. (1996). Expression and modulation of 5-hydroxytryptamine₁A receptors in P11 cells. *J Pharmacol Exp Ther* 278, 1138–1145.

Hinton, J. M., Adams, D., & Garland, C. J. (1999). 5-Hydroxytryptamine stimulation of phospholipase D activity in the rabbit isolated mesenteric artery. *Br J Pharmacol* 126, 1601–1608.

Hirst, W. D., Price, G. W., Rattray, M., & Wilkin, G. P. (1997). Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. *Br J Pharmacol* 120, 509–515.

Hirst, W. D., Cheung, N. Y., Rattray, M., Price, G. W., & Wilkin, G. P. (1998). Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT₁ receptor subtypes to adenylyl cyclase. *Brain Res Mol Brain Res* 61, 90–99.

Hjorth, S. (1985). Hypothermia in the rat induced by the potent serotonergic agent 8-OH-DPAT. *J Neural Transm* 61, 131–135.

Hjorth, S., & Tao, R. (1991). The putative 5-HT₁B receptor agonist CP-93,129 suppresses rat hippocampal 5-HT release in vivo: comparison with RU 24969. *Eur J Pharmacol* 209, 249–252.

Hoyer, D., & Middlemiss, D. N. (1989). Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. *Trends Pharmacol Sci* 10, 130–132.

Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). *Pharmacol Rev* 46, 157–203.

Hsieh, C. L., Bowcock, A. M., Farrer, L. A., Hebert, J. M., Huang, K. N., Cavalli-Sforza, L. L., Julius, D., & Francke, U. (1990). The serotonin receptor subtype 2 locus HTR2 is on human chromosome 13 near genes for esterase D and retinoblastoma-1 and on mouse chromosome 14. *Somat Cell Mol Genet* 16, 567–574.

Huidobro-Toro, J. P., Valenzuela, C. F., & Harris, R. A. (1996). Modulation of GABAA receptor function by G protein-coupled 5-HT₂C receptors. *Neuropharmacology* 35, 1355–1363.

Hung, B. C., Loo, D. D., & Wright, E. M. (1993). Regulation of mouse choroid plexus apical Cl⁻ and K⁺ channels by serotonin. *Brain Res* 617, 285–295.

Hurley, J. H. (1999). Structure, mechanism, and regulation of mammalian adenylyl cyclase. *J Biol Chem* 274, 7599–7602.

Hutson, P. H., Dourish, C. T., & Curzon, G. (1988). Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A receptors. *Eur J Pharmacol* 150, 361–366.

Iken, K., Chheng, S., Fargin, A., Goulet, A. C., & Kouassi, E. (1995). Serotonin upregulates mitogen-stimulated B lymphocyte proliferation through 5-HT₁A receptors. *Cell Immunol* 163, 1–9.

Ishida, T., Kawashima, S., Hirata, K., & Yokoyama, M. (1998). Nitric oxide is produced via 5-HT₁B and 5-HT₂B receptor activation in human coronary artery endothelial cells. *Kobe J Med Sci* 44, 51–63.

Ishizuka, J., Beauchamp, R. D., Townsend, C. M., Greeley, G. H., & Thompson, J. C. (1992). Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoma cells. *J Cell Physiol* 150, 1–7.

Izumi, J., Washizuka, M., Miura, N., Hiraga, Y., & Ikeda, Y. (1994). Hippocampal serotonin 5-HT₁A receptor enhances acetylcholine release in conscious rats. *J Neurochem* 62, 1804–1808.

Jalonen, T. O., Margraf, R. R., Wiert, D. B., Charniga, C. J., Linne, M. L., & Kimelberg, H. K. (1997). Serotonin induces inward potassium and calcium currents in rat cortical astrocytes. *Brain Res* 758, 69–82.

Jasper, J. R., Kosaka, A., To, Z. P., Chang, D. J., & Eglen, R. M. (1997). Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT₇ receptor (h5-HT₇b). *Br J Pharmacol* 122, 126–132.

Jin, H., Oksenberg, D., Ashkenazi, A., Peroutka, S. J., Duncan, A. M., Rozmahel, R., Yang, Y., Mengod, G., Palacios, J. M., & O’Dowd, B. F. (1992). Characterization of the human 5-hydroxytryptamine₁B receptor. *J Biol Chem* 267, 5735–5738.

Julius, D., MacDermott, A. B., Axel, R., & Jessell, T. M. (1988). Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. *Science* 241, 558–564.

Julius, D., Livelli, T. J., Jessell, T. M., & Axel, R. (1989). Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. *Science* 244, 1057–1062.

Julius, D., Huang, K. N., Livelli, T. J., Axel, R., & Jessell, T. M. (1990). The 5HT₂ receptor defines a family of structurally distinct but functionally conserved serotonin receptors. *Proc Natl Acad Sci USA* 87, 928–932.

Kahan, C., Julius, D., Pouyssegur, J., & Seuwen, K. (1992). Effects of 5-HT₁C-receptor expression on cell proliferation control in hamster fibroblasts: serotonin fails to induce a transformed phenotype. *Exp Cell Res* 200, 523–527.

Karschin, A., Ho, B. Y., Labarca, C., Elroy-Stein, O., Moss, B., Davidson, N., & Lester, H. A. (1991). Heterologously expressed serotonin 1A receptors couple to muscarinic K⁺ channels in heart. *Proc Natl Acad Sci USA* 88, 5694–5698.

Kaufman, M. J., Hartig, P. R., & Hoffman, B. J. (1995). Serotonin 5-HT₂C receptor stimulates cyclic GMP formation in choroid plexus. *J Neurochem* 64, 199–205.

Kaumann, A. J. (1991). 5-HT₄-like receptors in mammalian atria. *J Neural Transm Suppl* 34, 195–201.

Kellermann, O., Tournois, C., Richard, S., Manivet, P., Maroteaux, L., & Launay, J. M. (1998). Signaling pathways and targets of the 5-HT₂B receptor in the 1C11 serotonergic cell line. *Ann N Y Acad Sci* 861, 248.

Kellett, E., Carr, I. C., & Milligan, G. (1999). Regulation of G protein activation and effector modulation by fusion proteins between the human 5-hydroxytryptamine₁A receptor and the alpha subunit of Gᵢ₁: differences in receptor-constitutive activity imparted by single amino acid substitutions in Gi₁α. *Mol Pharmacol* 56, 684–692.

Kelly, J. S., Larkman, P., Penington, N. J., Rainnie, D. G., McAllister-Williams, H., & Hodgkiss, J. (1991). Serotonin receptor heterogeneity and the role of potassium channels in neuronal excitability. *Adv Exp Med Biol* 287, 177–191.

Kirchgesner, A. L., Liu, M. T., Howard, M. J., & Gershon, M. D. (1993). Detection of the 5-HT₁A receptor and 5-HT₁A receptor mRNA in the rat bowel and pancreas: comparison with 5-HT₁P receptors. *J Comp Neurol* 327, 233–250.

Kobilka, B. K., Frielle, T., Collins, S., Yang-Feng, T., Kobilka, T. S., Francke, U., Lefkowitz, R. J., & Caron, M. G. (1987). An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. *Nature* 329, 75–79.

Kohen, R., Metcalf, M. A., Khan, N., Druck, T., Huebner, K., Lachowicz, J. E., Meltzer, H. Y., Sibley, D. R., Roth, B. L., & Hamblin, M. W. (1996). Cloning, characterization, and chromosomal localization of a human 5-HT₆ serotonin receptor. *J Neurochem* 66, 47–56.

Kuemmerle, J. F., Murthy, K. S., Grider, J. R., Martin, D. C., & Makhlouf, G. M. (1995). Coexpression of 5-HT₂A and 5-HT₄ receptors coupled to distinct signaling pathways in human intestinal muscle cells. *Gastroenterology* 109, 1791–1800.

Kursar, J. D., Nelson, D. L., Wainscott, D. B., & Baez, M. (1994). Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine₂B receptor. *Mol Pharmacol* 46, 227–234.

Kurscheid-Reich, D., Throckmorton, D. C., & Rasmussen, H. (1995). Serotonin activates phospholipase D in rat mesangial cells. *Am J Physiol* 268, F997–F1003.

Langlois, X., el Mestikawy, S., Arpin, M., Triller, A., Hamon, M., & Darmon, M. (1996). Differential addressing of 5-HT₁A and 5-HT₁B receptors in transfected LLC-PKI epithelial cells: a model of receptor targeting in neurons. *Neuroscience* 74, 297–302.

Launay, J. M., Birraux, G., Bondoux, D., Callebert, J., Choi, D. S., Loric, S., & Maroteaux, L. (1996). Ras involvement in signal transduction by the serotonin 5-HT₂B receptor. *J Biol Chem* 271, 3141–3147.

Launay, J. M., Loric, S., Mutel, V., & Kellermann, O. (1998). The 5-HT₂B receptor controls the overall 5-HT transport system in the 1C11 serotonergic cell line. *Ann N Y Acad Sci* 861, 247.

Lawrence, A. J., & Marsden, C. A. (1992). Terminal autoreceptor control of 5-hydroxytryptamine release as measured by in vivo microdialysis in the conscious guinea-pig. *J Neurochem* 58, 142–146.

Le Grand, B., Panissie, A., Pauwels, P. J., & John, G. W. (1998). Activation of recombinant h5-HT₁B and h5-HT₁D receptors stably expressed in C6 glioma cells produces increases in Ca²⁺-dependent K⁺ current. *Naunyn Schmiedebergs Arch Pharmacol* 358, 608–615.

Leeb-Lundberg, L. M. F., Kang, D. S., Lamb, M. E., & Fathy, D. B. (2001). The human B₁ bradykinin receptor exhibits high ligand-independent, constitutive activity. *J Biol Chem* 276, 8785–8792.

Lefebvre, H., Dhib, M., Godin, M., Contesse, V., Delarue, C., Rieu, M., Wolf, L. M., Vaudry, H., & Kuhn, J. M. (1997). Effect of the serotonin 5-HT₄ receptor agonist cisapride on aldosterone secretion in corticotropin insufficiency and primary hyperaldosteronism. *Neuroendocrinology* 66, 229–233.

Lefebvre, H., Cartier, D., Duparc, C., Contesse, V., Lihrmann, I., Delarue, C., Vaudry, H., Fischmeister, R., & Kuhn, J. M. (2000). Effect of serotonin₄ (5-HT₄) receptor agonists on aldosterone secretion in idiopathic hyperaldosteronism. *Endocr Res* 26, 583–587.

Leone, M., Attanasio, A., Croci, D., Ferraris, A., D’Amico, D., Grazzi, L., Nespolo, A., & Bussone, G. (1998). 5-HT₁A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. *Neuroreport* 9, 2605–2608.

Leonhardt, S., Herrick-Davis, K., & Titeler, M. (1989). Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. *J Neurochem* 53, 465–471.

Lesage, A. S., Wouters, R., Van Gompel, P., Heylen, L., Vanhoenacker, P., Haegeman, G., Luyten, W. H., & Leysen, J. E. (1998). Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT₁B and 5-HT₁D receptors expressed in various mammalian cell lines. *Br J Pharmacol* 123, 1655–1665.

Leung, G. P., Dun, S. L., Dun, N. J., & Wong, P. Y. (1999). Serotonin via 5-HT₁B and 5-HT₂B receptors stimulates anion secretion in the rat epididymal epithelium. *J Physiol (Lond)* 51, 657–667.

Levy, F. O., Gudermann, T., Birnbaumer, M., Kaumann, A. J., & Birnbaumer, L. (1992a). Molecular cloning of a human gene (S31) encoding a novel serotonin receptor mediating inhibition of adenylyl cyclase. *FEBS Lett* 296, 201–206.

Levy, F. O., Gudermann, T., Perez-Reyes, E., Birnbaumer, M., Kaumann, A. J., & Birnbaumer, L. (1992b). Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT₁D subtype. *J Biol Chem* 267, 7553–7562.

Levy, F. O., Holtgreve-Grez, H., Tasken, K., Solberg, R., Ried, T., & Gudermann, T. (1994). Assignment of the gene encoding the 5-HT₁E serotonin receptor (S31) (locus HTR1E) to human chromosome 6q14-q15. *Genomics* 22, 637–640.

Leysen, J. E., Niemegeers, C. J., Tollenaere, J. P., & Laduron, P. M. (1978). Serotonergic component of neuroleptic receptors. *Nature* 272, 168–171.

Lione, A. M., Errico, M., Lin, S. L., & Cowen, D. S. (2000). Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT₁B receptors in transfected BE(2)-C neuroblastoma cells is inhibited by RGS4. *J Neurochem* 75, 934–938.

Liu, Y. F., & Albert, P. R. (1991). Cell-specific signaling of the 5-HT₁A receptor. Modulation by protein kinases C and A. *J Biol Chem* 266, 23689–23697.

Liu, Y. F., Jakobs, K. H., Rasenick, M. M., & Albert, P. R. (1994). G protein specificity in receptor-effector coupling. Analysis of the roles of G₀ and G₁₂ in GH4C1 pituitary cells. *J Biol Chem* 269, 13880–13886.

Liu, Y. F., Ghahremani, M. H., Rasenick, M. M., Jakobs, K. H., & Albert, P. R. (1999). Stimulation of cAMP synthesis by Gᵢ-coupled receptors upon ablation of distinct Gαi protein expression. Gᵢ subtype specificity of the 5-HT₁A receptor. *J Biol Chem* 274, 16444–16450.

Loric, S., Launay, J. M., Colas, J. F., & Maroteaux, L. (1992). New mouse 5-HT₂-like receptor. Expression in brain, heart and intestine. *FEBS Lett* 312, 203–207.

Loric, S., Maroteaux, L., Kellermann, O., & Launay, J. M. (1995). Functional serotonin-2B receptors are expressed by a teratocarcinoma-derived cell line during serotonergic differentiation. *Mol Pharmacol* 47, 458–466.

Lovenberg, T. W., Baron, B. M., de Lecea, L., Miller, J. D., Prosser, R. A.,

Rea, M. A., Foye, P. E., Racke, M., Slone, A. L., & Siegel, B. W. (1993a). A novel adenylyl cyclase-activating serotonin receptor (5-HT₇) implicated in the regulation of mammalian circadian rhythms. *Neuron* 11, 449–458.

Lovenberg, T. W., Erlander, M. G., Baron, B. M., Racke, M., Slone, A. L., Siegel, B. W., Craft, C. M., Burns, J. E., Danielson, P. E., & Sutcliffe, J. G. (1993b). Molecular cloning and functional expression of 5-HT₁E-like rat and human 5-hydroxytryptamine receptor genes. *Proc Natl Acad Sci USA* 90, 2184–2188.

Lubbert, H., Hoffman, B. J., Snutch, T. P., van Dyke, T., Levine, A. J., Hartig, P. R., Lester, H. A., & Davidson, N. (1987). cDNA cloning of a serotonin 5-HT1C receptor by electrophysiological assays of mRNA-injected Xenopus oocytes. *Proc Natl Acad Sci USA* 84, 4332–4336.

Lucaites, V. L., Nelson, D. L., Wainscott, D. B., & Baez, M. (1996). Receptor subtype and density determine the coupling repertoire of the 5-HT₂ receptor subfamily. *Life Sci* 59, 1081–1095.

Luttrel, L. M., van Biesen, T., Hawes, B. E., Koch, W. J., Krueger, K. M., Touhara, K., & Lefkowitz, R. J. (1997). G-protein-coupled receptors and their regulation: activation of the MAP kinase signaling pathway by G-protein-coupled receptors. *Adv Second Messenger Phosphoprotein Res* 31, 263–277.

Maenhaut, C., Van Sande, J., Massart, C., Dinsart, C., Libert, F., Monferini, E., Giraldo, E., Ladinsky, H., Vassart, G., & Dumont, J. E. (1991). The orphan receptor cDNA RDC4 encodes a 5-HT1D serotonin receptor. *Biochem Biophys Res Commun* 180, 1460–1468.

Malmberg, A., & Strange, P. G. (2000). Site-directed mutations in the third intracellular loop of the serotonin 5-HT₁A receptor alter G protein coupling from Gᵢ to Gₛ in a ligand-dependent manner. *J Neurochem* 75, 1283–1293.

Manivet, P., Mouillet-Richard, S., Callebert, J., Nebigil, C. G., Maroteaux, L., Hosoda, S., Kellermann, O., & Launay, J. M. (2000). PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. *J Biol Chem* 275, 9324–9331.

Marcoli, M., Maura, G., Tortarolo, M., & Raiteri, M. (1997). Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in rat cerebellum: involvement of 5-hydroxytryptamine2C receptors. *J Neurochem* 69, 427–430.

Markstein, R., Hoyer, D., & Engel, G. (1986). 5-HT₁A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. *Naunyn Schmiedebergs Arch Pharmacol* 333, 335–341.

Maroteaux, L., Saudou, F., Amlaiky, N., Boscher, U., Plassat, J. L., & Hen, R. (1992). Mouse 5HT₁B serotonin receptor: cloning, functional expression, and localization in motor control centers. *Proc Natl Acad Sci USA* 89, 3020–3024.

Marracci, S., Cini, D., & Nardi, I. (1997). Cloning and developmental expression of 5-HT₁A receptor gene in Xenopus laevis. *Brain Res Mol Brain Res* 47, 67–77.

Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. *Cell* 80, 179–185.

Martin, K. F., Hannon, S., Phillips, I., & Heal, D. J. (1992). Opposing roles for 5-HT₁B and 5-HT₃ receptors in the control of 5-HT release in rat hippocampus in vivo. *Br J Pharmacol* 106, 139–142.

Maswood, N., Caldarola-Pastuszka, M., & Uphouse, L. (1998). Functional integration among 5-hydroxytryptamine receptor families in the control of female rat sexual behavior. *Brain Res* 802, 98–103.

Matsuda, H., Li, Y., & Yoshikawa, M. (2000). Possible involvement of 5-HT and 5-HT₂ receptors in acceleration of gastrointestinal transit by escin Ib in mice. *Life Sci* 66, 2233–2238.

Matthes, H., Boscher, U., Amlaiky, N., Grailhe, R., Plassat, J. L., Muscatelli, F., Mattei, M. G., & Hen, R. (1993). Mouse 5-hydroxytryptamine₅A and 5-hydroxytryptamine₅B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. *Mol Pharmacol* 43, 313–319.

Maura, G., & Raiteri, M. (1996). Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. *J Neurochem* 66, 203–209.

Maura, G., Marcoli, M., Tortarolo, M., Andrioli, G. C., & Raiteri, M. (1998). Glutamate release in human cerebral cortex and its modulation by 5-hydroxytryptamine acting at h 5-HT1D receptors. *Br J Pharmacol* 123, 45–50.

Maura, G., Marcoli, M., Pepicelli, O., Rosu, C., Viola, C., & Raiteri, M. (2000). Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT₂C and 5-HT₁A receptors. *Br J Pharmacol* 130, 1853–1858.

Mayer, S. E., & Sanders-Bush, E. (1994). 5-Hydroxytryptamine type 2A and 2C receptors linked to Na⁺/K⁺/Cl⁻ cotransport. *Mol Pharmacol* 45, 991–996.

McAllister, G., Charlesworth, A., Snodin, C., Beer, M. S., Noble, A. J., Middlemiss, D. N., Iversen, L. L., & Whiting, P. (1992). Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT₁-like subtype. *Proc Natl Acad Sci USA* 89, 5517–5521.

McDuffie, J. E., Coaxum, S. D., & Maleque, M. A. (1999). 5-Hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures. *Proc Soc Exp Biol Med* 221, 386–390.

McDuffie, J. E., Motley, E. D., Limbird, L. E., & Maleque, M. A. (2000). 5-Hydroxytryptamine stimulates phosphorylation of p44/p42 mitogen-activated protein kinase activation in bovine aortic endothelial cell cultures. *J Cardiovasc Pharmacol* 35, 398–402.

McLean, P. G., & Coupar, I. M. (1996). Further investigation into the signal transduction mechanism of the 5-HT₄-like receptor in the circular smooth muscle of human colon. *Br J Pharmacol* 118, 1058–1064.

Mendez, J., Kadia, T. M., Somayazula, R. K., El-Badawi, K. I., & Cowen, D. S. (1999). Differential coupling of serotonin 5-HT₁A and 5-HT₁B receptors to activation of ERK2 and inhibition of adenylyl cyclase in transfected CHO cells. *J Neurochem* 73, 162–168.

Mengod, G., Nguyen, H., Le, H., Waeber, C., Lubbert, H., & Palacios, J. M. (1990). The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. *Neuroscience* 35, 577–591.

Metcalf, M. A., McGuffin, R. W., & Hamblin, M. W. (1992). Conversion of the human 5-HT₁D beta serotonin receptor to the rat 5-HT₁B ligand-binding phenotype by Thr355Asn site directed mutagenesis. *Biochem Pharmacol* 44, 1917–1920.

Meyerhof, W., Obermuller, F., Fehr, S., & Richter, D. (1993). A novel rat serotonin receptor: primary structure, pharmacology, and expression pattern in distinct brain regions. *DNA Cell Biol* 12, 401–409.

Mialet, J., Berque-Bestel, I., Eftekhari, P., Gastineau, M., Giner, M., Dahmoune, Y., Donzeau-Gouge, P., Hoebeke, J., Langlois, M., Sicsic, S., Fischmeister, R., & Lezoualc’h, F. (2000). Isolation of the serotoninergic 5-HT₄e receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. *Br J Pharmacol* 129, 771–781.

Miczek, K. A., Hussain, S., & Faccidomo, S. (1998). Alcohol-heightened aggression in mice: attenuation by 5-HT₁A receptor agonists. *Psychopharmacology (Berl)* 139, 160–168.

Middlemiss, D. N., & Fozard, J. R. (1983). 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. *Eur J Pharmacol* 90, 151–153.

Middlemiss, D. N., & Hutson, P. H. (1990). The 5-HT₁B receptors. *Ann N Y Acad Sci* 600, 132–147.

Middleton, J. P., Albers, F. J., Dennis, V. W., & Raymond, J. R. (1990). Thapsigargin demonstrates calcium-dependent regulation of phosphate uptake in HeLa cells. *Am J Physiol* 259, F727–F731.

Millan, M. J., Dekeyne, A., & Gobert, A. (1998). Serotonin (5-HT)₂C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. *Neuropharmacology* 37, 953–955.

Miller, K. J., & Gonzalez, H. A. (1998). Serotonin 5-HT₂A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cells. *Ann N Y Acad Sci* 861, 169–173.

Miquel, M. C., Doucet, E., Riad, M., Adrien, J., Verge, D., & Hamon, M. (1992). Effect of the selective lesion of serotonergic neurons on the regional distribution of 5-HT<sub>1A</sub> receptor mRNA in the rat brain. *Brain Res Mol Brain Res* 14, 357–362.

Mitsikostas, D. D., Sanchez del Rio, M., Moskowitz, M. A., & Waeber, C. (1999). Both 5-HT<sub>1B</sub> and 5-HT<sub>1F</sub> receptors modulate c-fos expression within rat trigeminal nucleus caudalis. *Eur J Pharmacol* 369, 271–277.

Moiseiwitsch, J. R., Raymond, J. R., Tamir, H., & Lauder, J. M. (1998). Regulation by serotonin of tooth-germ morphogenesis and gene expression in mouse mandibular explant cultures. *Arch Oral Biol* 43, 789–800.

Molderings, G. J., Frolich, D., Likungu, J., & Gothert, M. (1996). Inhibition of noradrenaline release via presynaptic 5-HT<sub>1Dα</sub> receptors in human atrium. *Naunyn Schmiedebergs Arch Pharmacol* 353, 272–280.

Mons, N., Decorte, L., Jaffard, R., & Cooper, D. M. (1998). Ca<sup>2+</sup>-sensitive adenylyl cyclases, key integrators of cellular signalling. *Life Sci* 62, 1647–1652.

Monsma, F. J., Shen, Y., Ward, R. P., Hamblin, M. W., & Sibley, D. R. (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. *Mol Pharmacol* 43, 320–327.

Montiel, C., Herrero, C. J., Garcia-Palomero, E., Renart, J., Garcia, A. G., & Lomax, R. B. (1997). Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT<sub>2</sub> receptors. *Eur J Pharmacol* 332, 183–193.

Morecroft, I., & MacLean, M. R. (1998). 5-Hydroxytryptamine receptors mediating vasoconstriction and vasodilation in perinatal and adult rabbit small pulmonary arteries. *Br J Pharmacol* 125, 69–78.

Mork, A., & Geisler, A. (1990). 5-Hydroxytryptamine receptor agonists influence calcium-stimulated adenylate cyclase activity in the cerebral cortex and hippocampus of the rat. *Eur J Pharmacol* 175, 237–244.

Mukhin, Y. V., Garnovskaya, M. N., Collinsworth, G., Grewal, J. S., Pendergrass, D., Nagai, T., Pinckney, S., Greene, E. L., & Raymond, J. R. (2000). 5-Hydroxytryptamine<sub>1A</sub> receptor/G<sub>iβγ</sub> stimulates mitogen-activated protein kinase via NAD(P)H oxidase and reactive oxygen species upstream of src in Chinese hamster ovary fibroblasts. *Biochem J* 347, 61–67.

Mulheron, J. G., Casanas, S. J., Arthur, J. M., Garnovskaya, M. N., Getty, T. W., & Raymond, J. R. (1994). Human 5-HT<sub>1A</sub> receptor expressed in insect cells activates endogenous G<sub>o</sub>-like G protein(s). *J Biol Chem* 269, 12954–12962.

Nakaki, T., Roth, B. L., Chuang, D. M., & Costa, E. (1985). Phasic and tonic components in 5-HT<sub>2</sub> receptor-mediated rat aorta contraction: participation of Ca++ channels and phospholipase C. *J Pharmacol Exp Ther* 234, 442–446.

Nebigil, C. G., Choi, D. S., Dierich, A., Hickel, P., Le Meur, M., Mes-saddeq, N., Launay, J. M., & Maroteaux, L. (2000a). Serotonin 2B receptor is required for heart development. *Proc Natl Acad Sci USA* 97, 9508–9513.

Nebigil, C. G., Launay, J. M., Hickel, P., Tournois, C., & Maroteaux, L. (2000b). 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. *Proc Natl Acad Sci USA* 97, 2591–2596.

Nelson, C. S., Cone, R. D., Robbins, L. S., Allen, C. N., & Adelman, J. P. (1995). Cloning and expression of a 5HT7 receptor from Xenopus laevis. *Recept Channels* 3, 61–70.

Nelson, D. L., Pedigo, N. W., & Yamamura, H. I. (1981). Multiple <sup>3</sup>H-5-hydroxytryptamine binding sites in rat brain. *J Physiol* 77, 369–372.

Newman-Tancredi, A., Wootton, R., & Strange, P. G. (1992). High-level stable expression of recombinant 5-HT<sub>1A</sub> 5-hydroxytryptamine receptors in Chinese hamster ovary cells. *Biochem J* 285, 933–938.

Ng, G. Y., George, S.R., Zastawny, R. L., Caron, M., Bouvier, M., Dennis, M., & O’Dowd, B. F. (1993). Human serotonin<sub>1B</sub> receptor expression in Sf9 cells: phosphorylation, palmitoylation, and adenylyl cyclase inhibition. *Biochemistry* 32, 11727–11733.

Ni, Y. G., Panicker, M. M., & Miledi, R. (1997). Efficient coupling of 5-HT<sub>1a</sub> receptors to the phospholipase C pathway in Xenopus oocytes. *Brain Res Mol Brain Res* 51, 115–122.

Nishizuka, Y. (1995). Protein kinase C and lipid signaling for sustained cellular responses. *FASEB J* 9, 484–496.

Niswender, C. M., Sanders-Bush, E., & Emeson, R. B. (1998). Identification and characterization of RNA editing events within the 5-HT<sub>2C</sub> receptor. *Ann N Y Acad Sci* 861, 38–48.

Niswender, C. M., Copeland, S. C., Herrick-Davis, K., Emeson, R. B., & Sanders-Bush, E. (1999). RNA editing of the human serotonin 5-hydroxytryptamine<sub>2C</sub> receptor silences constitutive activity. *J Biol Chem* 274, 9472–9478.

Nitsch, R. M., Deng, M., Growdon, J. H., & Wurtman, R. J. (1996). Serotonin 5-HT<sub>2a</sub> and 5-HT<sub>2c</sub> receptors stimulate amyloid precursor protein ectodomain secretion. *J Biol Chem* 271, 4188–4194.

Obosi, L. A., Hen, R., Beadle, D. J., Bermudez, I., & King, L. A. (1997). Mutational analysis of the mouse 5-HT<sub>7</sub> receptor: importance of the third intracellular loop for receptor-G-protein interaction. *FEBS Lett* 412, 321–324.

Okoro, E. O. (1999). Overlap in the pharmacology of L-type Ca<sup>2+</sup>-channel blockers and 5-HT<sub>2</sub> receptor antagonists in rat aorta. *J Pharm Pharmacol* 51, 953–957.

Oksenberg, D., Marsters, S. A., O’Dowd, B. F., Jin, H., Havlik, S., Per-outka, S. J., & Ashkenazi, A. (1992). A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT<sub>1B</sub> receptors. *Nature* 360, 161–163.

Olsen, M. A., Nawoschik, S. P., Schurman, B. R., Schmitt, H. L., Burno, M., Smith, D. L., & Schechter, L. E. (1999). Identification of a human 5-HT<sub>6</sub> receptor variant produced by alternative splicing. *Brain Res Mol Brain Res* 64, 255–263.

Ouadid, H., Seguin, J., Dumuis, A., Bockaert, J., & Nargeot, J. (1992). Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. *Mol Pharmacol* 41, 346–351.

Palacios, J. M., Waeber, C., Hoyer, D., & Mengod, G. (1990). Distribution of serotonin receptors. *Ann N Y Acad Sci* 600, 36–52.

Palego, L., Giromella, A., Marazziti, D., Borsini, F., Naccarato, A. G., Giannaccini, G., Lucacchini, A., Cassano, G. B., & Mazzoni, M. R. (1999). Effects of postmortem delay on serotonin and (+)8-OH-DPAT-mediated inhibition of adenylyl cyclase activity in rat and human brain tissues. *Brain Res* 816, 165–174.

Palego, L., Giromella, A., Marazziti, D., Giannaccini, G., Borsini, F., Big-azzi, F., Naccarato, A. G., Lucacchini, A., Cassano, G. B., & Mazzoni, M. R. (2000). Lack of stereoselectivity of 8-hydroxy-2(di-N-propylamino)tetralin-mediated inhibition of forskolin-stimulated adenylyl cyclase activity in human pre- and post-synaptic brain regions. *Neurochem Int* 36, 225–232.

Pan, H., Wang, H. Y., Friedman, E., & Gershon, M. D. (1997). Mediation by protein kinases C and A of G<sub>o</sub>-linked slow responses of enteric neurons to 5-HT. *J Neurosci* 17, 1011–1024.

Panicker, M. M., Parker, I., & Miledi, R. (1991). Receptors of the serotonin 1C subtype expressed from cloned DNA mediate the closing of K<sup>+</sup> membrane channels encoded by brain mRNA. *Proc Natl Acad Sci USA* 88, 2560–2562.

Parekh, A. B., Foguet, M., Lubbert, H., & Stuhmer, W. (1993). Ca<sup>2+</sup> oscillations and Ca<sup>2+</sup> influx in Xenopus oocytes expressing a novel 5-hydroxytryptamine receptor. *J Physiol* 469, 653–671.

Parker, E. M., Grisel, D. A., Iben, L. G., & Shapiro, R. A. (1993). A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine<sub>1B</sub> receptors. *J Neurochem* 60, 380–383.

Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T., & Toth, M. (1998). Increased anxiety of mice lacking the serotonin<sub>1A</sub> receptor. *Proc Natl Acad Sci USA* 95, 10734–10739.

Pauwels, P. J., Palmier, C., Wurch, T., & Colpaert, F. C. (1996). Pharmacology of cloned human 5-HT<sub>1D</sub> receptor-mediated functional responses in stably transfected rat C6-glial cell lines: further evidence differentiating human 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors. *Naunyn Schmiedebergs Arch Pharmacol* 353, 144–156.

Pazos, A., Cortes, R., & Palacios, J. M. (1985). Quantitative autoradio-

graphic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. *Brain Res* 346, 231–249.

Pedigo, N. W., Yamamura, H. I., & Nelson, D. L. (1981). Discrimination of multiple \[^{3}H\]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. *J Neurochem* 36, 220–226.

Penington, N. J., & Kelly, J. S. (1990). Serotonin receptor activation reduces calcium current in an acutely dissociated adult central neuron. *Neuron* 4, 751–758.

Penington, N. J., Kelly, J. S., & Fox, A. P. (1991). A study of the mechanism of Ca\(^{2+}\) current inhibition produced by serotonin in rat dorsal raphe neurons. *J Neurosci* 11, 3594–3609.

Penington, N. J., Kelly, J. S., & Fox, A. P. (1993). Whole-cell recordings of inwardly rectifying K\(^{+}\) currents activated by 5-HT\(_{1A}\) receptors on dorsal raphe neurones of the adult rat. *J Physiol* 469, 387–405.

Peroutka, S. J. (1995). 5-HT receptors: past, present and future. *Trends Neurosci* 18, 68–69.

Peroutka, S. J., & Snyder, S. H. (1979). Multiple serotonin receptors: differential binding of \[^{3}H\]5-hydroxytryptamine, \[^{3}H\]lysergic acid diethylamide and \[^{3}H\]spiroperidol. *Mol Pharmacol* 16, 687–699.

Pino, R., Cerbai, E., Calamai, G., Alajmo, F., Borgioli, A., Braconi, L., Cassai, M., Montesi, G. F., & Mugelli, A. (1998). Effect of 5-HT\(_4\) receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes. *Cardiovasc Res* 40, 516–522.

Plassat, J. L., Boschert, U., Amlaiky, N., & Hen, R. (1992). The mouse 5HT\(_5\) receptor reveals a remarkable heterogeneity within the 5HT\(_1D\) receptor family. *EMBO J* 11, 4779–4786.

Plassat, J. L., Amlaiky, N., & Hen, R. (1993). Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. *Mol Pharmacol* 44, 229–236.

Pritchett, D. B., Bach, A. W., Wozny, M., Taleb, O., Dal Toso, R., Shih, J. C., & Seeburg, P. H. (1988). Structure and functional expression of cloned rat serotonin 5HT-2 receptor. *EMBO J* 7, 4135–4140.

Pullarkat, S. R., Mysels, D. J., Tan, M., & Cowen, D. S. (1998). Coupling of serotonin 5-HT\(_1B\) receptors to activation of mitogen-activated protein kinase (ERK-2) and p70 S6 kinase signaling systems. *J Neurochem* 71, 1059–1067.

Quick, M. W., Simon, M. I., Davidson, N., Lester, H. A., & Aragay, A. M. (1994). Differential coupling of G protein alpha subunits to seven-helix receptors expressed in Xenopus oocytes. *J Biol Chem* 269, 30164–30172.

Radja, F., Daval, G., Hamon, M., & Verge, D. (1992). Pharmacological and physicochemical properties of pre-versus postsynaptic 5-hydroxytryptamine\(_{1A}\) receptor binding sites in the rat brain: a quantitative autoradiographic study. *J Neurochem* 58, 1338–1346.

Raiteri, M., Maura, G., Bonanno, G., & Pittaluga, A. (1986). Differential pharmacology and function of two 5-HT1 receptors modulating transmitter release in rat cerebellum. *J Pharmacol Exp Ther* 237, 644–648.

Ramboz, S., Oosting, R., Amara, D. A., Kung, H. F., Blier, P., Mendelson, M., Mann, J. J., Brunner, D., & Hen, R. (1998). Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. *Proc Natl Acad Sci USA* 95, 14476–14481.

Rapport, M. M., Green, A. A., & Page, I. H. (1948). Crystalline serotonin. *Science* 108, 329–330.

Raymond, J. R. (1991). Protein kinase C induces phosphorylation and desensitization of the human 5-HT\(_1A\) receptor. *J Biol Chem* 266, 14747–14753.

Raymond, J. R. (1995). Multiple mechanisms of receptor-G protein signaling specificity. *Am J Physiol* 269, F141–F158.

Raymond, J. R., Fargin, A., Middleton, J. P., Graff, J. M., Haupt, D. M., Caron, M. G., Lefkowitz, R. J., & Dennis, V. W. (1989). The human 5-HT\(_1A\) receptor expressed in HeLa cells stimulates sodium-dependent phosphate uptake via protein kinase C. *J Biol Chem* 264, 21943–21950.

Raymond, J. R., Albers, F. J., Middleton, J. P., Lefkowitz, R. J., Caron, M. G., Obeid, L. M., & Dennis, V. W. (1991). 5-HT\(_1A\) and histamine H\(_1\) receptors in HeLa cells stimulate phosphoinositide hydrolysis and phosphate uptake via distinct G protein pools. *J Biol Chem* 266, 372–379.

Raymond, J. R., Albers, F. J., & Middleton, J. P. (1992). Functional expression of human 5-HT1A receptors and differential coupling to second messengers in CHO cells. *Naunyn Schmiedebergs Arch Pharmacol* 346, 127–137.

Raymond, J. R., Kim, J., Beach, R. E., & Tisher, C. C. (1993a). Immunohistochemical mapping of cellular and subcellular distribution of 5-HT\(_1A\) receptors in rat and human kidneys. *Am J Physiol* 264, F9–F19.

Raymond, J. R., Olsen, C. L., & Gettys, T. W. (1993b). Cell-specific physical and functional coupling of human 5-HT\(_1A\) receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha. *Biochemistry* 32, 11064–11073.

Rees, S., den Daas, I., Foord, S., Goodson, S., Bull, D., Kilpatrick, G., & Lee, M. (1994). Cloning and characterisation of the human 5-HT\(_5A\) serotonin receptor. *FEBS Lett* 355, 242–246.

Rhoden, K. J., Dodson, A. M., & Ky, B. (2000). Stimulation of the Na\(^{+}\)-K\(^{+}\)pump in cultured guinea pig airway smooth muscle cells by serotonin. *J Pharmacol Exp Ther* 293, 107–112.

Roth, B. L., Nakaki, T., Chuang, D. M., & Costa, E. (1984). Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. *Neuropharmacology* 23, 1223–1225.

Roth, B. L., Nakaki, T., Chuang, D. M., & Costa, E. (1986). 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester. *J Pharmacol Exp Ther* 238, 480–485.

Roth, B. L., Willins, D. L., Kristiansen, K., & Kroeze, W. K. (1998). 5-Hydroxytryptamine\(_2\)-family receptors (5-hydroxytryptamine\(_2A\), 5-hydroxytryptamine\(_2B\), 5-hydroxytryptamine\(_2C\)): where structure meets function. *Pharmacol Ther* 79, 231–257.

Ruat, M., Traiffort, E., Arrang, J. M., Tardivel-Lacombe, J., Diaz, J., Leurs, R., & Schwartz, J. C. (1993a). A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. *Biochem Biophys Res Commun* 193, 268–276.

Ruat, M., Traiffort, E., Leurs, R., Tardivel-Lacombe, J., Diaz, J., Arrang, J. M., & Schwartz, J. C. (1993b). Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT\(_7\)) activating cAMP formation. *Proc Natl Acad Sci USA* 90, 8547–8551.

Saltzman, A. G., Morse, B., Whitman, M. M., Ivanschenko, Y., Jaye, M., & Felder, S. (1991). Cloning of the human serotonin 5-HT\(_2\) and 5-HT\(_1C\) receptor subtypes. *Biochem Biophys Res Commun* 181, 1469–1478.

Sandén, N., Thorlin, T., Blomstrand, F., Persson, P. A. I., & Hansson, E. (2000). 5-Hydroxytryptamine\(_2B\) receptors stimulate Ca\(^{2+}\) increases in cultured astrocytes from three different brain regions. *Neurochem Int* 36, 427–434.

Sanders-Bush, E., Burris, K. D., & Knoth, K. (1988). Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. *J Pharmacol Exp Ther* 246, 924–928.

Saudou, F., & Hen, R. (1994). 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. *Neurochem Int* 25, 503–532.

Saxena, R., Saksa, B. A., Fields, A. P., & Ganz, M. B. (1993). Activation of Na/H exchanger in mesangial cells is associated with translocation of PKC isoforms. *Am J Physiol* 265, F53–F60.

Schmuck, K., Ullmer, C., Engels, P., & Lubbert, H. (1994). Cloning and functional characterization of the human 5-HT\(_2B\) serotonin receptor. *FEBS Lett* 342, 85–90.

Schnur, S. L., Smith, E. R., Lee, R. L., Mas, M., & Davidson, J. M. (1989). A component analysis of the effects of DPAT on male rat sexual behavior. *Physiol Behav* 45, 897–901.

Schoeffter, P., & Waeber, C. (1994). 5-Hydroxytryptamine receptors with a 5-HT\(_6\) receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes. *Naunyn Schmiedebergs Arch Pharmacol* 350, 356–360.

Schoeffter, P., Waeber, C., Palacios, J. M., & Hoyer, D. (1988). The 5-hydroxytryptamine 5-HT\(_1D\) receptor subtype is negatively coupled to adenylyl cyclase in calf substantia nigra. *Naunyn Schmiedebergs Arch Pharmacol* 337, 602–608.

Schoeffter, P., Ullmer, C., Gutierrez, M., Weitz-Schmidt, G., & Lubbert, H. (1995). Functional serotonin 5-HT<sub>1D</sub> receptors and 5-HT<sub>1D</sub> beta receptor mRNA expression in human umbilical vein endothelial cells. *Naunyn Schmiedebergs Arch Pharmacol* 352, 580–582.

Schoeffter, P., Ullmer, C., Bobirac, I., Gabbiani, G., & Lubbert, H. (1996). Functional, endogenously expressed 5-hydroxytryptamine 5-ht7 receptors in human vascular smooth muscle cells. *Br J Pharmacol* 117, 993–994.

Sebben, M., Ansanay, H., Bockaert, J., & Dumuis, A. (1994). 5-HT<sub>6</sub> receptors positively coupled to adenylyl cyclase in striatal neurones in culture. *Neuroreport* 5, 2553–2557.

Seletti, B., Benkelfat, C., Blier, P., Annable, L., Gilbert, F., & de Montigny, C. (1995). Serotonin<sub>1A</sub> receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses. *Neuropsychopharmacology* 13, 93–104.

Seuwen, K., Magnaldo, I., & Pouyssegur, J. (1988). Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT<sub>1B</sub> receptors coupled to a G<sub>i</sub>-protein. *Nature* 335, 254–256.

Sharp, T., & Hjorth, S. (1990). Application of brain microdialysis to study the pharmacology of the 5-HT<sub>1A</sub> autoreceptor. *J Neurosci Methods* 34, 83–90.

Sharp, T., Bramwell, S. R., & Grahame-Smith, D. G. (1989). 5-HT<sub>1</sub> agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. *Br J Pharmacol* 96, 283–290.

Shen, Y., Monsma, F. J. Jr., Metcalf, M. A., Jose, P. A., Hamblin, M. W., & Sibley, D. R. (1993). Molecular cloning and expression of a 5-hydroxytryptamine<sub>7</sub> serotonin receptor subtype. *JBiol Chem* 268, 18200–18204.

Shenker, A., Maayani, S., Weinstein, H., & Green, J. P. (1987). Pharmacological characterization of two 5-hydroxytryptamine receptors coupled to adenylate cyclase in guinea pig hippocampal membranes. *Mol Pharmacol* 31, 357–367. Erratum: *Mol Pharmacol* 32, 564 (1987).

Shiah, I. S., Yatham, L. N., Lam, R. W., Tam, E. M., & Zis, A. P. (1998). Cortisol, hypothermic, and behavioral responses to ipsapirone in patients with bipolar depression and normal controls. *Neuropsychobiology* 38, 6–12.

Shimizu, M., Nishida, A., Zensho, H., & Yamawaki, S. (1996). Chronic antidepressant exposure enhances 5-hydroxytryptamine<sub>7</sub> receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. *J Pharmacol Exp Ther* 279, 1551–1558.

Singh, J. K., Yan, Q., Dawson, G., & Banerjee, P. (1996). Cell-specific regulation of the stably expressed serotonin 5-HT<sub>1A</sub> receptor and altered ganglioside synthesis. *Biochim Biophys Acta* 1310, 201–211.

Sleight, A. J., Boess, F. G., Bos, M., & Bourson, A. (1998). The putative 5-ht6 receptor: localization and function. *Ann NY Acad Sci* 861, 91–96.

Stam, N. J., Van Huizen, F., Van Alebeek, C., Brands, J., Dijkema, R., Tonnaer, J. A., & Olijve, W. (1992). Genomic organization, coding sequence and functional expression of human 5-HT<sub>2</sub> and 5-HT<sub>1A</sub> receptor genes. *Eur J Pharmacol* 227, 153–162.

Stam, N. J., Vanderheyden, P., van Alebeek, C., Klomp, J., de Boer, T., van Delft, A. M., & Olijve, W. (1994). Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT<sub>2C</sub> receptor. *Eur J Pharmacol* 269, 339–348.

Stam, N. J., Roesink, C., Dijcks, F., Garritsen, A., van Herpen, A., & Olijve, W. (1997). Human serotonin 5-HT<sub>7</sub> receptor: cloning and pharmacological characterisation of two receptor variants. *FEBS Lett* 413, 489–494.

Steward, L. J., Ge, J., Stowe, R. L., Brown, D. C., Bruton, R. K., Stokes, P. R., & Barnes, N. M. (1996). Ability of 5-HT<sub>4</sub> receptor ligands to modulate rat striatal dopamine release in vitro and in vivo. *Br J Pharmacol* 117, 55–62.

Stowe, R. L., & Barnes, N. M. (1998). Selective labelling of 5-HT<sub>7</sub> receptor recognition sites in rat brain using [³H]5-carboxamidotryptamine. *Neuropharmacology* 37, 1611–1619.

Stroebel, M., & Goppelt-Struebe, M. (1994). Signal transduction pathways responsible for serotonin-mediated prostaglandin G/H synthase expression in rat mesangial cells. *J Biol Chem* 269, 22952–22957.

Strosznajder, J., Chalimoniuk, M., & Samochocki, M. (1996). Activation of serotonergic 5-HT<sub>1A</sub> receptor reduces Ca²⁺ and glutamatergic receptor-evoked arachidonic acid and NO/cGMP release in adult hippocampus. *Neurochem Int* 28, 439–444.

Sugimoto, Y., Yamada, J., & Yoshikawa, T. (1999a). A neuronal nitric oxide synthase inhibitor 7-nitroindazole reduces the 5-HT<sub>1A</sub> receptor against 8-OH-DPAT-elicited hyperphagia in rats. *Eur J Pharmacol* 376, 1–5.

Sugimoto, Y., Yoshikawa, T., & Yamada, J. (1999b). Involvement of nitric oxide in the 5-HT<sub>1A</sub> autoreceptor-mediated hyperphagia in rats. *Adv Exp Med Biol* 467, 109–111.

Sun, Q. Q., & Dale, N. (1998). Differential inhibition of N and P/Q Ca²⁺ currents by 5-HT<sub>1A</sub> and 5-HT<sub>1D</sub> receptors in spinal neurons of Xenopus larvae. *J Physiol (Lond)* 510, 103–120.

Takuwa, N., Ganz, M., Takuwa, Y., Sterzel, R. B., & Rasmussen, H. (1989). Studies of the mitogenic effect of serotonin in rat renal mesangial cells. *Am J Physiol* 257, F431–F439.

Tamir, H., Hsiung, S. C., Yu, P. Y., Liu, K. P., Adlersberg, M., Nunez, E. A., & Gershon, M. D. (1992). Serotonergic signalling between thyroid cells: protein kinase C and 5-HT<sub>2</sub> receptors in the secretion and action of serotonin. *Synapse* 12, 155–168.

Tanaka, C., & Nishizuka, Y. (1994). The protein kinase C family for neural signaling. *Annu Rev Neurosci* 17, 551–567.

Taussig, R., & Zimmermann, G. (1998). Type-specific regulation of mammalian adenylyl cyclases by G protein pathways. *Adv Second Messenger Phosphoprotein Res* 32, 81–98.

Terron, J. A. (1996). The relaxant 5-HT receptor in the dog coronary artery smooth muscle: pharmacological resemblance to the cloned 5-ht7 receptor subtype. *Br J Pharmacol* 118, 1421–1428.

Timpe, L. C., & Fantl, W. J. (1994). Modulation of a voltage-activated potassium channel by peptide growth factor receptors. *J Neurosci* 14, 1195–1201.

Tohda, M., Tohda, C., Oda, H., & Nomura, Y. (1995). Possible involvement of botulinum ADP-ribosyltransferase sensitive low molecular G-protein on 5-hydroxytryptamine (5-HT)-induced inositol phosphates formation in 5-HT<sub>2C</sub> cDNA transfected cells. *Neurosci Lett* 190, 33–36.

Torres, G. E., Chaput, Y., & Andrade, R. (1995). Cyclic AMP and protein kinase A mediate 5-hydroxytryptamine type 4 receptor regulation of calcium-activated potassium current in adult hippocampal neurons. *Mol Pharmacol* 47, 191–197.

Tournois, C., Mutel, V., Manivet, P., Launay, J. M., & Kellermann, O. (1998). Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism. *J Biol Chem* 273, 17498–17503.

Trillat, A. C., Malagie, I., Sceance, K., Pons, D., Anmella, M. C., Jacquot, C., Hen, R., & Gardier, A. M. (1997). Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT<sub>1B</sub> receptors: in vivo microdialysis studies. *J Neurochem* 69, 2019–2025.

Tsou, A. P., Kosaka, A., Bach, C., Zuppan, P., Yee, C., Tom, L., Alvarez, R., Ramsey, S., Bonhaus, D. W., & Stefanich, E. (1994). Cloning and expression of a 5-hydroxytryptamine<sub>7</sub> receptor positively coupled to adenylyl cyclase. *J Neurochem* 63, 456–464.

Uezono, Y., Bradley, J., Min, C., McCarty, N. A., Quick, M., Riordan, J. R., Chavkin, C., Zinn, K., Lester, H. A., & Davidson, N. (1993). Receptors that couple to 2 classes of G proteins increase cAMP and activate CFTR expressed in Xenopus oocytes. *Recept Channels* 1, 233–241.

Ullmer, C., Schmuck, K., Kalkman, H. O., & Lubbert, H. (1995). Expression of serotonin receptor mRNAs in blood vessels. *FEBS Lett* 370, 215–221.

Ullmer, C., Boddeke, H. G., Schmuck, K., & Lubbert, H. (1996). 5-HT<sub>2B</sub> receptor-mediated calcium release from ryanodine-sensitive intracellular stores in human pulmonary artery endothelial cells. *Br J Pharmacol* 117, 1081–1088.

Van den Wyngaert, I., Gommeren, W., Verhasselt, P., Jurzak, M., Leysen, J., Luyten, W., & Bender, E. (1997). Cloning and expression of a human serotonin 5-HT<sub>4</sub> receptor cDNA. *J Neurochem* 69, 1810–1819.

Vane, J. R. (1959). The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation. *Br J Pharmacol Chemother* 14, 87–98.

Van Sande, J., Allgeier, A., Massart, C., Czernilofsky, A., Vassart, G., Dumont, J. E., & Maenhaut, C. (1993). The human and dog 5-HT<sub>1D</sub> receptors can both activate and inhibit adenylate cyclase in transfected cells. *Eur J Pharmacol* 247, 177–184.

Varrault, A., & Bockaert, J. (1992). Differential coupling of 5-HT<sub>1A</sub> receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase. *Naunyn Schmiedebergs Arch Pharmacol* 346, 367–374.

Varrault, A., Bockaert, J., & Waeber, C. (1992a). Activation of 5-HT<sub>1A</sub> receptors expressed in NIH-3T3 cells induces focus formation and potentiates EGF effect on DNA synthesis. *Mol Biol Cell* 3, 961–969.

Varrault, A., Journot, L., Audigier, Y., & Bockaert, J. (1992b). Transfection of human 5-hydroxytryptamine<sub>1A</sub> receptors in NIH-3T3 fibroblasts: effects of increasing receptor density on the coupling of 5-hydroxytryptamine<sub>1A</sub> receptors to adenylyl cyclase. *Mol Pharmacol* 41, 999–1007.

Verbeuren, T. J. (1993). Vasodilator effect of tertatolol in isolated perfused rat kidneys: involvement of endothelial 5-HT<sub>1A</sub> receptors. *Cardiology* 83, 5–9.

Verbeuren, T. J., Mennecier, P., & Laubie, M. (1991). 5-Hydroxytryptamine-induced vasodilation in the isolated perfused rat kidney: are endothelial 5-HT<sub>1A</sub> receptors involved? *Eur J Pharmacol* 201, 17–27.

Verge, D., Daval, G., Patey, A., Gozlan, H., el Mestikawy, S., & Hamon, M. (1985). Presynaptic 5-HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT<sub>1A</sub> subtype. *Eur J Pharmacol* 113, 463–464.

Verge, D., Daval, G., Marcinkiewicz, M., Patey, A., el Mestikawy, S., Gozlan, H., & Hamon, M. (1986). Quantitative autoradiography of multiple 5-HT<sub>1</sub> receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. *J Neurosci* 6, 3474–3482.

Vilaro, M. T., Cortes, R., Gerald, C., Branchek, T. A., Palacios, J. M., & Mengod, G. (1996). Localization of 5-HT<sub>4</sub> receptor mRNA in rat brain by in situ hybridization histochemistry. *Brain Res Mol Brain Res* 43, 356–360.

Villalon, C. M., Centurion, D., Lujan-Estrada, M., Terron, J. A., & Sanchez-Lopez, A. (1997). Mediation of 5-HT-induced external carotid vasodilation in GR 127935-pretreated vagosympathectomized dogs by the putative 5-HT<sub>7</sub> receptor. *Br J Pharmacol* 120, 1319–1327.

Voigt, M. M., Laurie, D. J., Seeburg, P. H., & Bach, A. (1991). Molecular cloning and characterization of a rat brain cDNA encoding a 5-hydroxytryptamine<sub>1B</sub> receptor. *EMBO J* 10, 4017–4023.

Waeber, C., & Moskowitz, M. A. (1995). Autoradiographic visualization of [³H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain. *Eur J Pharmacol* 283, 31–46.

Waeber, C., Grailhe, R., Yu, X. J., Hen, R., & Moskowitz, M. A. (1998). Putative 5-ht<sub>5</sub> receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation. *Ann N Y Acad Sci* 861, 85–90.

Wainscott, D. B., Cohen, M. L., Schenck, K. W., Audia, J. E., Nissen, J. S., Baez, M., Kursar, J. D., Lucaites, V. L., & Nelson, D. L. (1993). Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine<sub>2F</sub> receptor. *Mol Pharmacol* 43, 419–426.

Walter, A. E., Hoger, J. H., Labarca, C., Yu, L., Davidson, N., & Lester, H. A. (1991). Low molecular weight mRNA encodes a protein that controls serotonin 5-HT1c and acetylcholine M<sub>1</sub> receptor sensitivity in Xenopus oocytes. *J Gen Physiol* 98, 399–417.

Watson, J. M., Burton, M. J., Price, G. W., Jones, B. J., & Middlemiss, D. N. (1996). GR127935 acts as a partial agonist at recombinant human 5-HT<sub>1Dα</sub> and 5-HT<sub>1Dβ</sub> receptors. *Eur J Pharmacol* 314, 365–372.

Watts, S. W. (1998). Activation of the mitogen-activated protein kinase pathway via the 5-HT<sub>2A</sub> receptor. *Ann N Y Acad Sci* 861, 162–168.

Weinshank, R. L., Zgombick, J. M., Macchi, M. J., Branchek, T. A., & Hartig, P. R. (1992). Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT<sub>1Dα</sub> and 5-HT<sub>1Dβ</sub>. *Proc Natl Acad Sci USA* 89, 3630–3634.

Weiss, S., Sebben, M., Kemp, D. E., & Bockaert, J. (1986). Serotonin 5-HT<sub>1</sub> receptors mediate inhibition of cyclic AMP production in neurons. *Eur J Pharmacol* 120, 227–230.

Wischmeyer, E., & Karschin, A. (1996). Receptor stimulation causes slow inhibition of IRK1 inwardly rectifying K<sup>+</sup> channels by direct protein kinase A-mediated phosphorylation. *Proc Natl Acad Sci USA* 93, 5819–5823.

Wisden, W., Parker, E. M., Mahle, C. D., Grisel, D. A., Nowak, H. P., Yocca, F. D., Felder, C. C., Seeburg, P. H., & Voigt, M. M. (1993). Cloning and characterization of the rat 5-HT<sub>5B</sub> receptor. Evidence that the 5-HT<sub>5B</sub> receptor couples to a G protein in mammalian cell membranes. *FEBS Lett* 333, 25–31.

Witz, P., Amlaïky, N., Plassat, J. L., Maroteaux, L., Borrelli, E., & Hen, R. (1990). Cloning and characterization of a Drosophila serotonin receptor that activates adenylate cyclase. *Proc Natl Acad Sci USA* 87, 8940–8944.

Wolf, W. A., & Schutz, L. J. (1997). The serotonin 5-HT<sub>2C</sub> receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. *J Neurochem* 69, 1449–1458.

Wurch, T., Palmier, C., Colpaert, F. C., & Pauwels, P. J. (1997). Sequence and functional analysis of cloned guinea pig and rat serotonin 5-HT<sub>1D</sub> receptors: common pharmacological features within the 5-HT<sub>1D</sub> receptor subfamily. *J Neurochem* 68, 410–418.

Xie, E., Zhu, L., Zhao, L., & Chang, L. S. (1996). The human serotonin 5-HT<sub>2C</sub> receptor: complete cDNA, genomic structure, and alternatively spliced variant. *Genomics* 35, 551–561.

Yamada, J., Sugimoto, Y., Yoshikawa, T., & Horisaka, K. (1996). Effects of a nitric oxide synthase inhibitor on 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT-induced hyperphagia in rats. *Eur J Pharmacol* 316, 23–26.

Yamada, J., Sugimoto, Y., & Yoshikawa, T. (1998). Effects of adrenalectomy on hyperphagia induced by the 5-HT<sub>1A</sub> receptor agonist 8-OH-DPAT and 2-deoxy-D-glucose in rats. *Neuroreport* 9, 1831–1833.

Yamaguchi, F., & Brenner, S. (1997). Molecular cloning of 5-hydroxytryptamine (5-HT) type 1 receptor genes from the Japanese puffer fish, *Fugu rubripes*. *Gene* 191, 219–223.

Yu, L., Nguyen, H., Le, H., Bloem, L. J., Kozak, C. A., Hoffman, B. J., Snutch, T. P., Lester, H. A., Davidson, N., & Lubbert, H. (1991). The mouse 5-HT<sub>1C</sub> receptor contains eight hydrophobic domains and is X-linked. *Brain Res Mol Brain Res* 11, 143–149.

Zgombick, J. M., & Branchek, T. A. (1998). Native 5-HT<sub>1B</sub> receptors expressed in OK cells display dual coupling to elevation of intracellular calcium concentrations and inhibition of adenylate cyclase. *Naunyn Schmiedebergs Arch Pharmacol* 358, 503–508.

Zgombick, J. M., Beck, S. G., Mahle, C. D., Craddock-Royal, B., & Maayani, S. (1989). Pertussis toxin-sensitive guanine nucleotide-binding protein(s) couple adenosine A<sub>1</sub> and 5-hydroxytryptamine<sub>1A</sub> receptors to the same effector systems in rat hippocampus: biochemical and electrophysiological studies. *Mol Pharmacol* 35, 484–494.

Zgombick, J. M., Schechter, L. E., Macchi, M., Hartig, P. R., Branchek, T. A., & Weinshank, R. L. (1992). Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine<sub>1E</sub> receptor. *Mol Pharmacol* 42, 180–185.

Zgombick, J. M., Schechter, L. E., Adham, N., Kucharewicz, S. A., Weinshank, R. L., & Branchek, T. A. (1996). Pharmacological characterizations of recombinant human 5-HT<sub>1Dα</sub> and 5-HT<sub>1Dβ</sub> receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT<sub>1D</sub> subtypes. *Naunyn Schmiedebergs Arch Pharmacol* 354, 226–236.

Zifa, E., & Fillion, G. (1992). 5-Hydroxytryptamine receptors. *Pharmacol Rev* 44, 401–458.
